 
 
 
Protocol : I4T-MC-JVDL(c)  
 
 An Open -Label, Multicenter, Phase [ADDRESS_1179549] -Line EGFR TKI Therapy 
 
 
[STUDY_ID_REMOVED]  
 
 
Approval Date: 28- Mar-2018  
I4T-MC-JVDL( c) Clinical Protocol Page 1
LY3009806 ; LY3012211Protocol I4T-MC-JVDL (c)
An Open- Label, Multicenter, Phase [ADDRESS_1179550] -Line EGFR TKI Therapy
Confidential Information
The information contained in this protocol is confidential and is intended for the use of 
clinical investigators.   It is the property of Eli Lilly and Company or its subsidiaries and 
should not be copi[INVESTIGATOR_848389] (LY3009806 ), necitumumab (LY3012211) ,and osimertinib (AZD9291) unless 
such persons are bound by a confidentiality agreement with Eli Lilly a nd Company or its 
subsidiaries.
Note to Regulatory Authorities:   This document may contain protected personal data 
and/or commercially confidential information exempt from public disclosure.  Eli Lilly and 
Company requests consultation regarding release/redaction prior to any public release.  In 
the [LOCATION_002], this document is subject to Freedom of Information Act (FOIA) 
Exemption 4 and may not be reproduced or otherwise disse minated without the written 
approval of Eli Lilly and Company or its subsidiaries.
Ram ucirumab (LY3009806 ),Necitumumab (LY3012211) , and Osimertinib (AZD9291 )
Eli Lilly and Company
Indianapolis, Indiana [LOCATION_003] [ZIP_CODE]
Protocol Electronically Signed and Approved by [CONTACT_229490] 29 March 2016.
Amendm ent (a) Electronically Signed and Approved by [CONTACT_11007] 15 November 2016 .
Amendm ent (b) Electronically Signed and Approved by [CONTACT_11007] 9 June 2017.
Amendm ent (c) Electronically Signed and Approved by [CONTACT_81098].
Approval Date: 28-Mar-2018 GMT
I4T-MC-JVDL( c) Clinical Protocol Page 2
LY3009806 ; LY3012211Table of Contents
Section Page
1. Synopsis ............................................................................................................................. [ADDRESS_1179551] ivities....................................................................................................... 12
3. Introduction ...................................................................................................................... 19
3.1. Study  Rati onale ............................................................................................................ 19
3.2. Background .................................................................................................................. 21
3.2.1. Ramucirumab ....................................................................................................... 21
3.2.2. Necitumumab ....................................................................................................... 21
3.2.3. Osimert inib.......................................................................................................... 22
3.3. Benefit/Risk Assessment .............................................................................................. [ADDRESS_1179552] ives and Endpo ints.................................................................................................. 25
5. Study  Design ..................................................................................................................... 26
5.1. Overall Design ............................................................................................................. 26
5.1.1. Dose -Finding Portion:  Dose -Limit ing Toxi city Observat ion................................ 27
5.1.2. Dose -Expansion Portion:  Expansio n Cohort ........................................................ [ADDRESS_1179553] ions.................................................................................................... 40
6.3.1. Diet...................................................................................................................... 40
6.3.2. Contraception ....................................................................................................... 41
6.4. Screen Failures ............................................................................................................. 41
7. Treatments ........................................................................................................................ 42
7.1. Treatments Administered ............................................................................................. 42
7.1.1. Packaging and Labelling ...................................................................................... 43
7.2. Method of Treatment Assignment ................................................................................ 44
7.2.1. Selection and Timing o f Doses ............................................................................. 44
[IP_ADDRESS]. Dose -Limit ing Toxicit y Observat ion............................................................... 44
I4T-MC-JVDL( c) Clinical Protocol Page 3
LY3009806 ; LY30122117.[IP_ADDRESS]. Definit ion of Dose -Limit ing Toxicit ies..................................................... [ADDRESS_1179554] ments, Delays, and Discont inuat ion............................... 54
7.4.4. Dose Delays for Reasons Not Related to Study  Treatm ent.................................... 55
7.5. Preparati on/Handling/Storage/Accountabilit y............................................................... 55
7.6. Treatment Compliance .................................................................................................55
7.7. Concomitant Therapy ................................................................................................... 56
7.7.1. Supportive Care ................................................................................................... 56
[IP_ADDRESS]. Infusio n-Related Reactions -Ramucirumab and 
Necitumumab .................................................................................................56
[IP_ADDRESS].1. Infusio n-Related Reactions -Ramucirumab .............................................. 56
[IP_ADDRESS].2. Infusio n-Related Reactions -Necitumumab .............................................. 57
[IP_ADDRESS]. Supportive Care for Ramucirumab .................................................................. 59
[IP_ADDRESS].1. Supportive Care by  [CONTACT_702368] ............................... 59
[IP_ADDRESS].1.1. Hypertensio n....................................................................................... 59
[IP_ADDRESS].1.2. Proteinuria .......................................................................................... 59
[IP_ADDRESS].1.3. Thromboembo lic Events ..................................................................... 59
[IP_ADDRESS].1.4. Bleeding/Hem orrhage ......................................................................... 59
[IP_ADDRESS].1.5. Gastrointestinal Perforation .................................................................60
[IP_ADDRESS].1.6. Reversible Posterior Leukoencephalopathy  
Syndrome ............................................................................................ 60
[IP_ADDRESS].1.7. Congest ive Heart Failure ..................................................................... 60
[IP_ADDRESS].1.8. Fistul a Form ation................................................................................ 61
[IP_ADDRESS].1.9. Surgery  and Im paired Wound Healing ................................................ 61
[IP_ADDRESS].1.10. Liver Failure and Other Significant Liver Injury .................................61
[IP_ADDRESS].2. Supportive Care Agents for Ramucirumab -
Guidelines ................................................................................................ 61
[IP_ADDRESS].2.1. Antiemetic Agents .............................................................................. 61
[IP_ADDRESS].2.2. Analgesic Agents ................................................................................ 61
[IP_ADDRESS].2.3. Appet ite Stimulants ............................................................................. 62
[IP_ADDRESS].2.4. Granulocyte -Colony St imulat ing Factors ............................................. 62
[IP_ADDRESS].2.5. Erythroid Growth Factors .................................................................... 62
[IP_ADDRESS].2.6. Other Supportive Care Agents ............................................................. 62
I4T-MC-JVDL( c) Clinical Protocol Page 4
LY3009806 ; LY30122117.7.1.3. Supportive Care for Necitumumab by [CONTACT_848425] ............................................................................................... 62
[IP_ADDRESS].1. Skin React ions.......................................................................................... 62
[IP_ADDRESS].2. Conj unctivitis........................................................................................... 64
[IP_ADDRESS].3. Electrolyte Abnormalit ies......................................................................... 64
[IP_ADDRESS].4. Thromboembo lic Events ........................................................................... 64
[IP_ADDRESS].5. Pneumo nia and Sepsis ............................................................................... 64
[IP_ADDRESS].6. Cardi orespi [INVESTIGATOR_328423] ...................................................................... 65
[IP_ADDRESS]. Supportive Care for Osimert inib by [CONTACT_848425] ............................................................................................... 65
[IP_ADDRESS].1. Diarrhea .................................................................................................... 65
[IP_ADDRESS]. 2. Skin React ions.......................................................................................... 66
[IP_ADDRESS].3. QTc .......................................................................................................... 67
[IP_ADDRESS].4. Intersti tial Lung Disease ........................................................................... [ADDRESS_1179555] to Follow -Up........................................................................................................ 70
9. Study  Assessments and Procedures ................................................................................... 72
9.1. Efficacy Assessments ................................................................................................... 72
9.1.1. Efficacy Assessments at Baseline and during Study 
Treatment ............................................................................................................. 72
[IP_ADDRESS]. Baseline Tumor Imaging ................................................................................ 72
[IP_ADDRESS]. Tumor Im aging during Study  Treatm ent......................................................... [ADDRESS_1179556] ....................................................................... 75
[IP_ADDRESS]. Infusio n-Related Reactions -Ramucirumab and 
Necitumumab .................................................................................................75
[IP_ADDRESS]. Adverse Events of Special Interest -Ramucirumab ......................................... 75
[IP_ADDRESS]. Adverse Events of Special Interest -Necitumumab ......................................... 75
[IP_ADDRESS]. Adverse Events of Special Interest –Osimertinib ............................................ 75
9.2.2. Serious Adverse Events ........................................................................................ 75
9.2.3. Pregnancy ............................................................................................................ 76
I4T-MC-JVDL( c) Clinical Protocol Page 5
LY3009806 ; LY30122119.2.4. Suspected Unexpected Serious Adverse React ions............................................... 77
9.2.5. Com plaint Handling ............................................................................................. 77
9.3. Treatment of Overdose .................................................................................................77
9.4. Safety........................................................................................................................... 77
9.4.1. Other Saf ety Measures ......................................................................................... 77
[IP_ADDRESS]. Electrocardiograms ......................................................................................... [ADDRESS_1179557] ical Considerat ions................................................................................ 82
10.3. Statistical Analyses ...................................................................................................... 83
10.3.1. Efficacy Analyses ................................................................................................ 83
10.3.2. Safety Analyses .................................................................................................... 83
10.3.3. Other Analyses ..................................................................................................... 83
[IP_ADDRESS]. Patient Disposi tion.......................................................................................... 83
[IP_ADDRESS]. Patient Characteri stics.................................................................................... 83
[IP_ADDRESS]. Concomitant Therapy ..................................................................................... 84
[IP_ADDRESS]. Postdiscontinuati on Therapy ........................................................................... 84
[IP_ADDRESS]. Treatment Compliance .................................................................................... 84
[IP_ADDRESS]. Pharmacokinet ic Analyses .............................................................................. 84
[IP_ADDRESS]. Immunogenicit y Analyses .............................................................................. 84
[IP_ADDRESS]. Biomarker Analysis ........................................................................................ 84
10.3.4. Interim Analysis ................................................................................................... 84
11. References ........................................................................................................................ 85
I4T-MC-JVDL( c) Clinical Protocol Page 6
LY3009806 ; LY3012211List of Tables
Table Page
Table JVDL.1. Baseline Schedule of Act ivities.............................................................. [ADDRESS_1179558] ives and Endpo ints....................................................................... 25
Table JVDL.6. Dose Finding Portion Treatment Regimens/ Dosing Schedule ................ [ADDRESS_1179559] ions....................................................................... 63
I4T-MC-JVDL( c) Clinical Protocol Page 7
LY3009806 ; LY3012211List of Figures
Figure Page
Figure JVDL.1. Illustrati on of  study  design. ..................................................................... 27
Figure JVDL.2. Predi cted C min,ss following diffe rent dose regimens. ................................ 32
Figure JVDL.3. Continued access diagram. ...................................................................... 69
I4T-MC-JVDL( c) Clinical Protocol Page 8
LY3009806 ; LY3012211List of Appendices
Appendix Page
Appendix 1. Abbreviat ions and Definit ions................................................................ [ADDRESS_1179560] -Line EGFR TKI 
Therapy ................................................................................................ 106
I4T-MC-JVDL( c) Clinical Protocol Page 9
LY3009806 ; LY30122111.Synopsis
Protocol Title:
An Open -Label, Multicenter, Phase [ADDRESS_1179561] -Line EGFR TKI Therapy
Summary of Study Design :
Study I4T -MC -JVDL i s an open -label, multicenter Phase 1 study with an expansion cohort to evaluate the safety 
and preliminary efficacy of ramucirumab or necitumumab in combination with osimertinib .  The dose -limiting 
toxicity (DLT )observation period and expansion cohort (sa fety and preliminary efficacy) will include patients with 
advanced T790M -positive epi[INVESTIGATOR_3506] ( EGFR )-mutant non -small cell lung cancer after 
progression on first -line EGFR tyrosine kinase inhibitor therapy.
Objectives and Endpoints:
Objectives Endpoints
Phase 1a: 
Dose -
Finding 
PortionPrimary:
To assess the safety and tolerability of 
ramucirumab or necitumumab in combination 
with osimertinibDose -limit ing toxicities, observed during 2cycles 
(28 days) for ramucirumab arm ( Arm A)and 
1cycle (21 day s)for necitumumab arm ( Arm B)
Safety (includ ingbut not limited to):
TEAEs, SAEs, and deaths
Secondary:
To assess the PK of ramucirumab or 
necitumumab in combination with osimertinibPK:  Cminand approximate C max of ramucirumab
andnecitumumab in serum
Phase 1b:
Dose -
Expansion 
PortionPrimary:
To assess the safety and tolerability of 
ramucirumab in combination with osimertinibSafety (includ ingbut not limited to):
TEAEs, SAEs, and deaths
Secondary:
To assess the preliminary efficacy of 
ramucirumab in combination with osimertinib *
To assess the PK of ramucirumab in combination 
with osimertinibEfficacy:   ORR (RECIST 1.1) , DCR, DOR, PFS, 
and OS *
PK:  Cminand approximate C max of ramucirumab
in serum
Abbreviations:   Cmax= maximum concentration; C min= minimum concentration; DCR = disease control rate; 
DOR= duration of response; ORR =objective response rate; OS =overall survival; PFS =progr ession -free 
survival; PK =pharmacokinetics; RECIST 1.1= Response Evaluation Criteria In Solid Tumors Version 1.1 ; 
SAEs =serious adverse events; TEAEs =treatment -emergent adverse events.
*Note:  Patients in the Dose -Finding Portion will be included in the overall preliminary efficacy analyses.
I4T-MC-JVDL( c) Clinical Protocol Page 10
LY3009806 ; LY3012211Treatment Arms and Duration:
Phase 1a:  Dose -Finding Portion (3 + 3 dose de -escalation design)
Length of Study Portion
The duration of the Dose -Finding Portion from first patient enrolled to the last patient completing the
DLT observation period is estimated to be approximately 6 months.
Arm A:   28days (2 cycles)for ramucirumab in combination with osimertinib for DLT observation
Arm B:   21 days (1 cycle) for necitumumab in combination with osimertinib for DLT observation
Allpatients will be treated until confirmed progressive disease, unacceptable toxicity, or discontinuation 
for any other reason .
Dosing Schedules
Arm A:
Dose Level 0: ramucirumab 10 mg/kg on Day 1 every 2 weeks ( Q2W )and osimertinib 80 mg daily , in 
3 patien ts
Dose Level -1:ramucirumab 8 mg/kg on Day 1 Q2W and osimertinib 80 mg daily, in 3 patients
Arm B:   
Dose Level 0: necitumumab 800 mg on Days 1 and 8 every 3 weeks ( Q3W )and osimertinib 80 mg 
daily , in 3 patients
Dose Level -1: necitumumab 600 mg on Days 1 and 8 Q3W and osimertinib 80 mg daily , in 3 patients
Number of patients :up to 24 DLT -evaluable patients (up to 12 enrolled in each arm)
Phase 1b:  Dose -Expansion Portion
Length of Study Portion
The duration of the Dose -Expansio n Portion (excluding the Continued Access Period) from first 
patient enrolled to the completion of the study is approximately [ADDRESS_1179562].
I4T-MC-JVDL( c) Clinical Protocol Page 11
LY3009806 ; LY3012211Treatment Cohort
Cohort A:  ramuciru mab at recommended dose + osimertinib 80 mg daily (22patients)
Number of patients:   22evaluable patients
Statistical Analysis:   
For Dose -Finding Portion , a 3+3 dose de-escalatio ndesign will be used to assess the safety of ramucirumab or 
necitumumab in combination with osimertinib .  Additio nal patients will be enrol led to achieve the minimum of 
3evaluable patients at each dose level for each arm , if dropouts or dose interruptions or reductions occur that result 
in a patient being non -evaluable for DLTs.  Data will be reviewed by [CONTACT_702369] (3 patients) for each arm .
For Dose -Expansion Portion , the primary data analysis will be conducted approximately [ADDRESS_1179563] patient 
receive sinitial dose , and the final analysis will occur upon the completion of the study .  All patients enrolled in the 
Dose -Finding Po rtion (Arm A )and the Dose -Expansion Portion (Cohort A ) will be included for all planned 
analy ses.  Patient s enrolled in Arm B of the Dose -Finding Portion will be analyzed separately.
Descriptive statistics will be derived where appropriate.  The rate of DLTs will be summarized by [INVESTIGATOR_216]; dose 
exposure for each study drug will be calculated.
I4T-MC-JVDL( c) Clinical Protocol Page 12
LY3009806 ; LY30122112.Schedule of A ctivities
Table JVDL .1. Baseline Schedule of A ctivities
Days before C1D12814[ADDRESS_1179564] be signed before any protocol -specific 
procedures are performed ; if the ICF is revised during 
the course of the study, re -consenting of patients may 
be required if deemed necessary by [CONTACT_848426]/ERB.
Inclusion/exclusion criteria X
Physical examination X Including height, weight, and vital signs (temperature, 
blood pressure, pulse rate, and respi[INVESTIGATOR_39870] n rate)
ECOG performance status X
Medical history X Including assessment of preexisting conditions, 
historical illnesses, and habits (s uch as tobacco and 
alcohol use)
Prior and current medication X
AE collection X CTCAE Version 4.[ADDRESS_1179565] or MRI 
ECG X Triplic ate, see Exclusion Criterion [40] in Section 6.2.
ECHO or MUGA X
Hematology X
Coagulation X
Clinical chemistry X
T3, free T4, TSH X
Urinaly sis X
Tumo r tissue X It is required to provide a tumor tissue specimen from 
a biopsy taken after disease progression on the most 
recent EGFR TKI treatment.
Pregnancy  test X Applies only to women of childbearing potential . See 
Appendix 3 .
Sample collection See Appendix 4 .
Pharmacokinetics X
Immunogenicity X
Pharmacogenetics (whole blood) X
Biomarkers X
Abbreviations:  AE = adverse event; C1D1 =Cycle 1 Day 1; CTCAE =Common Terminology Criteria for Adverse 
Events (NCI 2009); ECG =electrocardiogram; ECHO = echocardiogram; ECOG = Eastern Cooperative 
Oncology Group (Oken et al. 1982); ICF =informed consen t form; IRB/ERB =institutional review board / 
ethical review board; MUGA = multi ple-gated acquisition; RECIST 1.1=Response Criteria in Solid Tumors 
Version 1.1 (Eisenhauer et al. 2009) ; TSH =thyroid-stimulating hormone .
Note:  Baseline Period begins when the ICF (study entry) is signed and ends at the first dose of study treatment (or 
at discontinuation, if no treatment is given).
I4T-MC-JVDL (c)Clinical Protocol Page 13
LY3009806 ; LY3012211Table JVDL .2. On-Study -Treatment Schedule of A ctivities
Treatment Period Schedule for Ramucirumab Arm and Cohort
Study Period Treatment Period Comments
Cycle (14-day 
cycle ± 3 days)1 2 3 4 5 6 7 8 9-X
Relative Day 
within Dosing 
Cycle1 1 1 1 1 1 1 1 1Visits will be changed to once every 6 weeks if a patient permanently 
discontinues from ramucirumab but still on treatment with osimertinib.  
Procedure Category Procedure
Physical ExaminationPhysical exam 
(including weight)X X X X X X X X XPatients should be weighed at the beginning of each cycle.  Height 
measurements to be performed at baseline only.
ECOG performance 
status X X X X X X X X X Comple te prior to treatment infusion.
Vital signs X X X X X X X X XIncludes blood pressure, pulse, respi[INVESTIGATOR_697], and temperature.  To be 
obtained at every treatment visit ,immediately prior to and at the completion 
of each infusion.  If there is a postinfusion observation period, then vital signs 
measurements should also be obtained at the end of the observation period.   
In the event of an IRR, the res pi[INVESTIGATOR_848390]. Refer to
Section [IP_ADDRESS] for detail s.
Lab/Diagnostic TestsHematology X X X X X X X X XPerformed within 3days prior to treatment on Day [ADDRESS_1179566]/ALT are required to be collected.  If 
enrollment serum chemistry profile is collected within 4 days of C1D1, the 
profile does not need to be repeated.
Coagulation profile X X X XPerformed within 3days prior to treatment on C1D1.  Beginning at Cycle 4, 
within 3 days prior to treatment on Day 1 of thecycle s, coagulation profile 
performed every 4 cycles or more frequently, as clinically indicated if patient 
is on oral anticoagulation therapy.  Coagulation parameters to be tested 
include INR or PT, and PTT/aPTT .
Urinalysis X X X X X X X X XWhile a patient is being treated with ramucirumab collect every cycle, 
dipstick or routine analysis measurements should be done within [ADDRESS_1179567] ( see Appendix 3 , minimum sensitivity 25 IU/L or equivalent 
units of β-hCG).  Within 3 days prior to treatment on Day 1 of e very 2 cycles, 
(or per institutional guidelines, whichever is more frequent) pregnan cy 
testing for women of childbearing potential will be performed.
ECG X X X X X X X X XTwelve -lead ECG within 3 days prior to treatment on Day 1 of each cycle
(and if clinically indicated) for first 6 months then every other cycle , at the 
discontinuation of any study drugs, and at the short -term follow-up.
ECHO or MUGA X Every 12 weeks from C1D1 andif clinically indicated
I4T-MC-JVDL (c)Clinical Protocol Page 14
LY3009806 ; LY3012211Treatment Period Schedule for Ramucirumab Arm and Cohort
Study Period Treatment Period Comments
Cycle (14-day 
cycle ± 3 days)[ADDRESS_1179568] infusion of 
ramucirumab on C1D1 of treatment.  If a patient experiences an IRR on 
ramuciru mab, blood samples for immunogenicity an d PK analysis will be 
taken at the following time points:  (1) as soon as possible after the onset of 
the IRR, (2) at the resolution of the IRR, and (3) 30 days after the IRR.
Tumor tissue XPatients may be asked to undergo optional collection of an additional biopsy 
specimen after treatment with study drug(s) has been initiated .  See Section 
9.8.[ADDRESS_1179569] ion/CTCAE GradingToxicity assessment XAll AEs/SAEs will be collect ed for up to 30 days after the patient and 
investigator agree that the patient will no longer continue study treatment.
Efficacy AssessmentImaging/Tumor 
Assessments 
(every 6 wk ± 7 d)X X XDisease assessment will be every 6 weeks (±7 days) as calculated from the 
first dose of study therapy.  After 24 weeks, tumor assessment will be 
conducted every 12 weeks (± 7 days).  The method used at baseline must be 
used consistently for tumo r assessment .  CT scan or MRI of chest and upper 
abdomen including both adrenal glands are required, with pelvic imaging 
performed if clinically indicated.
Concomitant TherapyConcomitant 
medicationsX X X X X X X X XConcomitant medications will be recorded throughout the treatment period, 
including those taken during the [ADDRESS_1179570] dose of all study 
treatment.
Premedication Premedication X X X X X X X X X
Osimertinib (8 0 mg) will be self-administered per os (by [CONTACT_1966]) once daily
with administer diary .Treatment Administration Ramucirumab (I.V. ) X X X X X X X X X
Osimertinib (orally) X
Patient Disposition XAt the time that the patient is discontinued from any component of the study 
treatment or study participation, information regarding the patient status will 
be collected.
Abbreviations:  β-hCG=beta human chorionic gonadotropin; AE = adverse event; ALT = alanine aminotransferase; AST = aspartate aminotransferase; C1 D1 = Cycle 1Day 1; CT = computed 
tomography; CTCAE =Common Terminology Criteria for Adverse Events; D =Day; ECG =electrocardiogram; ECHO = echocardiogram; ECOG = Eastern Cooperative Oncology Group; 
EGFR =epi[INVESTIGATOR_3506]; INR =International Normalized Ratio; IRR = infusion -related reacti on; I.V.=intravenous; MRI =magnetic resonance imaging; MUGA =multiple -gated 
acquisition; PT=prothrombin time; PTT/aPTT =partial thromboplastin time / activated partial thromboplastin time; SAE = serious adverse event ; TKI =tyrosine kinase inhibitor ; wk=week .
I4T-MC-JVDL (c)Clinical Protocol Page 15
LY3009806 ; LY3012211Treatment Period Schedule for Necitumumab Arm
Comments
Repeat every 3 weeks
Cycle
(3-week 
cycle)1-X
Relative 
day 
within a 
cycle1 8Except for the C1D1 visit, allowable cycle windows are ±3 days, unless indicated otherwise .
Visits will be changed to once every 6 weeks if a patient permanently discontinues from necitumumab but 
still on treatment with osimertinib.  
Procedure Category Procedure
Physical ExaminationPhysical exam (including 
weight)XPatients should be weighed at the beginning of each cycle.  Height measurements to be performed at 
baseline only.
ECOG performance 
statusX Comple te prior to treatment infusion.
Vital signs X XIncludes blood pressure, pulse, respi[INVESTIGATOR_697], and temperature.  To be obtained at every treatment visit ,
immediately prior to and at the completion of each infusion.  If there is a postinfusion observation period, 
then vital signs measurements should also be obtained at the end of the observation period.   In the event of 
an IRR, the respi[INVESTIGATOR_848390].  Refer to Section [IP_ADDRESS] for detail s.
Laboratory /
Diagnostic TestsHematology X XAdditional tests can be used for on -study dosing decisions. Pretreatment laboratory data may not be older 
than 72 hours (Day 1 of each cycle) or 24 hours (Day 8).  Hepatic monitoring tests to be done in the event 
of a treatment -emergent hepatic abnormality .  In case of neutropenia orthrombocytopenia Grade 4 during 
Cycle 1 (dose finding part only), repeat every 2 days until recovery.
Chemistry X XAdditional tests can be used for on -study dosing decisions.  Pretreatment laboratory data may not be older 
than 72 hours (Day 1 of each cycle) or 24 hours (Day 8).  Hepatic monitoring tests to be done in the event 
of a treatment -emergent hepatic abnormality.   In case of Grade 3 elevation of transaminases, bilirubin, or 
change of electrolytes (see DLT criteria), repeat every 2 days until recovery.
Coagulation X** To be performed within 3 days prior to treatment on Day 1 of the cycle for every second cycle starting 
from Cycle 2
T3, free T4, TSH X** To be performed within 3 days prior to treatment on Day 1 of the cycle for every second cycle starting 
from Cycle 2
Urinalysis X** To be performed within [ADDRESS_1179571] ( see Appendix 3 , minimum sensitivity 25 IU/L or equivalent units of β-hCG).  Within 
3days prior to treatment on Day 1 of every 2 cycles (or per institutional guidelines, whichever is more 
frequent) ,pregnan cy testing for women of childbearing potential will be performed.
ECG X** To be performed within [ADDRESS_1179572] 6 months, then every 
other cycle
ECHO or MUGA X* * Every [ADDRESS_1179573] infusion of necitumumab on C1D1 of 
treatment.  If a patient experiences an IRR on necitumumab, blood samples for immunogenicity and PK 
analysis will be taken at the following time points:  (1) as soon as possible after the onset of the IRR, (2) at 
the resolution of the IRR, and (3) 30 days after the IRR.
Tumor tissue XPatients may be asked to undergo optional collection of an additional biopsy specimen after treatment with 
study drug(s) has been initiated.  See Section 9.8.2 for additional details.
I4T-MC-JVDL (c)Clinical Protocol Page 16
LY3009806 ; LY3012211Comments
Repeat every 3 weeks
Cycle
(3-week 
cycle)1-X
Relative 
day 
within a 
cycle1 8Except for the C1D1 visit, allowable cycle windows are ±3 days, unless indicated otherwise .
Visits will be changed to once every 6 weeks if a patient permanently discontinues from necitumumab but 
still on treatment with osimertinib.  
Procedure Category Procedure
Adverse Events 
Collection/CTCAE 
GradingToxicity assessment X XAll AEs/SAEs will be collect ed for up to 30 days after the patient and investigator agree that the patient will 
no longer continue study treatment.
Efficacy AssessmentImaging/Tumor 
Assessments 
(every 6 wk ± 7d)XDisease assessment per RECIST version 1.1 will be performed every 6 weeks (±7 days) as calculated from 
the first dose of study therapy.  After 24 weeks, tumor assessment will be conducted every 12 weeks 
(±7days).  The method used at baseline must be used consistently for tumor assessment .  CT scan or MRI 
of chest and upper abdomen including both adrenal glands are required, with pelvic imaging performed if 
clinically indicated.
Concomitant Therapy Concomitant medication s X XConcomitant medications will be recorded throughout the treatment period, including those taken during 
the [ADDRESS_1179574] dose of all study treatment.
Treatment 
AdministrationNecitumumab (I.V.) X X
Osimertinib (80 mg) will be self -administered per os (by [CONTACT_1966]) once daily with administer diary .
Osimertinib (orally) X
Patient Disposition XAt the time that the patient is discontinued from any component of the study treatment or study 
participation, information regarding the patient status will be collected.
Abbreviations:  β-hCG=beta human chorionic gonadotropin ;AE = adverse event ; C1D1 =Cycle 1 Day 1; CT = computed tomography; CTCAE = Common Terminology Criteria for Adverse Events; 
D =Day; ECG =electrocardiogram; ECHO = echocardiogram; EGFR =epi[INVESTIGATOR_3506]; DLT = dose -limiting toxicity; ECOG = Eastern Cooperative Oncology Group; 
IRR = infusion -related reaction; I.V.=intravenous; MRI = magnetic resonance imaging; MUGA =multiple -gated acquisition; PK=pharmacokinetic; SAEs =serious adverse events; TKI =tyrosine 
kinase inhibitor; TSH = thyroid -stimulating hormone ; wk =week .
I4T-MC-JVDL (c)Clinical Protocol Page 17
LY3009806 ; LY3012211Table JVDL .3. Post -Treatment Follow -Up Schedule of A ctivities
ProcedureShort-Term 
Follow -UpaLong -Term 
Follow -UpbInstructions
Physical examination X Including weight and vital signs (temperature, blood pressure, pulse rate, and respi[INVESTIGATOR_1487])
Concomitant medication X
AE collection X CTCAE Version 4.0
ECOG performance status X
Radiologic imaging and measurement 
of palpable or visible lesionsX X Perform every 6weeks (7days) according to RECIST 1.1, by [CONTACT_848427].  After 24 weeks, tumor assessment will be conducted every 12 weeks (± 7 days), until:
 the patient has objective disease progression ,or
 thestudy’s final analysis ofoverall survival .
After the patient has objective disease progression, radiologic tests are no longer required .
Collection of survival information X X Perform every 2months (±7 days).  If an in -person visit is not possible, confirm survival by [CONTACT_848428].
Collection of post -study-treatment 
anticancer therapy informationX X Perform every 2 mo nths (±7 days) for the first 2 years after discontinuation from study treatment and every 6months
(±14 days) thereafter until death or study completion.
Hematology X
Coagulation X
Clinical chemistry X
T3, free T4, TSH X
Urinalysis X
Sample collection For all sample collection, see 
Appendix 4 . Pharmacokinetics
Biomarkers
Abbreviations:  AE =adverse event; CTCAE =Common Terminology Criteria for Adverse Events (NCI 2009); ECHO = echocardiogram; ECOG = Eastern Cooperative Oncology Group (Oken et al. 
1982); MUGA = multiple -gated acquisition; q =every; RECIST 1.1 =Response Criteria In Solid Tumors Version 1.1 (Eisenhauer et al. 2009) ; TSH = thyroid -stimulating hormone .
aShort -term (Safety) follow -up begins the day after the patient and the investigator agree that the patient will no longer c ontinue study treatment ,and lasts approximately 30 days (±7 days).  No 
follow -up procedures will be performed for a patient who withdraws informed consent unless he or she has explicitly provided permiss ion and consent.   ECHO or MUGA may be performed duri ng 
short -term follow- up if clinically indicated.
bLong -term (Survival) follow- upbegins the day after short -term follow- upis completed , and lasts u ntil disease progression on or after the study regimen, all p atients will be assessed every 2 months 
(±7 da ys) to obtain information about survival status and detailed information on any subsequent systemic anticancer therapy and di sease progression (for patients not having a radiographic 
progression) for as long as the patient is alive, or until study completi on.
I4T-MC-JVDL (c)Clinical Protocol Page 18
LY3009806 ; LY3012211Table JVDL .4. Continued A ccess Schedule of A ctivities
Procedure b Study Treatment Follow -Up a
AE collection X X CTCAE Version 4.[ADDRESS_1179575] blood samples for 
pharmacokinetics and immunogenicity analy sis at the following time 
points:  (1) as soon as possible after the onset of the IRR, (2) at the 
resolution of the IRR, and (3) 30 days after the IRR.
Administer study drug X
Abbreviations:  AE =adverse event; CTCAE = Common Terminology Criteria for Adverse Events; IRR =infusion -related reaction.
aContinued access follow -up begins 1 day  after the patient and the investigator agree that the patient will no longer continue treatment in the continued access 
period and lasts approximately 30 days. No follow -up procedures will be performed for a patient who withdraws informed consent unless he or she has 
explicitly  provided permission and consent.
bEfficacy  assessments will be done at the investigator’s discretion based on the standard of care.
I4T-MC-JVDL( c) Clinical Protocol Page 19
LY3009806 ; LY30122113.Introduction
3.1. Study Rationale
Lung cancer is the most commo n cancer worldwide and the leading cause of cancer -related 
mortalit y, with an est imated 1.[ADDRESS_1179576] imated 1.4 millio n cancer -related 
deaths per y ear (Bray  et al . 2012; Bunn 2012). Non-small  cell lung cancer (NSCLC) accounts 
for approximately  85% of  all lung cancers.  The incidence of epi[INVESTIGATOR_152752] 
(EGFR ) mutations in the Caucasian populat ion is about 10% but can be as high as 40% in East 
Asian populat ions (Bell et al . 2005; Shigematsu et al. 2005; Jänne et al. 2015).
Molecul arly targeted therapi[INVESTIGATOR_848391] (Mok et al. 2009; Zhou et al. 2011; 
Rosell et al. 2012; Sequist et al. 2013) .EGFR tyrosine kinase inhibitors (TKIs; for example, 
erlotinib, gefit inib, and afat inib) significant ly prolong progressi on-free survival ( PFS)in pat ients 
with metastati c NSCLC whose tumors had EGFR exon 19 delet ions or exon 21 (L858R) 
subst itution mutati ons whe n compared with plat inum -based chemotherapy doublets andhave 
beco me the standard of care in countries where approved. The rationale for such treatment is 
supported by  [CONTACT_848429].21 (Shepherd et al. 2005) and IPASS (Mok et al. 
2009).
Despi[INVESTIGATOR_848392] , EGFR mutation-positive pat ients 
eventually develop disease progression after 9 to 12 months of treatment . One important
mechanism o f acqui red resistance is the T790M gatekeeper EGFR mutation in exon 20, which is 
found in about 50 % to 60% of patients upon disease progression fro m first-line EGFR TKI 
therapy .  Thi s mutati on increases the affinit y of the kinase for ATP, and thus reduces the 
inhibitor efficacy  (Peters et al. 2014).  Prio r to the availabilit y of third-generat ion EGFR TKI 
targeting T790M, these patients are candidates for systemic chemotherapy (NCCN Guideline v .4 
2016) unless oligoprogressive disease is diagnosed.  Of note, exist ing data for cytotoxic 
chemotherapy in pat ients wi th acqui red resistance to EGFR inhibitors suggest that benefits are 
also of relat ively short durati on, wi th studi es showing median PFS ( mPFS)of 4.0 to 5.5 m onths 
(Goldberg et al . 2013; Mok et al . 2014).
Osimert inib, a third -generat ion EGFR TKI target ing activat ing EGFR mutations including 
T790M but sparing wild -type EGFR , is an oral , irreversible, select ive inhibitor.  Osimertinib 
(TAGRISSO®, package insert [ PI]and Summary  of Product Characterist ics[SmPC]) 80-mg 
once -daily  tablet has been recent ly approved in the [LOCATION_002] (US) and European Union (EU) 
for the treatm ent of  patients wi th metastati c EGFR T790M mutation -positive NSCLC, who have 
progressed on or after EGFR TKI therapy . Ongoing Phase 1/[ADDRESS_1179577] ive 
response rat e (ORR) of 61% in patients with EGFR T790M -posit ive NSCLC after prior EGFR
TKI therapy , including an ORR o f 70% at the 80 -mg dose level. ORR was 21% in patients with 
EGFR -mutant NSCLC but negat ive for T790M ( Jänne et al. 2015). Based on these data, several 
Phase 3 registration studies are currently ongo ing.
I4T-MC-JVDL( c) Clinical Protocol Page 20
LY3009806 ; LY3012211Separately , necitumumab (PORTRAZZA®, PI), an EGFR -directed monoclonal ant ibody  (mAb), 
has obtained marketing authorizat ion in the US and EU, in co mbination wit h gemcitabine and 
cisplatin, for first-line treatment of patients with metastatic squamous NSCLC. Although 
another EGFR mAb cetuximab has been prove nto be ineffect ive with respect to ORR when 
given as single agent to patients with progressive disease ( PD)to erl otinib or gefit inib (Hanna et
al. 2006; Neal et al . 2010) , the combi nation of cetuximab with afatinib has demonstrated 
promising results. Among 126 patients with acquired resistance to erlotinib or gefit inib, ORR
was 29% and comparable in T790M -positive and T790M -negat ive tumors (32% vs. 25%; 
p=0.341). Median PFS was 4.7 months (95% confidence interval [ CI]:4.3-6.4), and the median 
durati on of  confirmed obj ective response (OR) w as 5.7 m onths (range: 1.8-24.4) .Patients with 
T790M -positive and T790M -negat ive tumors had median durat ions of co nfirmed OR of 
5.6months (range: 1.8-24.4) and 9.5 months (range: 2.9-14.8), respectively. Median PFS was 
similar for T790M -negative and T790M -positivepatients (4.6 vs. 4.8 months; p =0.643)
(Janjigian et al. 2014) .
On the basis of the clinica l data thatsuggested modest benefit from cont inued EGFR TKI 
therapy  despi [INVESTIGATOR_848393] ( Goldberg et al. 2013; Yoshimura et al. 2013 ), synergist ic 
effect of combining EGFR mAb and EGFR TKI,and preclinical data thatsupport the use of 
necitumumab together with EGFR TKI (Lilly unpublished data S180914, S089213), we 
hypothesize that simultaneous inhibit ion of the EGFR signaling pathway  using both osimertinib 
and necitumumab would improve efficacy o f osimertinib in pati ents that progress on prior EGFR
TKI and have T790M -positive NSCLC. A separate study of necitumumab in combinat ion with 
osimer tinibis being conducted in NSCLC EGFR -mutant patients that progressed on 
first-generation EGFR TKI and are negat ive for T790M (N CT02496663).
In addit ion, inhibi tion of  angiogenesis is considered a promising approach to the treatment of 
cancer. Ramucirumab (Cyramza®), a hum an immunogl obulin G, subclass 1 (IgG1) anti-vascular 
endothelial growth factor (VEGF ) Receptor 2 (VEGFR2) mAb , has obtained m arket ing 
authori zation in the US, EU, and Japan for the treatm ent of advanced gastric or gastroesophageal 
junct ion (GEJ) adenocarcino ma as monotherapy (REGARD) or in combinat ion with paclitaxel 
(RAINBOW); in the US and EU for the treatm ent of advanced NSCLC in combinat ion with 
docetaxel (REVEL); and in the US and EU for the treatm ent of m etastati c col orectal  cancer 
(mCRC) in combinat ion with FOLFIRI ( irinotecan, 5 -fluorouracil, and fo linic acid; RAISE). 
Recent ly, ATLAS (Johnson et al. 2013) and BeTa (Herbst et al. 2011) trials reported that the 
combinat ion of the ant iangiogenic agent bevacizumab with erlotinib provided addit ional PFS and 
overall survival ( OS)benefit in the subgroup of patients with EGFR mutations. Additionally, the 
JO25567 study , which is a rando mized Phase [ADDRESS_1179578] -line therapy for patients with EGFR -mutant NSCLC, showed that mP FS was 16.0 months 
(95% CI: 13.9-18.1) with erlotinib plus bevacizumab and 9.7 months (95% CI: 5.7-11.1) with 
erlotinib alo ne (hazard ratio [HR]: 0.54 [ 95% CI : 0.36-0.79]; log-rank test p = 0. 0015). A 
greater proportion of patients achieved disease control with erlotinib plus bevacizumab (99% vs .
88%; p= 0.0177) (Seto et al. 2014). RELAY, a P hase [ADDRESS_1179579] -line therapy for patients with EGFR -mutant NSCLC ,is ongo ing
([STUDY_ID_REMOVED]) .
I4T-MC-JVDL( c) Clinical Protocol Page 21
LY3009806 ; LY3012211Considering the improvement in PFS and disease control rate (DCR ) with the combinat ion of 
erlotinib and be vacizumab in EGFR -mutant NSCLC, as well as promising ORR in EGFR -mutant 
lung cancer patients treated with combinat ion of  afatinib and cetuximab after progression on 
first-generation EGFR TKI, we would like to examine whether the combination o f osimert inib 
and ramucirumab or necitumumab in EGFR -mutant NSCLC after progression on first -line EGFR 
TKI woul d also l ead to improvement in efficacy  in pati ents wi th acquired T790M. This study  
allows for an efficient andstreamlined approach for ident ifying combinat ions that may have the 
best success in future randomized controlled trials.
3.2. Background
3.2.1. Ramucirumab
Ramucirumab (Cy ramza®), a human IgG1anti-VEGFR 2 mAb, has obtained marketing 
authori zation in the US, EU, and Japan for the treatment of advanced gastric or GEJ (gastric-
GEJ) adenocarcino ma as monothe rapy (REGARD ) or in co mbinat ion withpacli taxel  
(RAINBOW ), with disease progressi on on or after pri or fluoropy rimidine -and/or pl atinum -
containing chemotherapy .  Ramuci rumab is also approved in the US and EU for the treatment of 
advanced NSCLC in combinat ion with docetaxel (REVEL ), with disease progressi on on or after 
prior platinum -based chemotherapy .  Pati ents wi th EGFR or anaplast ic lympho ma kinase 
geno mic tumor aberrations should have disease progression on app roved therapy  for these 
aberrat ions prior to receiving ramucirumab.  Ramucirumab is also approved in the US and EU 
for the treatm ent of  mCRC in co mbination wit h FOLFIRI ( RAISE ) with disease progression on 
or after therapy  with bevacizumab, oxaliplatin, and a fluoropy rimidine.
In addit ion, the toxicit y profile of ramucirumab has been manageable given as a monotherapy  or 
in combinat ion.  In REGARD, a single -agent, placebo -controlled, Phase 3 gastric cancer study , 
25patients (10.5%) receiving ramucirumab disc ontinued study  treatm ent due to adverse events 
(AEs).  The m ost comm on adverse drug reactions reported in ≥10% of ram ucirumab -treated 
patients were abdominal pain, diarrhea, and hypertensio n.  Clinically relevant reactions 
(including Grade ≥3) associated w ith antiangiogenic therapy  observed in ramucirumab -treated 
patients across clinical trials were proteinuria, infusion -related reacti ons, and gastrointestinal 
(GI) perforations.
3.2.2. Necitumumab
Necitumumab (LY3012211) is a recombinant human mAb of the IgG [ADDRESS_1179580] in 
tumor cells through ant ibody -dependent cell cy totoxici ty.  Necitumumab (PORTRAZZA®, PI) in 
combinat ion with gemci tabine and cisplat in, has been approved for first -line treatment of 
patients wi th metastati c squamous NSCLC in the US and EU .
The pi[INVESTIGATOR_22735], rando mized Phase 3 trial SQUIRE (I4X -IE-JFCC) compared gemcitabine/cisplat in 
plus necitumumab (GC+N) versus gemcitabine/cisplat in (GC) as first -line therapy in 1093 
I4T-MC-JVDL( c) Clinical Protocol Page 22
LY3009806 ; LY3012211patients wi th Stage IV squam ous NSCLC (Thatcher et al . 2015 ).  The study  met its primary  
objective, demonstrating a statist ically significant i mprovement in OS in the GC+N Arm 
compared wi th the GC Arm  (HR = 0.84; p =0.012).  This was supported by a statist ically 
significant improvemen t in PFS (HR = 0.85; p =0.02).  Several prespecified subgroup analyses 
for OS and PFS showed a consistent treatment effect in favor of GC+N.  Post -progression 
anticancer therapy  was similar (47% vs. 45%).  The safet y data obtained in SQUIRE overall 
were consistent w ith the safet y profile expected for an ant i-EGFR mAb, with skin react ions (any  
grade:  79% vs. 12%, including Grade ≥3:  8.2% vs. 0.6%) and hy pomagnesemia (any  grade:  
31% vs. 16%, including Grade ≥3:  9.3% vs. 1.1%) being the most frequently reported even ts 
(pool ed term s) occurring at higher rates for patients receiving necitumumab.  The Grade ≥3 
treatm ent-emergent adverse events (TEAEs )with highest incidence for which incidence was 
higher in the necitumumab arm than in the control arm were hypo magnesemia (8.7% vs. 1.1%), 
rash (3.7% vs. 0.2%), pulmo nary embolism (3.5% vs. 1.8%), hy pokal emia (3.0% vs. 1.5%), and 
vomiting (2.8% vs. 0.9%).
In another randomized Phase 3 trial, INSPI[INVESTIGATOR_21392] (I4X -IE-JFCB [JFCB]), 947 patients were 
planned to be randoml y assigned to necitumumab plus pemetrexed -cisplat in (PC+N) versus 
pemetrexed -cisplat in (PC) as first -line therapy for Stage IV nonsquamous NSCLC (Paz-Ares et 
al. 2015 ).  Enrollment was halted, fo llowing an independent data monitoring committee (IDMC) 
recommendat ion, after [ADDRESS_1179581] the 
experimental group; the trial cont inued for patients that had been enrolled.  Based on the final 
analysis, PC+N did not improve the efficacy outcome over PC alone in advanced nonsquamous 
NSCLC (OS HR = 1.01, p=0.96; PFS HR = 0.96, p=0.66).  The addi tion of  necitumumab 
resul ted in a higher frequency  of Grade ≥3 TEAEs.  Grade ≥3 TEAEs occurring more frequent ly 
in the necitumumab arm included skin or subcutaneous disorders (14.1 vs. 0.3%), 
thromboembo lic events (9.5 vs. 6.4%), hy pomagnesaemia (7.6 vs. 2 .2%), asthenia (6.9 vs. 1.9%), 
vomiting (6.6 vs. 3.2%), dy spnea (5.3 vs. 2.6%), and diarrhea (4.3 vs. 2.2%).
Therando mized Phase [ADDRESS_1179582] igator’s Brochure (IB).
3.2.3. Osimertinib
Osimert inib ( AZD9291 ) is a novel , third-generati on, and irreversible EGFR TKI wi th select ivity 
against mutant versus wild -type forms of EGFR . Osimert inib is a mo no-anilino -pyrimidine 
compound that i s structurally  and pharmacol ogically  distinct from all other TKIs, including 
another thi rd-genera tion com pound, rocilet inib (CO -1686) (Cross et al. 2014).
I4T-MC-JVDL( c) Clinical Protocol Page 23
LY3009806 ; LY3012211Osimert inib (TAGRISSO®, PI[INVESTIGATOR_65073] ) 80-mg once -daily  tablet has been recent ly approved in 
the US and EU for the treatment of pat ients with metastati c EGFR T790M mutation -positive 
NSCLC who have progressed on or after EGFR TKI therapy .
Osimert inib potently inhibit s EGFR phosphorylat ion in act ivating mutations and resistance cell 
lines in vitro, with much less activit y against wild -type EGFR lines.
Preclinica l data com paring efficacy of afat inib+cetuximab (A+C) and osimertinib showed that 
both A+C and osimertinib inhibited proliferat ion of T790M -positive cells in lo ng-term (10-day) 
growth inhibit ion assays, but osimertinib induced more growth inhibi tion than A +C (Meador et 
al. 2015). Moreover , xenograft -derived A+C resistant cell lines displayed in vitro and in vivo 
sensit ivity to osimertinib , but osimertinib -resistant cell lines demo nstrated cross -resistance to 
A+C. Interestingly, addit ion of cetuximab to osimertinib did not confer addit ive benefit in any 
preclinical disease setting .
Available data fro m a Phase 1 clinical trial wit h osimertinib reveals high response rates in 
patients wi th EGFR TKI resi stance whose tumors harbored EGFR -T790M (ORR 61%; 95% CI:
52%-70%) and lower response rates in pat ients whose tumors lacked EGFR -T790M (ORR 21%; 
95% CI: 12%- 34%). The mPFS was 9.6 months (95% CI :8.3 to not reached) in EGFR
T790M -positivepatients and 2.8 months (95% CI :2.1 to 4.3) in EGFR T790M -negat ive 
patients. The most commo n AEs were diarrhea (47%), rash (40%), nausea (22%), and decreased 
appeti te (21%) (Jänne et al. 2015) .
Due to i ts margin o f potency  between T790M mutant EGFR and wild -type EGFR , the incidence 
and severit yof wild-typeEGFR AEs (for example, rash and diarrhea) appear to be lower than 
those observed with first-and second -generati on EGFR TKIs.
3.3. Benefit/Risk Assessment
Osimert inib inhibits EGFR tyrosine kinase act ivity by [CONTACT_848430]. Necitumumab binds to the extracellular domain o f EGFR and 
prevents ligand activation o f the receptor.  In EGFR -dependent human xenograft models of lung 
cancer, necitumumab led to significant and durable tumor regression.  
 
 
 
 
By [CONTACT_848431] o f EGFR , neci tumumab m ay provi de addi tional 
antitumor effect vi a act ivation of antibody -dependent cellular cy totoxi city and inhibi tion of  the 
autocrine loop of cancer cell signaling ( Riemenschneider et al. 2005; Patel  et al . 2011).
Phase [ADDRESS_1179583] shown that various combinat ions of EGFR TKIsand EGFR -directed mAb
can be administered to patients with NSCLC, although efficacy and/or safety profile of such 
combinat ion has not been encouraging ( Ramalingam et al. 2008; Janjigian et al. 2011; Wheler et 
al. 2013; Janjigian et al. 2014) .However, combi ned EGFR inhibit ion with third-generati on 
CCI
I4T-MC-JVDL( c) Clinical Protocol Page 24
LY3009806 ; LY3012211EGFR TKI and EGFR -directed mAb has not been prospectively studied in pat ients with acqui red 
resistance to first-generation EGFR TKIs (Janjigian et al. 2011) .
On the basis of preclinical data of necitumumab in lung adenocarcinoma harboring a drug 
sensit ive L858R and drug resistant T790M mutation , we hypothesi ze that simul taneous 
inhibit ion of the EGFR signaling pathway using both osimertinib and necitumumab would 
improve efficacy of osimert inib in tum ors that progres s on pri or first-generat ion EGFR TKI in 
patients wi th T790M -positiveNSCLC .  Both necitumumab and osimert inib may cause skin rash, 
hence some overlap is expected; however, the rate of rash wit h third-generati on EGFR TKIs is 
believed to be less than that of the first-and second -generat ion.
Separately, the combinati on of  an EGFR TKI and an ant iangiogenic agent has shown promising 
efficacy  improvement wi thout si gnificant addi tional toxici ty.Recently, ATLAS (Johnson et al. 
2013) and BeTa (Herbst et al. 2011) trials reported that the combination of bevacizumab with 
erlotinib provi ded addi tional PFS and OS benefit in the subgroup of patients with EGFR
mutati ons. In addit ion, the JO2556 [ADDRESS_1179584] -line therapy for patients with EGFR -mutant NSCLC, 
showed that mPFS was 16.0 months (95% CI :13.9-18.1) with erlotinib plus bevacizumab and 
9.7 m onths (5.7 -11.1) with erlotinib alone ( HR: 0.54 [95% CI:0.36–0.79]; log-rank test 
p=0.0015). A greater proportion of patients achieved disease control wit h erlotinib plus 
bevacizumab (99% vs. 88%; p=0.0177) (Seto et al. 2014). No significant toxicit y was observed 
with the addi tion of  bevacizumab to erlotinib. Similarly, BELIEF, which is a s ingle -arm Phase [ADDRESS_1179585]-line erlotinib plus bevacizumab in patients with EGFR -mutant NSCLC, showed 
that for all 109 patients, the 1-year PFS is 55.6% (95% CI: 44.7–66.6%), with a median o f 13.6 
months, while for patients with T790M -positive NSCLC determined pretreatm ent by a sensit ive
method , 1-year PFS is 60.2% (95% CI: 45.6-74.8%) with a median of 15.4 months (Stahel  et al . 
2015). RELAY, a Phase [ADDRESS_1179586]-
line therapy  for pati ents with EGFR -mutant NSCLC ,is ongoing ([STUDY_ID_REMOVED]) .
Considering the improvement in PFS and DCR with the combinat ion of erlotinib and 
bevacizumab in EGFR -mutant NSCLC, as well as no si gnificant worsening toxicit y observed
with the addi tion of  bevacizumab to erlotinib , we anticipate a similarly favorable benefit/ risk 
ratiowould apply to the same class of agents with similar mechanisms o f action.Therefore, we
woul d like to examine whether the combinat ion of osimert inib and ramucirumab in 
EGFR -mutant T790M -positive NSCLC after progressio n on first -line EGFR TKI woul d also 
lead to improvement in efficacy  with tolerable toxici ty.
This study  will provide benefi t-risk data on the coadministration of osimertinib with 
ramucirumab or neci tumumab. More i nformat ion about the known benefits, risks , seri ous 
adverse events (SAEs) and ant icipated AEs of ramucirumab, necitumumab, and osimertinib are 
to be found in the IB of each agent .
I4T-MC-JVDL( c) Clinical Protocol Page 25
LY3009806 ; LY30122114.Objectives and Endpoints
Table JVDL .5shows the object ives and endpoints of the study.
Table JVDL .5. Objectives and Endpoints
Objectives Endpoints
Phase 1a:  
Dose -
Finding 
PortionPrimary:
To assess the safety and tolerability of 
ramucirumab or necitumumab in combination 
with osimertinibDose -limiting toxicities, observed during 2 cycles 
(28 days) for ramucirumab arm (Arm A) and 1 
cycle (21 days) for necitumumab arm (Arm B)
Safety (including but not limited to):
TEAEs, SAEs, and deaths
Secondary:
To assess the PK of ramucirumab or 
necitumumab in combination with osimertinibPK:  Cminand approximate C max of 
ramucirumab andnecitumumab in serum
Phase 1b:  
Dose -
Expansion 
PortionPrimary:
To assess the safety and tolerability of 
ramucirumab in combination with osimertinibSafety (including but not limited to):
TEAEs, SAEs, and deaths
Secondary:
To assess the preliminary efficacy of 
ramucirumab in combination with osimertinib *
To assess the PK of ramucirumab in combination 
with osimertinibEfficacy:  ORR (RECIST 1.1), DCR, DOR, PFS, 
and OS *
PK:  Cminand approximate C max of 
ramucirumab in serum
Tertiary/Exploratory:
To explore the association between biomarkers 
and clinical outcomesBiomarkers:  Genetic and other molecular 
markers (e.g. assess ments of DNA, RNA, and 
protein )from tissue and blood samples
Abbreviations:  C max= maximum concentration; C min= minimum concentration; DCR = disease control rate; 
DNA =deoxyribonucleic acid; DOR= duration of response; ORR =objective response rate; OS =overall 
survival; PFS =progr ession -free survival; PK =pharmacokinetics; RECIST 1.1=Response Evaluation Criteria 
In Solid Tumors Version 1.1; RNA =ribonucleic acid; SAEs =serious adverse events; TEAEs =treatment -
emergent adverse events.
*Note:  Patients in the Dose -Finding Portion will be included in the overall preliminary efficacy analyses.
I4T-MC-JVDL( c) Clinical Protocol Page 26
LY3009806 ; LY30122115.Study  Design
5.1. Overall Design
Study  I4T-MC-JVDL (JVDL) is an open -label, mult icenter Phase 1study  with an expansi on 
cohort to eval uate the safet y and preliminary  efficacy  of ramuci rumab or neci tumumab in 
combinat ion with osimert inibin patients with advanced T790M -positive EGFR -mutantNSCLC
who have relapsed after first -line EGFR TKI therapy .
The study  consists of the Dose -Finding P ortion (dose-limit ing toxicit y [DLT ]observat ion) and 
the Dose -Expansio n Portion (expansio n cohort).
Phase 1a:  Dose-Finding Portion consists of 2arms.  Arm  A is the combinat ion of 
ramucirumab and osimert inib and Ar m B is the combinat ion of necitumumab and 
osimert inib.
Phase 1b:  Dose -Expansion Portion consists of 1cohort.  Cohort A is the combinat ion of 
ramucirumab and osimert inib.
Figure JVDL .1illustrates the study  design.
I4T-MC-JVDL( c) Clinical Protocol Page 27
LY3009806 ; LY3012211Abbreviations:   D1 = Day 1; D8 = Day 8; DLT = dos e-limiting toxicity; n = number of patients; 
Neci =Necitumumab; Osim = Osimertinib; PK=pharmacokinetics; Ram = ramucirumab .
Note:  The results of the interim analysis will confirm the dosing regimen to be used in the expansion cohort .  Dose 
reductio ns,delay s, and discontinuations may occur per the guidelines in Section 7.4.  
Figure JVDL .1. Illustration of study design .
5.1.1. Dose -Finding Portion :  Dose -Limiting Toxicity Observation
The Dose -Finding Portion will emplo y a 3+3 dose de -escalat ion design with a fixed dose of 
osimert inibat 80 mg once daily (QD).  The DLT observat ion peri od is 2 cycles (4 weeks )for 
Arm A and 1cycle (3 weeks )for Arm B, as shown in Figure JVDL .1.
DLT s will be determined based on the incidence, intensit y, and durat ion of AEs that occur up to 
[ADDRESS_1179587] dose of both study  drugs (see 
Section7.2.1.1 for selection and timing of doses).  Adverse events will be grade daccording to 
the Nati onal Cancer Inst itute (NCI) Commo n Termino logy Criteria for Adverse Events 
Versi on4.0 (CTCAE v4.0).
The definit ion for DLTs and the criteria used to determine progress of the study are provided in 
Secti on7.2.1.1 .

I4T-MC-JVDL( c) Clinical Protocol Page 28
LY3009806 ; LY30122115.1.2. Dose -Expansion Portion :  Expansion Cohort
Based on the safet y profile observed du ring the Dose -Finding P ortion, the sponsor may 
determine the dosing regimen to be investigated in the Dose -Expansio n Portion of  the stud y and 
expand to further evaluat ion ofthe combinat ion therapy  in this pat ient populat ion.
The patients in the Dose -Expansio n Portion will meet the same eligibilit y criteria as for 
Dose -Finding Portionof the study .The Dose -Expansio n Portion consists of [ADDRESS_1179588] validated andperform ed locally  will be assigned to ramucirumab + osimert inib(Cohort A). 
All patients will be treated until PD, intol erable toxicit y despi [INVESTIGATOR_756991],or 
patient/invest igator decisio n to terminate the study participat ion.Dose reductions, delays, and 
discontinuat ions m ay occur per the guidelines in Section  7.4.
The purpose of the Dose -Expansio n Portion is to gather addit ional safet y, tolerabili ty, 
pharmacokinet ics (PK), and preliminary efficacy  information regarding ramucirumab in 
combinat ion with osimert inib.  
Note:  For both study portions, tests for T790M that are currently recommended for the 
use of osimertinib in the US and in the EU, respectively, include the following:
In the US, as approved by [CONTACT_848432], the cobas®EGFR Mutati on 
Test Version [ADDRESS_1179589] been established as follows:
•Tarceva®(erlotinib) -Exon 19 del etions and L858R
•Tagrisso®(osimertinib) -T790M
In the EU, according to the currently approved SmPC for osimertinib as a treatment for 
locally advanced or metastatic NSCLC, a validated test is recommended to determine 
EGFR T790M mutation status. As indicated in the SmPC, the mutation status shoul d be 
tested using eit her tumor DNA derived from  a tissue sample or circulat ing tumor DNA 
(ctDNA) obtained fro m a plasma sample. Only robust, reliable ,and sensit ive tests with 
demonstrated utilit y for the determinat ion ofT790M m utation status of tum or-derived 
DNA (fro m a tissue or a pl asma sample) should be used.  Posit ive determinat ion of 
T790M mutation status using eit her a ti ssue-based or plasma -based test indicates 
eligibilit y for treatment with osimertinib . If a plasma -based ctDNA test i s used and the 
resul t is negat ive, it is advisable to follow -up wi th a tissue test wherever possible due to 
the potenti al for false negat ive results using a plasma -based test.
5.2. Number of Patients
Approximately  90patients will be screened and up to 46patients enrolled.  For the Dose-Finding 
Porti on, up to 24 DLT -evaluable patients will be enro lled (12 in each arm) .  For the 
Dose -Expansion Porti on, 22evaluable pat ients will be enro lledinto Cohort A .
I4T-MC-JVDL( c) Clinical Protocol Page 29
LY3009806 ; LY30122115.3. Study Completion and End of Trial Definition
There will be a database lock to report the primary data analyses approximately  [ADDRESS_1179590] pati ent receive sinitial dose in the Dose -Expansion Portion of  the study .
The complet ionof the study  (Study  Completion) is defined as approximately  [ADDRESS_1179591] igators will cont inue to fo llow the study  schedul e for all pat ients unt il notified by [CONTACT_848433].  “End of trial” refers to the date of the last visit or last scheduled 
procedure for the last patient, including pat ients parti cipating in the cont inued access period (see 
Secti on7.8.1 ), if applicable.   Secti on  7.1describes the maximum durat ion of study treatm ent.
5.4. Scientific Rationale for Study Design
This is a Phase 1, open -label study  that will  evaluate safet y and preliminary  efficacy  of 
ramucirumab or neci tumumab in co mbina tion wi th osimertinib. This Phase 1 study  includes a 
3+3, dose de -escalat ing design for the Dose -Finding Portion fo llowed by [CONTACT_106347] -Expansio n 
Porti on wi th 1cohort. As detailed in Section  3.1, Study  Rati onale, and Secti on3.3, Benefit/Risk 
Assessment, this study  enrolls pat ients wi th EGFR -mutant NSCLC who recently developed 
disease progressi on on fi rst-line EGFR TKI therapy . Although the combinat ion of osimert inib 
and ramucirumab or necitumumab may  work in pati ents wi th either T790M -positive or T790M -
negat ive NSCLC, the response rates and other efficacy measures are expected to be different, 
and this study  only enrolls pat ients with T790M -positive NSCLC to reduce heterogeneit y of 
patients in a study  with relatively small sample size.
5.5. Justification for Dose
5.5.1. Dose Selection for Ramucirumab
Ramucirumab administered at 10 mg/kg on Day  1 on an every -2-week (Q2W) schedule will be 
examined in this study .  This dose regimen of ramucirumab is different compared to the REVEL 
study .  In REVEL, conducted in a second- line N SCLC setting, ram ucirumab was administered at 
a dose of 10 mg/kg every  3 weeks (Q3W) .  Exposure -response (efficacy/safet y) findings from
Phase [ADDRESS_1179592], RAINBOW, and REVEL and PK simulat ions were used 
to gui de the dose sel ection in this study .A recent safet y review of the DLT Assessment Period 
data from  Phase 1b of the study  RELAY concluded that ramucirumab at 10 mg/kg Q2W is safe 
and tol erable for EGFR mutation-positive NSCLC patients .
Efficacy
Exposure -efficacy response analyses performed on data obtained from REGARD, RAINBOW, 
and REVEL demonstrated that an increase in exposure is associated with improvement in 
efficacy  in terms of both OS and PFS.
The fo llowing 4 exposure measures were tested, and the findings were consistent for all of them:
minimum concentration after first dose administratio n,
I4T-MC-JVDL( c) Clinical Protocol Page 30
LY3009806 ; LY3012211minimum concentration at steady  state (C min,ss),
maximum concentration at steady  state , and
average concentration at steady  state .
In REGARD (n=72 [number of patients with evaluable PK data] ), patients with 
greater -than-median ramucirumab exposure demonstrated longer OS and PFS and significant ly 
better treatment effects (smaller HR) as compared to patie nts with less -than-median 
ramucirumab exposure.
In RAINBOW (n=321 [number of pat ients with eval uable PK data]), patients with ramucirumab 
exposure greater -than-median (in the thirdand fourth quartile groups) were associated with 
longer OS and PFS and significant ly better treatment effects (smaller HR) as compared to 
patients with ramucirum ab exposure lower -than-median (in the firstand second quartile groups).
In REVEL (n=376 [number of patients with evaluable PK data]), significantly lo nger OS and 
PFS favoring ramucirumab were generally observed in the highest exposure quartile group (the 
fourth group), while marginal increases on OS and PFS were observed in other exposure quartile 
groups.
Safety
Weekly doses of ramucirumab ranging fro m 2 to 16 mg/kg were eval uated in Phase 1 
Study I4T-MC-JVBM ( JVBM ).  Amaximal tolerated dose ( MTD) for wee kly dosing was 
ident ified as 13 mg/kg every week.  Every-2 -week (6 to 10 mg/kg) and every -3-week (15 to 20 
mg/kg) dose regimens were evaluated in an addit ional dose -ranging study  (Study I4T-MC-JVBN
[JVBN ]).  All dose regimens in Study JVBN were well tolerated and no MTD was ident ified in 
this study .
The same ramucirumab dose regimen (8 mg/kg every  2 weeks) was used in REGARD and 
RAINBOW.  REGARD demonstrated a well -tolerated safet y profile in the gastric cancer 
monotherapy  setting.  Due to the low inc idence of hypertensio n and neutropenia, no 
safet y-exposure rel ationship was ident ified.  In RAINBOW, ramucirumab in co mbinat ion with 
paclitaxel was also well tolerated in patients with gastric cancer, with manageable AEs.  An 
increasing ramucirumab exposur e was correl ated wi th increased incidence of Grade ≥[ADDRESS_1179593] 
antihypertensive medicat ion.  N eutropenia and leukopenia are known risks wit h paclitaxel 
treatm ent.  Overall, the safet y profile of ramucirumab plus paclitaxel was largely consistent with 
the safet y profiles of the individual treatment components and the combinat ion revealed no 
unexpected safety findings.
The safet y profile observed in REVEL was consistent with the safet y profile for ramucirumab 
established in gastric cancer (REGARD and RAINBOW), as well as the established safet y 
profile for docetaxel, and was manageable in the NSCLC pop ulation.  An increasing 
ramucirumab exposure was correl ated wi th increased incidence of Grade ≥3hypertensio n and 
febrile neutropenia.  Of note, there were no Grade 4 or 5 hy pertensio n events in REVEL.  
I4T-MC-JVDL( c) Clinical Protocol Page 31
LY3009806 ; LY3012211Hypertensio n was m anaged primarily by  [CONTACT_848434].  In 
addition, incidence of febrile neutropenia appeared to reach plateau at the third exposure quartile.
These exposure -efficacy  and exposure -safet y data indicate that there is an opportunity  to further 
enhance efficacy of ramuci rumab while m aintaining an acceptable safet y profile .  Based on PK 
simulat ion, a dose regimen of 10 mg/kg on Day  1 every 2 weeks was selected for Study JVDL
for the fo llowing reasons:
This dose regimen may produce C min,ss that is higher than the fourthCmin,ss quartile 
obtained fro m 10-mg/kg every -3-week regimen in REVEL, in at least 70% of the 
patient popul ation (Figure JVDL. 2) and i s therefore expected to produce better clinical 
efficacy  outcom es rel ative to the 10- mg/kg every -3-week regimen.
It is expected that ramucirumab -related AEs in the NSCLC indicat ion may not be 
significant ly increased using the selected ramucirumab dose of 10 mg/kg every 2 weeks, 
since the selected dose for Study  JVDL is still approximately  60% l ower than the 
maximum tolerated weekly dose identified in the Phase 1 dose- escalat ion study , 
Study JVBM (13 mg/kg weekly ).
The ram ucirumab exposure distribut ion of the 10- mg/kg every -2-week regimen 
significant ly overlaps with that of the 8 -mg/kg every -2-week regimen studied in 
REGARD and RAINBOW.
DLT observat ion is being conducted to assess the safet y and tol erabili ty of ramucirumab 
administered at 10 mg/kg every 2 weeks in co mbination with osimert inib administered daily at 
80mg.
This safet y assessment will examine if the higher ram ucirumab dose regimen of 10 mg/kg every  
[ADDRESS_1179594] ill maintain an acceptable safet y profile in co mbin ation wi th osimertinib in 
NSCLC pat ients.  Based upon the review of the safety assessment , study  modificat ions may be 
warranted.
Out of 12 DLT evaluable pat ients, only 1patient had DLT. No SAE or Grade 4 or 5 TEAEs 
were observed for the combinat ion of ra mucirumab 10 mg/kg Q2W pluserlotinib 150 mg/day; 
no unexpected safet y signals were identified .
I4T-MC-JVDL( c) Clinical Protocol Page 32
LY3009806 ; LY3012211Abbreviations:  C min,ss = minimum concentration at steady state; Q = every; W = week.
Box plots depi[INVESTIGATOR_163368] 5th, 25th, 50th, 75th, and 95th p ercentiles calculated from 
1000 simulation iterations.
Figure JVDL. 2. Predicted C min,ss following different dose regimens.
In summary, the dosing regimen sof ramucirumab 10 or 8mg/kg on Day 1 every 2 weeks in 
combinat ion with osimert inibareanticipated to produce a favorable benefit- risk profile in 
patients wi th EGFR mutation-positive metastatic NSCLC.
5.5.2. Dose Selection for Necitumumab
The recommended dose and treatment schedules for necitumumab are 800 m g QW, 800 m g 
Q2W , or 800 m g (Days 1 and 8 of a 21 -day cycle), based on safet y and PK data from 2 Phase 1 
studi es in heavily  pretreated pati ents wi th advanced solid tumors (JFCA and JFCE).  The 
necitumumab 800-mg dose administered intravenously ( I.V.) on Days 1 and 8 of each 21 -day 
cycle has also been used in the recent pi[INVESTIGATOR_22735], randomized Phase 3 trial SQUIRE in co mbinat ion 
with gemci tabine/cisplat in as first -line therapy in 1093 patients with Stage IV squa mous NSCLC 
(Thatcher et al. 2015 ).  The starting dose of ne citumumab will be at Dose Level [ADDRESS_1179595] m ajority of patients had sufficient exposure of necitumumab, as 
99.6% of patients had exposures superseding half -maximal effect ive concentration (82 µg/mL) 

I4T-MC-JVDL( c) Clinical Protocol Page 33
LY3009806 ; LY3012211for OS, wi th the m edian exposure result ing in clo se to m aximum  efficacy .  Neci tumumab 
disposi tion showed a l ess-than-proporti onal dependence on pati ent body  weight.  Simulations 
based on populat ion PK (PopPK) and pharmacodynamic models show that weight -or body  
surface area -based dosing would not lead to a decreased PK variabilit y or improvement of OS.
There was no correlation detected between necitumumab PK and hepat ic or renal funct ion 
markers, and there were no differences in disposit ion across age, sex, or race (White vs. Asian).  
No clear rel ationship was observed between drug exposure and safet y events.  In summary , 
PopPK/Pharmacodynamic analysis supports the adminis tration of  800 m g necitumumab on 
Days 1 and 8 of a 21- day cycle as an appropriate dose in the target populat ion.
5.5.3. Dose Selection for Osimertinib
Osimert inib was slowly absorbed fo llowing oral  dosing wit h median time to reach maximum 
plasma concentration in patients and healt hy vo lunteers ranging from 6 to 8 hours across doses.   
Osimert inib exhibited low to moderate apparent clearance and high vo lume of distri bution in a 
low fluctuati on of  exposure (m aximum/minimum pl asma concentration [C max:Cmin] rati o of
approximately  1.6) wi th steady -state achi eved by  [ADDRESS_1179596] imated mean maximum steady -state concentration and the area under the plasma 
concentration -time curve at steady  state (AUC ss) at [ADDRESS_1179597] ment is not required based on patient’s age, gender, body  
weight, ethnicit y or sm oking status.  Based on an exposure -response analysis o f the pool ed data 
from efficacy  studies (AURA Phase 1component, AURA extensio n and AURA2), there w as no 
evidence of a relat ionship between plasma exposure (A UC ss) of osimert inib and efficacy  
endpo ints (probabilit y of response or best percent change in tumor size or duration of response 
[DOR ]for T790M m utation-positive pat ients with advanced NSCLC who have progressed on or 
after EGFR TKI therapy ).  Overall, the PK profile of osimert inib supports once a day  continuous 
dosing.
The AURA studies in NSCLC pat ients with EGFR T790M mutation -positive tum ors who had 
progressed fo llowing pri or therapy  with an EGFR TKI agent have demonstrated that osimert inib 
80 m g QDoffers benefits .  ORR was 66.1% (95% CI: 61.2, 70.7) based on blinded independent 
central  review (BICR) ,which is substant ially higher than that reported with chemotherapy  in 
second -or later-lines.  The high ORR was regardl ess of line o f therapy  or other dem ographic or 
disease characteri stics. DOR was 8.5 m onths (95% CI: 8.5, not calcula ble[NC]) based on 
investigator assessment.  The preliminary est imate of mPFS was 9.7 m onths (95% CI: 8.3, NC) 
based on assessments of both BICR and invest igator .An improvement in patient-reported 
outcome(PRO) -reported lung cancer symptoms was supportive of the Response Evaluat ion 
Criteria In Solid T umors (RECIST )efficacy data.
Osimert inib 80 mg QDhas an acceptable safety  profile for the inten ded advanced NSCLC 
popul ation.
The 20- mg starting dose was sufficient to inhibit EGFR T790M, whereas doses equivalent to 
80mg or more were expected to lead to more profound inhibit ion of tumor growth (Cross et al. 
I4T-MC-JVDL( c) Clinical Protocol Page 34
LY3009806 ; LY30122112014).   The current ongoing Phase 2 (AURA2 )and Phase 3 (AURA3 )studi es empl oy 80-mg QD
regimen for advanced EGFR T790M -posit ive NSCLC patients.
In summary, PK analy sisandpreclinical and clinical data support 80 -mg once daily regimen in 
advanced EGFR T790M -posit ive NSCLC patients.
I4T-MC-JVDL( c) Clinical Protocol Page 35
LY3009806 ; LY30122116.Study  Population
Prospective approval o f protocol  deviati ons to recrui tment and enro llment criteria, also known as 
protocol  waivers or e xempt ions, is not permitted.
6.1. Inclusion Criteria
Patients are eligible to be included in the study  only  if they  meet all  of the f ollowing criteria:
[1] Have a diagnosis of NSCLC with at least [ADDRESS_1179598] techniques by [CONTACT_941] R esponse Evaluat ion Cri teria In Solid T umors 
Versi on 1.1 (RECIST 1.1; Eisenhauer et al. 2009)
[2] Have l ocally advanced or m etastatic NSCLC n ot amenable to curative therapy
[3] Have lung cancer with docum ented evidence of one of  the 2 commo n EGFR
mutati ons known to be associated with EGFR TKI sensit ivity (Ex19del, 
L858R)
[4] Have d isease progression immediately fo llowing first-line EGFR TKI 
treatm ent (wi th disease control  as the best response to the first-line EGFR TKI 
treatm ent) regardl ess of pri or chem otherapy
[5] Have T790M -positive status using a test validated andperformed locally after 
disease progressi on on EGFR TKI treatment
[6] Tumor tissue from a biopsy  taken after di sease progressio n on the m ost recent 
EGFR TKI treatment is required .  Patients for whom newly obtained samples 
cannot be obtained (for example, inaccessible or patient safet y concern) m ay 
submit an archived specimen only upon agreement fro m the Sponsor.
[7]Have Eastern Cooperative Onco logy Group Performance Status of 0 or 1 at 
the time o f enrollment (Oken et al. 1982)
[8]Have provided signed informed consent and are amenable to compliance with 
protocol  schedules and testing
[9]Have serum albumin that is ≥25 g/L at the time of enro llment
[10]Have urinary  protein that is <2 + on di pstick or routine urinalysis.  If urine 
dipstick or routine analysis indicates proteinuria ≥2+, then a 24- hour urine 
must be collected and must demonstrate <2 g of protein in 24 hours to allow 
participat ion in the study.
I4T-MC-JVDL( c) Clinical Protocol Page 36
LY3009806 ; LY3012211[11] Have adequate organ fun ction, as defined below , with all screening labs 
performed wi thin 7days of treatm ent init iation:
System Laboratory Value
Hematologic
Absolute neutrophil count (ANC) ≥1.5 x 109/L
Platelets ≥100 x 109/L
Hemoglobin≥9 g/dL or ≥5.6 mmol/L (packed red blood cell transfusions are 
not allowed within 1week prior to baseline hematology profile)
Renal
Creatinine OR
Measured or calculated creatinine 
clearancea(seeAppendix 6 )≤1.[ADDRESS_1179599] OR
≥50 mL/min
Hepatic
Total bilirubin ≤1.[ADDRESS_1179600] (SGOT) and ALT (SGPT)≤2.[ADDRESS_1179601] OR
≤[ADDRESS_1179602] for patients with liver metastases
Coagulationb
International Normalized Ratio (INR) or 
Prothrombin Time (PT)INR ≤1.[ADDRESS_1179603] or PT ≤ [ADDRESS_1179604] unless patient 
is receiving anticoagulant therapy as long as INR or PT is 
within therapeutic range of intended use of anticoagulants
Partial Thromboplastin Time (PTT) or 
Activated Partial Thromboplastin Time 
(aPTT)PTT or aPTT ≤ [ADDRESS_1179605] unless patient is 
receiving anticoagulant therapy as long as PTT or aPTT is 
within therapeutic range of intended use of anticoagulants
Abbreviations:  ALT (SGPT) = alanine aminotransferase (serum glutamic pyruvic transaminase);
aPTT =activated partial thromboplastin time; AST (SGOT) =aspartate aminotransferase (serum 
glutamic oxaloacetic transaminase); INR =international normalized ratio; PT =prothrombin time; 
PTT =partial thromboplastin time; ULN =upper limit of normal.
aCreatinine clearance should be calculated per institutional standard.
bPatients on full -dose anticoagulation must be on a stable dose (minimum duration 14 days) of oral 
anticoagulant or low molecular weight heparin.  If receiving warfarin, the patient must have an INR 
≤3.0x ULN and no active bleeding (i.e., no bleeding within [ADDRESS_1179606] dose of study 
treatment) or pathological condition present that carries a high risk of bleeding (e.g., tumor involving 
major vessels or known varices).
[12]Be at l east 18years ol d at the time of signing informed consent
[13]Have a life expectancy o f ≥3 m onths
[14]Have reso lution, except where otherwise stated in the inclusio n criteria, of all 
clinically significant toxic effects of prior systemic cancer therapy , surgery , or 
radiotherapy  to Grade ≤1 by [CONTACT_848435] n4.0
[15]For m ale pat ients, are sterile (including vasectomy confirmed by 
[CONTACT_848436]) or agree to use a highly effectiv e method of 
contraception (2 methods preferred) , and to not donate sperm starting wit h the 
first dose of study  therapy , during the study ,and for at least [ADDRESS_1179607] dose of study  therapy  or country  requi rements, whi chever i s 
longer.  Refe r toAppendix 1 for definit ionof highly effective method of 
contraception.
I4T-MC-JVDL( c) Clinical Protocol Page 37
LY3009806 ; LY3012211[16]For female patien ts, are surgically  sterile , postm enopausal (see Section 6.3.2
in detail ), or agree to use a highly effective method of contraception (2 
methods preferred) during the study , and for [ADDRESS_1179608] dose 
of study  treatm entor coun try requi rements, whichever is longer .  Ref er to 
Appendix 1 for definit ion of highly effective method of contraception.
[17]For fe male patients and of child -bearing potential ,must have a negative serum 
or urine pregnancy  test wi thin [ADDRESS_1179609] feeding
Note:  Non-childbearing potential (by [CONTACT_73534]) is defined 
in Secti on  6.3.2 .
6.2. Exclusion Criteria
Patients will  be excluded from  the study  if they  meet anyof the fo llowing cri teria:
[18]Previous treatment with an EGFR mAb (except for past treatment for 
squamous ce ll carcino ma of head and neck or mCRC)
[19]Previous treatment with a n EGFR TKI ( for example , erlotinib or gefit inib) 
within [ADDRESS_1179610] 
dose of study  treatm ent (If  sufficient wash -out time has not occurred due to 
schedule or PK properties, an alternative appropria te wash -out time based on 
known duration and time to reversibilit y of drug -related AEs could be agreed 
upon by [CONTACT_173630].)
[20]Previous treatment with osimert inib or other third -generat ion EGFR TKIs
[21]Patients wi th symptom atic orgrowing brain metastases less than [ADDRESS_1179611] 2 weeks prior to receiving treatment, are eligible.
I4T-MC-JVDL( c) Clinical Protocol Page 38
LY3009806 ; LY3012211[22]Have a serious conco mitant illness or m edical condi tion(s) including, but not 
limited to, the fo llowing:
Activeinfection including hepati tis B, h epatitis C, and human 
immunodeficiency  virus (HIV) infect ion.  Screening for chron ic condit ions 
is not required.
Active or uncontrolled clinically serious infection
Active substance abuse disorders
History of drug-induced interstitial lung disease (ILD) , ILD, or radiation 
pneumo nitis requi ring treatm ent wi th steroi d prior to study  enro llment, or 
any evidence of clinically act ive ILD
Known allergy  or hy persensi tivity react ion to any of the treatm ent 
components
[23]Have history  of another m alignancy in 3 ye ars, EXCEPT :
adequately  treated n onmelano matous skin cancer ,
curatively  treated cervi cal carcino ma in situ,
other noninvasive car cinoma or in situ neoplasm, or
prostate cancer that is not expected to impact patient survival
[24]Have a significant bleeding disorder or vasculit is or had a Grade ≥3 bleeding 
epi[INVESTIGATOR_5319] 12 weeks prior to enrollment.  Patients with a history  of gross 
hemopt ysis (defined as bright red blood of ≥1/2 teaspoon) within 2 month 
prior to enrollment are excluded.
[25]Have experienc ed any arteri al thromboti c event or arteri al thromboembolic 
event , including myo cardial  infarcti on, unstable angina (history  or evi dence o f 
current clinically relevant coronary  artery  disease of current ≥Class III as 
defined by [CONTACT_848437] 
[Cam peau 1976] or congest ive heart failure of current ≥Class III as defined by 
[CONTACT_328474]), cerebrovascular accident, or transient 
ischemic attack, within 6months prior to enrollment
[26]Have a history  of deep vein thrombosis, pulmo nary embo lism, or any  other 
significant venous thromboembolism (venous catheter thrombosis or 
superficial venous thrombosis not considered “significant” ) during the
3months pri or to study  enro llment. Patients with venous thromboemb olism  
occurring 3 to 6 months prior to study  enro llment are allowed, if being treated 
with low m olecular wei ght heparin.
[27]Have a history  of GI perforation and/or fistula wit hin6 months prior to 
enrollment
I4T-MC-JVDL( c) Clinical Protocol Page 39
LY3009806 ; LY3012211[28]Have a bowel obstruction, history  or presence of inflammatory enteropathy or 
extensive intestinal resect ion (hemico lectomy or extensive small intest ine 
resection wit h chronic diarrhea), Crohn’s disease, ulcerat ivecolitis, or chronic 
diarrhea
[29]Have uncontrolled hypertensio n, as defined in CTCAE Versio n 4.0, prior to 
initiating study treatment, despi[INVESTIGATOR_848394]. CTCAE 
Versi on 4.0 defines uncontrolled hypertensio n as Grade >2 hy pertensi on; 
clinically, the patient continues to experience elevated blood pressure (systolic
>160 mmHg and/or diastolic > 100 mmHg) despi[INVESTIGATOR_848395].
[30]Arereceiving chronic therapy  with any of the fo llowing medicat ions within 
7days prior to enrollment:
a.nonsteroidal ant i-inflammatory agents (NSAIDs; such as indo methacin, 
ibuprofen, naproxen , or similar agents)
b.other antiplatelet agents (such as clopi[INVESTIGATOR_7745], ticlopi[INVESTIGATOR_5325], dip yridam ole, or 
anagrelide)
Aspi[INVESTIGATOR_702354] 325 mg/day is permitted.
[31]Have had a serious or non -healing wound, ulcer, or bone fracture within
28days prior to enrollment
[32]Have an elect ive or a planned major surgery during the course of the tri al
[33]Have undergone major surgery  within 28 days prior to enrollment, or minor 
surgi cal procedure such as central  venous access device placement with in 
7days priorto enrollment
[34]Are current ly enrolled in , or di scont inued wit hin the l ast [ADDRESS_1179612] or any other ty pe of medical 
research judged not to be scient ifically or medically co mpat ible with this 
study (except in the setting of EGFR TKI as detailed above).  Patients 
participat ing in surveys or observat ional studi es are eligible to participate in 
this study .
[35]Are pregnant, or breastfeeding
[36]Have radio logically  docum ented evidence of majo r blood vessel invasion or 
encasement by  [CONTACT_67380]
[37] Have radiographic evidence of pulmo nary intratum or cavi tation, regardl ess of 
tumor histology
[38]Are receiving concurrent treatment with other anticancer therapy , including 
other chemotherapy , immunotherapy , hormonal therapy , chem oembo lization, 
or targeted therapy or radi otherapy  treatm ent to more than 30% of the bone 
marrow or with a wide field o f radiation within 4 weeks prior to enrollment 
(except in the setting of EGFR TKI as detailed above ).
I4T-MC-JVDL( c) Clinical Protocol Page 40
LY3009806 ; LY3012211[39] Are curren tly receiving ( or unable to stop use at least [ADDRESS_1179613] dose of osimertinib) medications or herbal  supplements 
known to be potent inducers o f CYP3A4 (refer to  Appendix 7 ).
[40]Have any of the fo llowing cardi ac abnorm al findings:
Mean resting corrected QT interval (QTc) > 470 msec obtained fro m 
3electrocardi ograms (ECGs), using the screening clinic ECG 
machine -derived QTc value
Any clinically  important abnorm alities in rhy thm, conducti on,or 
morphol ogy of resting ECG; for example , com plete l eft bundle branch 
block, thi rd-degree heart block, or second -degree heart block
Any factors that increase the risk o f QTc prol ongati on or risk of arrhy thmic 
events such as heart failure, hy pokalemia, congenit al long QT syndrom e, 
family history  of long QT syndrom e or un explained sudden death under 
40years of age in first -degree relatives ,or any  concomi tant m edicat ion 
known to prolong the QT interval
Have a history  of any of the fo llowing condi tions:  presyncope or syncope 
of either unexplained or cardiovascular etio logy, ventri cular arrhy thmia 
(including but not limited to ventricular tachycardia and ventricular 
fibrillat ion), or sudden c ardiac arrest
[41]Have undergone chest irradiat ion within [ADDRESS_1179614] not recovered fro m all radiation -related toxicit ies, or 
requi res corti costeroi ds.  A 2 -week washout is permitted for focal palliat ive 
radiation to n on-central nervous sy stem disease .
[42]Have refractory  nausea and vo miting, inabilit y to swallow the formulated 
product ,or previous significant bowel resect ion that woul d precl ude 
absorpti on
[43]Have any other serious uncontrolled medical disorders or p sychological 
condi tions that woul d, in the opi[INVESTIGATOR_3078] n of the investigator, limit the patient’s 
abilit y to complete the study  or si gnan informed consent document
[44]Have liver cirrhosis at a level of Child -Pugh B (or worse) or liver cirrhosis 
(any degree) a nd a history  of hepatic encephalopathy or clinical meaningful 
ascites result ing from cirrhosis
6.3. Lifestyle Re strictions
6.3.1. Diet
Patients shoul d maintain a normal diet unless modificat ions are required to manage an AE such 
as diarrhea, nausea, or vomit ing.
I4T-MC-JVDL( c) Clinical Protocol Page 41
LY3009806 ; LY30122116.3.2. Contraception
Based on ramucirumab’s mechanism o f action, it is likely  that ram ucirumab will  inhibi t 
angiogenesis and may potentially  resul t in adverse effects during pregnancy and postnatal 
development.
Therefore, 1) non-pregnant, non -breast -feeding women may only be enro lled if they are willing 
to use a highly effect ive method of contracepti onor are considered to be of non- childbearing 
potenti al and 2)only men m ay be enrolled who use a neffect ivemethod of contraception , or who 
are sterile (including co nfirmed vasectomy) and do not donate sperm (Section 6.1).
For female patients, non -childbearing potential (by [CONTACT_73534]) is define d as any  
one of the fo llowing:
≥45 y ears of age and has not had menses for greater than 2 y ears
Amenorrheic for < 2 y ears wi thout a hysterectomy and oophorectomy  and a
follicle -stimulat ing horm one(FSH) val ue in the postm enopausal range upon pretrial 
(screening) evaluat ion(FSH l evel >40 m IU/mL)
At least [ADDRESS_1179615] be confirmed with medical records of the actual procedure; otherwise, the 
patient m ust be willing to use an adequate barrier method throughout the s tudy, starting 
with the screening visit through [ADDRESS_1179616] dose of study  treatm ent.
Patients shoul d be informed that taking the study  medicat ion may involve unknown risks to the 
fetus (unborn baby ) if pregnancy were to occur during the study .  If there i s any quest ion that a 
patient will not reliably  com ply wi th the requi rements for contraception, that patient should not 
be entered into the study .
6.4. Screen Failures
Individuals who donotmeet thecriteria forparticipation inthisstudy (screen failure) may be
re-screened, only after di scussio n with and permissio n from theLilly clinical research physician 
(CRP ).
Repeat ing laboratory  tests during the screening period does not constitute 
re-screening. Screening laboratory  tests m ay not be repeated more than twice in order to meet 
eligibilit y during the screening period.
I4T-MC-JVDL( c) Clinical Protocol Page 42
LY3009806 ; LY30122117.Treatments
7.1. Treatments Administered
Ramucirumab or neci tumumab, and osimertinib will be administered per  Table JVDL .6.
For the Dose -Finding Portion, t he DLT observat ion peri od is for up to 2treatm ent cy clesfor 
Arm A (4 weeks) and 1 treatm ent cy cle for Arm  B (3 weeks) .
For the Dose -Expansio n Porti on, each pat ient will be treated until confirmed objective PD(see 
Secti on9.1.3 ), unacceptable toxicit y, or discont inuation for any other reason.
Across all study  periods, including the continued access period (Secti on7.8.1 ), pati ents will  be 
treated with ramucirumab or necitumumab and/or osimert inibuntil confirmed PD, unacceptable 
toxicity, or di scont inuat ion for any  other reason .
Table JVDL .6. Dose Finding Portion Treatment Regimens/ Dosing Schedule
Study Drug Dose Route Timing
Ramucirumaba Level 0: 10mg/kg
Level -1: 8 mg/kgI.V.Over 60 minutes infusion Day 1 of 
each 2 -week cycle
ARM A1-hour observation 
periodb
Osimertinibc80 mg PO Daily
OR
Necitumumabd Level 0: 800 mg
Level -1: 600 mgI.V.Over 60 minutes infusion Day s 1 and 
8 of each 3-week cycle
ARM B1-hour observation 
periode
Osimertinibc80 mg PO Daily
I4T-MC-JVDL( c) Clinical Protocol Page 43
LY3009806 ; LY3012211Abbreviations:  IRR = infusion -related reaction; I.V. = intravenous; PO = orally.
aPremedication is required prior to infusion of ramucirumab.  Recommended premedication agents include 
histamine H1 antagonists such as diphenhydramine hydrochloride (or equivalent).  Addit ional premedication 
may be provided at the investigator’s discretion.  Premedication must be provided in the setting of a prior 
Grade 1-[ADDRESS_1179617] and second doses of ramucirumab.  If 
there is no evidence of an IRR during the initial 2 infusions of ramucirumab, then no observation period is 
required for subsequent treatment cycles.  In the event an IRR occurs thereafter, then the 1- hour observation 
period should be reinstituted.   Refer to Section [IP_ADDRESS] for further i nstructio ns in detail.
cRefer to Section 7.4.3 for further instructions on taking osimertinib .
dPrior to necitumumab infusion, consider premedication for possible skin reactions.  Preemptive treatment with 
skin moisturizers, topi[INVESTIGATOR_8826], doxycycline, or sunscreen may be administered as clinically appropriate to 
patients receiving necitumumab .  For additional information regarding pree mptive management of skin toxicity, 
see Canadian recommendations (Melosky et al. 2009).
eMonitor patients from the start of the infusion until at least 1 hour after the end of the infusion in an area with 
resuscitation equipment and other agents (for exam ple, epi[INVESTIGATOR_848396]) available.   Refer 
to Section [IP_ADDRESS] for further instructions in detail.
The invest igator or his/her designee is responsible for the fo llowing:
explaining the correct use of the drug s and planned duration of each individual’s 
treatm entto the si tepersonnel
verifying that instructions are fo llowed properly
maintaining accurate and appropriate records ,including those of invest igational 
product dispensing and collection
ensure appropriate supply, storage, handling, distribut ion,and usage of trial 
treatm ents in accordance with the protocol and any applicable laws and 
regul ations
at the end of the study ,returning all unused medication to Lilly or its designee
Note : In some cases, sites may destroy  the m aterial  if, during the invest igator site select ion, the 
evaluator has verified and documented that the site has appropriate facilit ies and wri tten 
procedures to dispose clinical trial materials.
Patients will  be instructed to contact [CONTACT_240220] a com plaint 
or probl em with the investigational products so that the situation can be assessed.
7.1.1. Packaging and Labelling
All inves tigational product materials will  be provided by  [CONTACT_11007].  Clinical tri al materials will be 
labeled according to the coun try’s regulatory  requirem ents.  Ram ucirumab and necitumumab 
vials should be stored under refrigeration at 2°C to 8°C (36°F to 46°F).   Osi mertinib tablets in 
bottlesshoul d be stored at 25°C (77°F).  Excursions permitted to 15 °C to 30°C (59 °F to 86°F ).
I4T-MC-JVDL( c) Clinical Protocol Page 44
LY3009806 ; LY30122117.2. Method of Treatment Assignment
Patients m eeting all inclusio n/exclusio n criteria will be enrolled to study regimen .  Study  drug 
will be allocated to pati ents using an interact ive web -response system (IWRS) , which is 
web-based and accessible 24 hours a day .  The IWRS registration consists of assigning the 
patient a uni que study  identificat ion number for all patients.
7.2.1. Selection and Timing of Doses
A cycle is defined as an interval of 14days for Arm A /Cohort A and 21 day s for Arm  B.  A 
delay of a cycle due to holiday , weekend, bad weather, or other unforeseen circumstances will be 
permitted for a maximum of 3days and not counted as a protoco l deviati on.
The actual  doses of ram ucirumab administered will be determined by [CONTACT_95850]'s 
weight at the beginning of each cycle.  If the patient’s weight fluctuates by  [CONTACT_726] 10% fro m 
the wei ght used to cal culate the pri or dose, the dose must be recalculated.  Recalculat ion of the 
ramucirumab dose for wei ght fluctuati ons of  <10% i s permi tted but not requi red.
Ramucirumab will be administered , over 60 -minute I .V.infusio n.  The maximum ramucirumab 
infusio n rate i s 25 m g/min.
Necitumumab will be administered, over 60-minute I .V.infusio n, at a fixed dose.
Osimert inib will be taken by [CONTACT_848438] a day, at a fixed dose.  If a dose of osimertinib 
is missed, the missed dose should not be made up and the next dose should betakenas 
scheduled.   For a dministration to patients who have difficult y swallowing so lids, refer to 
osimert inib USPI [INVESTIGATOR_848397] .
A pat ient may cont inue to receive ramucirumab or necitumumab in combinat ion with osimert inib
at the assigned dose level until he or she m eets 1 or more of the specified reasons for 
discontinuat ion (as described in Sect ion  8).
[IP_ADDRESS]. Dose -Limiting Toxicity Observation
A 3+3 dose de-escalat iondesign will be used to assess the safet y of ramucirumab (Arm  A)or 
necitumumab (Arm  B)given in co mbinat ion with a fixed dose of osimertinib at 80 mg daily 
(QD). Eligible pat ients will be enroll ed into ei ther of the 2treatm ent arm s. If there is a DLT, a 
forced enrollment will be applied to push new pat ients towards that arm unt il the Dose -Finding 
Porti onis co mplete.  DLT observat ion peri od will  last for 2 cycles (4 weeks) for Arm  A and 
1cycle (3 weeks) for Arm B in this portion of th e study .  The following criteria will be used to 
determine the progress of the study :
Arm A -Ramucirumab and osimertinib 3+3 de-escalation design:
1)If none of the 3 DLT -evaluable patients treated at 10 mg/kg (Dose Level  0) of 
ramucirumab on Day  1 Q2W in combinat ion with 80 m g of osimert inibQD devel ops a 
DLT, the study  will open the Dose -Expansio n Portio nat Dose Level 0 .
I4T-MC-JVDL( c) Clinical Protocol Page 45
LY3009806 ; LY30122112)If [ADDRESS_1179618] 3 DLT -evaluable patients develops a DLT, 3 addit ional pat ients will be 
added to Dose L evel 0.  If ≤1 of 6 DLT -evaluable patients develops a DLT, the 
Dose -Expansion portion will start at Dose Level 0 .
3)If ≥2 of 6 DLT -evaluable patients develop a DLT, 3 eligible subjects will be enrolled and 
treated at 8 mg/kg (Dose Level -1) of ramucirumab onDay 1 Q2W in co mbinat ion with 
80 m g of osimert inibQD.
4)Similarly, if none of the 3 DLT -evaluable pat ients develops a DLT, the study  will open 
the Dose -Expansio n porti on at Dose Level -1.
5)If [ADDRESS_1179619] 3 DLT -evaluable patients at Dose Level -1 develops a DLT, 3 additional 
patients will  be added. If ≤1 of 6 DLT -evaluable patients develops a DLT, the 
Dose -Expansion portion will start at Dose Level -1.
6)If ≥[ADDRESS_1179620] udy 
will stop.
Arm B -Necitumumab and osimertinib 3+3 de-escalation design:
1)If none of the 3 DLT -evaluable patients treated at 800 mg (Dose Level 0) of 
necitumumab on Day s 1 and 8 Q3 W in combinat ion with 80 mg of  osimert inibQD 
develops a DLT, the study  will open the Dose -Expansio n porti onat Dose Level 0.
2)If [ADDRESS_1179621] 3 DLT -evaluable patients develops a DLT, 3 addit ional pat ients will be 
added to Dose Level 0.  If ≤1 of 6 DLT -evaluable patients develops a DLT, the 
Dose -Expansion portion will start at Dose Level 0 .
3)If ≥2 of 6 DLT -evaluable pati ents devel op a DLT, 3eligible subjects will be enrolled and 
treated at 600 mg (Dose Level -1) of necitumumab on Day s 1 and 8 Q3 Win combinat ion 
with 80 mg of  osimertinib QD.
4)Similarly, if none of the 3 DLT -evaluable pat ients develops a DLT, the study  will open 
the Dose -Expansio n porti on at Dose Level -1.
5)If [ADDRESS_1179622] 3 DLT -evaluable patients in Dose Level -1 devel ops a DLT, 3 addi tional 
patients will  be added. If ≤1 of 6 DLT -evaluable patients develops a DLT, the 
Dose -Expansion portion will start at Dose Level -1.
6)If ≥2 of 6 DLT -evaluable pati ents in Dose Level -1 devel op a DLT, Arm Bof the study  
will stop.
No intrapatientdose escalat ion is allowed.  Patients who wi thdraw from  the study  during the 
DLT observat ion period for reasons other than a treatment- related toxi city may be replac ed 
within the same dose level.
Ramucirumab or neci tumumab in co mbinat ion with osimertinib may cont inue at the assigned 
dose l evel unt il there is a radiographic documentation of PD, toxicit y requiring cessat ion, 
protocol  nonco mpliance,or wi thdrawal  of consent.
I4T-MC-JVDL( c) Clinical Protocol Page 46
LY3009806 ; LY3012211For each arm , if dropouts, dose interruptions, or reductions occur that result in a patient being 
nonevaluable for DLTs, a dditional pat ients will be enro lled to achieve the minimum o f 
3evaluable patients.  The need for patient replacement will be determined based on consultation 
with the invest igator and Lilly CRP/clin ical research scient ist (CRS).
[IP_ADDRESS].1. Definition of Dose -Limitin g Toxicities
A DLT is defined as one of the fo llowing AEs reported during the DLT observat ion peri od, if 
considered to be definitely , probably, or possibly related to ramucirumab, necitumumab, and/or 
osimert inibby [CONTACT_3170]; and fulfills an y one of the following cri teriausing NCI CTCAE 
Versi on4.0:
1. Any n onhematol ogic toxi city Grade ≥3 will be considered as DLT with the fo llowing 
exceptions :
a) Liver funct ion abnormalit y:  Grade ≥3 elevation in aminotransferase (AST) or alanine 
aminotransferase (ALT) that persi sts for lessthan [ADDRESS_1179623] or ALT, either one of the level ≥10x 
upper limit of normal ( ULN )lasting for ≥7 days will be considered a DLT .
b) Renal funct ion abnormalit y:  Grade ≥[ADDRESS_1179624] elevat ion that persists for 
lessthan 7 day s
c) Skin rash: Grade 3 rash that resolves to Grade ≤2 within 14 days with appropriate 
supportive th erapy
d) The fo llowing are not considered a DLT if they are transient (<7 day s) and, after 
treatm ent, decrease to Grade 2 or lower:
Grade ≥[ADDRESS_1179625] ion site reactions
Grade ≥3 mya lgia, fat igue, and constipatio n, wi th full supportive therapy
Grade ≥3 el ectroly te imbalance, nausea, vo miting, and diarrhea
2. Hem atologic toxici tywill be consi dered a DLT as the following :
a)Grade 4 toxicit y lasting ≥7 days, or
b) Grade 3 or 4 thrombocy topenia if associated with bleeding or requires platelet 
transfusio n, or
c)Febrileneutropeni a
3. Grade 5 toxicity (that is, death) if considered related to study  treatm ent
4. Any other significant toxicit y deemed by  [CONTACT_702379], for example:
a) Any toxicit y (such as confirmed ILD/pneumo nitis) that is possibly related to study  
treatm ent that requires the withdrawal o f the pati ent from the study  during observat ion 
period, or
b) A delay of >14 days due to persistent Grade ≥2 treatm ent-related toxicities in the 
initial 2 cycles , or
I4T-MC-JVDL( c) Clinical Protocol Page 47
LY3009806 ; LY3012211c) Ifa total  at least 75% of the planned dose for eitheragent cannot be administered in the 
first2cycle sdue to toxi city
Unless determined at the DLT review meeting to init iate Dose Levels -1, no i ntrasubject dose 
escalat ion or redu ction is allowed during the DLT observat ionperiod.  For the purpose of subject 
management, DLTs will lead to dose interruption during the DLT observat ion peri od.  
Depending on the AE profile, dose modificat ions of study drugs will be permitted after the i nitial 
DLT observat ion peri od.
Addit ional subjects will be enro lled in a cohort to achieve the min imum of [ADDRESS_1179626] 75% of the cohort -specified dose of study treatment. In addition, subjects with dosing 
delays in Cycle 1 of ≥2 weeks for non -DLT events will be considered not evaluable for making 
decisio ns and should be replaced.
After each of the 3 patients in a dose schedule co mpletes the observat ion peri od, a safet y analysis 
will occur; the data will be reviewed by  [CONTACT_848439]/CRS, and the 
findings documented, indicat ing whether each dose schedule is or is not wel l tolerated.  The 
resul ts will  inform the decisi on whether or not to mo ve onto the Dose -Expansio n porti on.
7.3. Blinding
This is an open -label study .
7.4. Dosage Modification
Doses of study  drugs m ay need to be de layed, reduced, or di scont inued to manage specific AE s 
or other toxicit ies.
7.4.1. Ramucirumab Dose Adjustments, Delays, and Discontinuation
The ram ucirumab dose may need to be delayed and/or reduced if the patient experiences an AE, 
including an adverse event of special interest (AESI) ( Secti on9.2.1 ).  Doses may be delayed to 
allow time for the patient to recover fro m the event.  Certain AEs require immediate and 
perm anent discont inuat ionof study  treatm ent(see Table JVDL. 8).  If administration of 
ramucirumab is delayed for more than 4 weeks (2 cycles) after Day  [ADDRESS_1179627] recent 
treatment cycle, the patient should be discont inued fro m ramucirumab treatm ent.  Any pat ient 
who requires a dose reduction will continue to receive a reduced dose until discont inuat ion from 
ramucirumab or di scontinuati on from the study .  Any patients requiri ng dose reduction to less 
than 6 mg/kg of ram ucirumab will have ramucirumab discont inued.  Such patients may cont inue 
with osimertinib as a single agent.
Table JVDL. 7presents the ramucirumab dose reductions for each treatment cohort.
I4T-MC-JVDL( c) Clinical Protocol Page 48
LY3009806 ; LY3012211Table JVDL. 8prese nts the criteria for dose modifications and dose discont inuat ions applicable if 
the pati ent experi ences a ram ucirumab AESI or other AEs at least possibly related to 
ramucirumab. Dose re -escalat ion for ram ucirumab is not permitted.
Table JVDL. 7. Ramucirumab Dose Reductionsa
Dose Schedule 1:
(14-day Cycle)Dose Schedule 2 :
(14-day Cycle)
Recommended Dose for Expansion Cohort 8 mg/kg
on D ay 110 mg/kg
on Day  [ADDRESS_1179628] dose reduction 6 mg/kg
on Day  18 mg/kg
on Day  1
Second dose reduction Not allowed 6 mg/kg
on Day  1
aRamucirumab dose reductions are allowed between cycles and within a given cycle.
I4T-MC-JVDL (c)Clinical Protocol Page 49
LY3009806 ; LY3012211Table JVDL. 8. Dose -Modification Guidelines for Ramucirumab for A dverse Events at Least Possibly Related to 
Ramucirumab, including Adverse Events of Special Interest
Adverse Event
NOTE: All Specific Adverse Events Listed 
are defined as AESIs in Section 9.2.1 ).CTCAE 
GradeDose -Modification Guidelines
NOTES: 
Dose reductions to occur as defined in Table JVDL. 7.
Treating physicians can modify or discontinue ramucirumab more conservatively than 
in the guidance below.
1. Infusion -related reaction
1.a. Infusion -related reaction 2 Interrupt and reduce the infusion rate by 50% for the duration of the infusion and for all 
future infusions.
Prior to all future infusions of ramucirumab, premedicate with:
an intravenous histamine H1 antagonist, such as diphenhydramine hydrochloride
dexamethasone or equivalent
acetaminophen/paracetamol
1.b. Infusion -related reaction 3-4 Immediately and permanently discontinue ramucirumab
2. Hypertension
2.a. Hypertension (non -life-threatening and 
associated with symptoms)
NOTE:  Hypertension should be monitored 
prior to each ramucirumab infusion.3Delay ramucirumab until the hypertension is controlled with medication and is 
resolved to Grade 0-2.
oIf controlled with medication and resolved to Grade 0 -2, then may resume 
ramucirumab at current dose.
oIf NOT controlled with medication and not resolved to Grade 0 -2 within a 
reasonable timeframe, discontinue ramucirumab at investigator’s discretion.
2.b. Uncontrolled hypertension, hypertensive 
crisis, o r hypertensive encephalopathy4 Immediately and permanently discontinue ramucirumab.
I4T-MC-JVDL (c)Clinical Protocol Page 50
LY3009806 ; LY3012211Dose -Modification Guidelines for Ramucirumab for Adverse Events at least Possibly Related to Ramucirumab, including Adverse Events of Special 
Interest (continued)
Adverse Event
NOTE: All Specific Adverse Events Listed are 
defined as AESIs in Section 9.2.1 ).CTCAE 
GradeDose -Modification Guidelines
NOTE:  Dose reductions to occur as defined in Table JVDL. 7.
3. Proteinuria
3.a. Proteinuria = 2+ (dipstick or routine urinalysis) a Administer ramucirumab at the current dose if clinically indicated.
Obtain 24 -hour urine protein results within 3 days prior to the next ramucirumab 
dose.
oIf urine protein is <2 g/24 h, administer ramucirumab at the patient's current 
dose.
oIf urine protein is 2 g/24 h, modify the ramucirumab dose based on 24 -hour 
collection.  See Proteinuria 2g/24 h (24 -hour urine collection) , Line 3.c in 
this table.
3.b. Proteinuria >2+ (dipstick or routine urinalysis) a Delay ramucirumab until urine protein returns to <2 g/24 h.
Obtain 24 -hour urine protein results within 3 days prior to the next ramucirumab 
dose.
oIf urine protein is <2 g/24 h, no further dose delay or dose reduction is 
required.
oIf urine protein remains 2 g/24 h and is not resolved within a reasonable 
timeframe, discontinue ramucirumab at investigator’s discretion.
3.c. Proteinuria 2 g/24 h (24 -hour urine collection) a First or second occurrence :  delay ramucirumab until urine protein returns to 
<2 g/24 h.
oIf urine protein returns to <2 g/24 h, reduce ramucirumab dose.
oIf urine protein remains 2g/24 h and is not resolved within a reasonable 
timeframe, discontinue ramucirumab at investigator’s discretion.
Third occurrence :  discontinue ramucirumab.
3.d. Proteinuria >3 g/24 h orin the setting of nephrotic 
syndrome aImmediately and permanently discontinue ramucirumab.
4. Arterial thromboembolic events, venous 
thromboembolic events3 or 4 Immediately and permanently discontinue ramucirumab.
5. Bleeding/hemorrhage 3 or 4 Immediately and permanently discontinue ramucirumab.
6. Gastrointestinal perforation Immediately and permanently discontinue ramucirumab.
I4T-MC-JVDL (c)Clinical Protocol Page 51
LY3009806 ; LY3012211Adverse Event
NOTE: All Specific Adverse Events Listed are 
defined as AESIs in Section 9.2.1 ).CTCAE 
GradeDose -Modification Guidelines
NOTE:  Dose reductions to occur as defined in Table JVDL. 7.
7. Reversible posterior leukoencephalopathy 
syndromeImmediately and permanently discontinue ramucirumab.
8. Congestive heart failure 3-4 Immediately and permanently discontinue ramucirumab.
9. Fistula formation Immediately and permanently discontinue ramucirumab.
10. Impaired wound healing
10.a. Prior to planned surgery Withhold ramucirumab.
10.b After surgery Resume ramucirumab based on clinical judgment.
10.c. Wound -healing complications developed during 
study treatmentDelay ramucirumab dosing until the wound is fully healed.
11. Liver injury/liver failure
11.a. Hepatic encephalopathy and/or hepatorenal 
syndrome resulting from liver cirrhosisImmediately and permanently discontinue ramucirumab.
[ADDRESS_1179629] possibly 
related to ramucirumabb
13.a Non-life threatening and reversible 3 May delay  ramucirumab until resolved to Grade 0 -1.
If resolved to Grade 0 -1, may reduce ramucirumab dose.
If NOT resolved to Grade 0 -1 within a reasonable timeframe, discontinue 
ramucirumab at investigator’s discretion .
13.b Adverse Event 4 Permanently discontinue treatment immediately, with the exception of Grade 4 fever 
or Grade 4 laboratory abnormality, in which case:
First occurrence:   Delay ramucirumab until resolved to Grade 0 -1.
oIf resolved to Grade 0 -1, may resume ramucirumab original dose at the 
discretio n of the investigator.
oIf NOT resolved to Grade 0 -1 within a reasonable timeframe, discontinue 
ramucirumab at investigator’s discretion.
Second occurrence:  Delay ramucirumab until resolved to Grade 0 -1.
oIf resolve d to Grade 0 -1, reduce ramucirumab dose.
oIf NOT resolved to Grade 0 -1 within a reasonable timeframe, discontinue 
ramucirumab at investigator’s discretion.
I4T-MC-JVDL (c)Clinical Protocol Page 52
LY3009806 ; LY3012211Dose -Modification Guidelines for Ramucirumab for Adverse Events at least Possibly Related to Ramucirumab, including Adverse Events of Special 
Interest (concluded)
Abbreviations:  AESI = adverse event of special interest; CTCAE = Common Terminology Criteria for Adverse Events; NCI = Natio nal Cancer Institute.
aPerform urinalysis within [ADDRESS_1179630] dose delays or reductions related to the persistence or mild worsening of those symptoms or laboratory values.  Grade 2 toxicities which represent 
clinically significant worsening of sympto ms from baseline, ramucirumab dose may be delayed at the discretion of the investigator.  If the toxicity is resolved 
to Grade 0-1, then reduce ramucirumab dose.  If the toxicity is not resolved to Grade 0 -1, then discontinue ramucirumab.
I4T-MC-JVDL( c) Clinical Protocol Page 53
LY3009806 ; LY30122117.4.2. Necitumumab Dose Adjustments, Delays, and Discontinuation
Prior to each administration of necitumumab, all toxicit ies associated with necitumumab must 
have reso lved to Grade ≤2 (except for alopecia and skin toxicity) or baseline.  Pretreatment 
laboratory  data m ay not be ol der than 72 hours (Day 1 of each cycle) or 24 hours (Day  8 of each 
cycle).
If the criteria are not met at the time of a planned treatment, the fo llowing general  rules for the 
management of t reatment delays apply:
In the case of reversible Grade 3-4 necitumumab -related toxi city, administrati on 
of neci tumumab will  be at the reduced dose or interrupted, but osimert inib will 
continue according to the planned schedule.
If administration of necitumumab is delayed for more than 6 weeks (2 cycles) 
after Day  [ADDRESS_1179631] recent treatment cy cle, the pati ent shoul d be di scontinued 
from necitumumab treatment.
The fo llowing are general dose -modificat ion gui delines for toxici ty associ ated wi th 
necitumumab.  Please see Section s7.7.1.1 and [IP_ADDRESS] for specific informat ion on the 
management of necitumumab -related hy persensi tivity/ infusio n-related reactions ( IRRs ), skin 
reacti ons, conjunctivit is, hypomagnesemia , and thromboembolic events .
For pati ents starting at necitumumab 600 mg on Days 1 and 8 , one dose reduction is permitted.  
Patients who cannot tolerate necitumumab 400 mg shoul d discont inue necitumumab; such 
patients m ay cont inue with osimertinib as a single agent.
For pati ents starting at dose level 800 mg on Days 1 and 8 , 2dose reductions are allowed 
following reversible CTCAE Grade ≥[ADDRESS_1179632] recent treatment cy cle, unless DLT criteria are met.  In 
this setting, necitumu mab may be re -administered at a reduced dose (600 mg) if necessary  only  if 
AE is reso lved to Grade ≤2.  A second dose reductio n is permitted f or thi s level  of event 
(Grade ≥3).  Necitumumab must be discont inued if further dose reduction is required beyond 
400mg on Days 1 and 8 Q3 W.  The patient may continue to receive osimertinib as a single 
agent.
Necitumumab dose adj ustments are allowed both within a cycle and between cycles.
Necitumumab may  be held up to 6 weeks (2 cy cles) from Day [ADDRESS_1179633] recent treatm ent 
cycle to permi t sufficient tim e for recovery  from the toxici ty.  If a dose del ay occurs, the 
investigator may  resume necitumumab dosing at the same dose level for the remainder of the 
study  or at reduced dose (assuming resolution to at least Grade [ADDRESS_1179634] 
Grade 2 for hematologic toxicit y).  If the patient experiences the same toxicit y with the same or 
greater severit y (CTCAE grade) requiring a dose delay within a cycle or at start of the next cycle, 
the pati ent m ust be do se reduced and not re -challenged a second time at the prior dose level.
If a patient experiences CTCAE Grade ≥[ADDRESS_1179635] be delayed (until the toxicit y reso lves to e ither 
I4T-MC-JVDL( c) Clinical Protocol Page 54
LY3009806 ; LY3012211baseline or at least Grade 2) and the dose of necitumumab must be reduced by  1dose l evel (see 
below).
If a patient experiences CTCAE Grade ≥[ADDRESS_1179636] be d elayed (unt il the toxicit y 
resolves to either baseline or at least Grade 1) and the dose of necitumumab must be reduced by  
1dose l evel (see bel ow).
For pati ents requi ring dose reduction(s), any  re-escal ation to a prior dose level is permitted only 
after consul tation wi th the Lilly CRP.  After re -escalat ion, subsequent dose adjust ments should 
be based on the dose of necitumumab that the patient is current ly receiving.  Following a dose 
reducti on, the dose of necitumumab may be re -escal ated to th e pre -reduction dose, provided that 
at least 2 administrations o f the reduced dose were given, and only  after consul tation wi th the 
Lilly CRP .
Table JVDL. 9presents the necitumumab dose reducti ons.
Table JVDL. 9. Dose Adjustments of Necitumumab
Dose Adjustment Level I.V. Dose Frequency
0 800 mg Days 1 and 8 Q3 W
-1 600 mg Days 1 and 8 Q3W
-2 400 mg Days 1 and 8 Q3W
Abbreviations:  I.V . = intravenous; Q3W = ever y 3weeks.
Events that necessitate more than [ADDRESS_1179637] dose reductions related to the persistence or 
mild worsening (for example, fro m Grade 1 to Grade 2) of those symptoms or laboratory  values.
In the event of alterations of necitumumab therapy due to a necitumumab -related toxicity, 
osimert inibneed not be altered, and the planned osimertinib schedule shoul d be maintained.  
Similarly, necitumumab therapy  should not be del ayed for osimertinib -related toxi cities.
7.4.3. Osimertinib Dose Adjustments, Delays, and Discontinuation
Patients receiving ramucirumab or necitumumab plus osimert inibcan have the osimertinib dose 
reduced if the toxicit y is specifically attributable to osimertinib at the di scret ion of the 
investigator.  Patients may cont inue treatment with ramucirumab or neci tumumab if they are 
discontinued fro m osimertinib.  Dose re -escalation for osimertinib is not permitted.
Patients shoul d be treated following the recommendatio ns, warnings ,and precautions given for 
osimert inib.
Table JVDL. 10shows the dose -modification criteria and guidelines for management of commo n 
osimer tinib toxicit ies.
I4T-MC-JVDL( c) Clinical Protocol Page 55
LY3009806 ; LY3012211Table JVDL. 10. Recommended Dose Modifications for Osimertinib
Target Organ Adverse Reaction a Dose Modification
Pulmonary Interstitial lung disease 
(ILD)/PneumonitisPermanently discontinue osimertinib .
Cardiac QTc interval greater than [ADDRESS_1179638] 2 separate ECGsWithhold osimertinib until QTc interval is 
less than 481 msec or recover y to baseline 
if baseline QTc is greater than or equal to 
481 msec, then resume at 40-mg dose.
QTc interval prolongation with 
signs/symptoms of life threatening 
arrhy thmiaPermanently discontinue osimertinib .
Asymptomatic, absolute decrease in 
LVEF of 10% from baseline and 
below 50%Withhold osimertinib for up to 4 weeks.
• If imp roved to baseline LVEF, resume.
• If not improved to baseline, permanently 
discontinue.
Symptomatic congestive heart 
failurePermanently discontinue osimertinib.
Other Grade 3 or higher adverse reaction Withhold osimertinib for up to 3 weeks.
If improvement to Grade 0 -2 within 
3 weeksOsimertinib may be restarted at the same 
dose (80 mg) or a lower dose (40 mg) .
If no improvement within 3 weeks Permanently discontinue osimertinib.
Abbreviations:  ECGs = electrocardiograms; LVEF = left ventricular ejection fractio n; QTc = QT interval corrected 
for heart rate .
aAdverse reactions graded by [CONTACT_29630] -Common Terminology Criteria for Adverse Events 
version 4.0 (NCI CTCAE v4.0 ).
7.4.4. Dose Delays for Reasons Not Related to Study Treatment
Dosing interruptions o fanystudy  drug are also permitted for reasons not related to study  
treatm ent (f or exam ple, el ective surgery, unrelated medical events, patient vacat ion, and/or 
holidays).
Patients shoul d resume the del ayed study  drug(s) wi thin 4 weeks for ram ucirumab and 6 weeks 
for necitumumab of the scheduled interruption, with every  effort made to start on Day  1 of the 
next dosing schedule, unless otherwise discussed with the Sponsor.  If a dose of osimert inib is 
missed, the patient should not make up for the missed dos eand should t ake the next dose at the 
regul ar time.  The reason for interruption should be documented on the case report form (CRF).
7.5. Preparation/Handling/Storage/Accountability
Refer to the respective IBs for detailed informat ion about preparation, handling, and storage of 
ramucirumab ,necitumumab ,and osimertinib.
7.6. Treatment Compliance
Ramucirumab and neci tumumab will be administered only at the invest igational sit es by [CONTACT_92346].  As a result, treatment compliance is ensured.
I4T-MC-JVDL( c) Clinical Protocol Page 56
LY3009806 ; LY3012211Patient com pliance wi th osimertinib will be assessed at each visit.  Compliance will be assessed 
by [CONTACT_81257], review of diary ,and count ing returned tablets.  Deviat ions from the 
prescribed dosage regimen should be recorded in the CRF.
A pat ient will be considered significant ly nonco mpliant if he or she misse d4 or more 
consecut ive dosesof osimertinib in a visit interval, or took <70% or >130% amount of expected 
study  drug in a visit interval during the study .  A pati ent will also be considered sig nificantly 
nonco mpliant if he or she is judged by  [CONTACT_487091].
Patients who are not evaluable for pharmacokinet ics, but who complete [ADDRESS_1179639] igator(s) and the Lilly CRP/CRS to ensure adequate 
PK data, unl ess accrual to that cohort has stopped due to a DLT.
7.7. Concomitant Therapy
A list of restricted and excluded conco mitant therapi [INVESTIGATOR_848398] [ADDRESS_1179640] data for 
special mo nitoring and, when necessary , supportive care.  For ramucirumab and necitumumab, 
these are referred to as AESI .
[IP_ADDRESS]. Infusion -Related Reactions -Ramucirumab and Necitumumab
IRRs have been i dentified as events of interest for both ramucirumab and necitumumab.  In the 
event of an IRR, blood samples will be co llected for PK and immunogenicit y analysis for 
ramucirumab and necitumuma b, respectively, at the fo llowing time points:  (i ) as cl ose as 
possible to the onset of the IRR, (ii) at the resolut ion of the IRR, and (iii) 30 days fo llowing the 
IRR.
IRRs m ay occur during or following ramucirumab or necitumumab administration.  Patient s 
shoul d be cl osely m onitored f or signs and symptoms indicat ive of an IRR from the init iation of 
the infusion in an area where resuscitat ion equipment and other agents (such as epi[INVESTIGATOR_848399]) are readily  available.
Signs and symptom s usua lly devel op during or shortly  after infusi on and generally resolve 
within 24 hours.  Symptoms of IRRs include rigors/tremors, back pain/spasms, chest pain and/or 
tightness, chills, flushing, dy spnea, wheezing, hypoxia, and paresthesia.  In severe cases, 
symptoms include bronchospasm, supraventricular tachycardia, and hypotensio n.
[IP_ADDRESS].1. Infusion -Related Reactions -Ramucirumab
Table JVDL. 8presents ram ucirumab dose m odificati on for patients who experience an IRR 
associ ated wi th ramucirumab.
I4T-MC-JVDL( c) Clinical Protocol Page 57
LY3009806 ; LY3012211Patients m ust be cl osely  monitored f or a [ADDRESS_1179641] 2 ramucirumab infusio ns, m easure blo od pressure and pulse at the fo llowing time 
points:  (i ) within 15 minutes prior to the infusio n, (ii) after comple tion of  the infusio n, and 
(iii)at the end of the [ADDRESS_1179642] -infus ion observatio n peri od.  F or all  subsequent infusio ns of 
ramucirumab, measure bl ood pressure and pul se prior to the infusio n.  Measure other vital signs 
as clinically indicated.
[IP_ADDRESS].2. Infusion -Related Reactions -Necitumumab
Hypersensi tivity/IRR s were reported with necitumumab.  The onset of events usually  occurred 
after the first or second administration of necitumumab.  Moni tor pati ents cl osely  for any  
potenti al adverse effects from  the start of the infusion until at least 1 hour after the end of the 
infusio n in an area with resuscitat ion equipment and other agents (for example, epi[INVESTIGATOR_848400]) available.
Table JVDL. 11provi des general  treatm ent recommendat ions for hypersensit ivity/IRRs to 
necitumumab. 
I4T-MC-JVDL( c) Clinical Protocol Page 58
LY3009806 ; LY3012211Table JVDL. 11. Necitumumab Infusion- Related Reaction Treatment Guidelines
Grade 
of 
ReactionManagement Recommendations
First Occurrence Second Occurrence
1  Decrease infusion rate by 50% for the duration of 
the infusion, and monitor patient for worsening of 
condition.a
 For all subsequent infusions, premedicate with 
diphenhydramine hydrochloride 50 mg I.V. (or 
equivalent); additional premedication may be 
administered at the investigator’s discretion. Decrease infusion rate by 50% for the duration of 
the infusion, and monitor patient for worsening of 
condition.a
 Administer dexamethasone 10 mg I.V. (or 
equivalent).
 For all subsequent infusions, premedicate with 
diphenhydramine hydrochloride 50 mg I.V. (or 
equivalent), acetaminophen 650 mg orally (or 
equivalent), and dexamethasone 10 mg I.V. (or 
equivalent); additional premedication may be 
administered at the investigator’s discretion.
2  Stop the infusion, and resume the infusion when the 
infusion reaction has resolved to ≤Grade 1; 
decrease infusion rate by 50% when the infusion 
resumes.a
 Monitor patient for worsening of condition.
 If necessary, administer diphenhydramine 
hydrochloride 50 mg I.V. (or equivalent), 
acetaminophen 650 mg orally for fever, and 
oxygen.
 For all subsequent infusions, premedicate with 
diphenhydramine hydrochloride 50 mg I.V. (or 
equivalent); additional premedication may be 
administered at the investigator’s disc retion. Stop the infusion, and resume the infusion when 
the infusion reaction has resolved to ≤ Grade 1; 
decrease infusion rate by 50% when the infusion 
resumes.a
 Administer dexamethasone 10 mg I.V. (or 
equivalent).
 Monitor patient for worsening of condition.
 If necessary, administer diphenhydramine 
hydrochloride 50 mg I.V. (or equivalent), 
acetaminophen 650 mg orally for fever, and 
oxygen.
 For all subsequent infusions, premedicate with 
diphenhydramine hydrochloride 50 mg I.V. (or 
equivalent), acetam inophen 650 mg orally (or 
equivalent), and dexamethasone 10 mg I.V. (or 
equivalent); additional premedication may be 
administered at the investigator’s discretion.
3-4  Stop the infusion and disconnect the infusion tubing 
from the patient.
 Administer diphe nhydramine hydrochloride 50 mg 
I.V. (or equivalent), dexamethasone 10 mg I.V. (or 
equivalent), bronchodilators for bronchospasm, 
epi[INVESTIGATOR_238], and other medications / treatments as 
medically indicated.
 Hospi[INVESTIGATOR_328433].
 Permanently discon tinue necitumumab.N/A
Abbreviations:  IRRs = infusion -related reactions; I.V. = intravenously; N/A = not applicable.
aOnce the infusion rate has been reduced for a Grade 1 or 2 hypersensitivity/IRRs, it is recommended that the 
lower infusion rate be utilized for all subsequent infusions.  The infusion duration should not exceed 2 hours .
I4T-MC-JVDL( c) Clinical Protocol Page 59
LY3009806 ; LY30122117.7.1.2. Supportive Care for Ramucirumab
[IP_ADDRESS].1. Supportive Care by [CONTACT_702368]
[IP_ADDRESS].1.1. Hypertension
An increased incidence of severe hypertension (CTCAE Grade 3) has bee n reported in patients 
receiving ramucirumab co mpared with placebo.  In most cases, hypertensio n was controlled 
using standard ant ihypertensive treatment.  Preexisting hypertensio n should be controlled before 
starting ramucirumab treatment.
Moni toring of b lood pressure is requi red during, and should occur prior to, ramucirumab therapy .  
Every  attem pt shoul d be made to control blood pressure to systolic <140 mmHg and diastolic 
<90 mmHg pri or to starting treatment with ramucirumab.  Routine clinical and labor atory  
monitoring is required in pat ients who again develop hy pertensi on or experi ence a deteri oration 
in previous hypertensio n.
[IP_ADDRESS].1.2. Proteinuria
Proteinuria is an adverse effect for all therapi[INVESTIGATOR_014] t argeting the VEGF/VEGFR [ADDRESS_1179643], 
including ramucirumab.  In ramucirumab clinical trials, the majorit y of events were Grade 1 or 2.  
Moni toring for the development or worsening of proteinuria during ramucirumab therapy  is 
requi red.  Di scontinue ram ucirumab if the pat ient experiences proteinuria >3 g/24 hours or 
neph rotic syndrom e.
[IP_ADDRESS].1.3. Thromboembolic Events
[IP_ADDRESS].1.3.1. Arterial Thromboembolic Events
Serious, som etimes fatal arterial thromboembo lic events (ATEs) , including myocardial 
infarction, cardiac arrest, cerebrovascular accident, and cerebral ischemia, have been reported in 
clinical tri als.
[IP_ADDRESS].1.3.2. Venous Thromboembolic Events
Venous thromboembo lic events (VTEs) are associated with cancer; however, the incidence of 
VTEs likely varies depending on the ty pe of cancer, stage, and intensit y of imaging.  
Addit ionally , VTEs have been associ ated wi th some ant iangiogenic therapy , although the 
incidence varies depending on the ty pe of therapy , use of concomitant chemotherapy agents, and 
specific disease state.  VTEs have been reported from clinical studies invest igating ramucirumab, 
particularly in the context of metastatic disease or in regions adjacent to implanted venous access 
devices.
[IP_ADDRESS].1.4. Bleeding/Hemorrhage
Ramucirumab is an ant iangiogenic therapy  and has the potential to increase the risk of severe 
bleeding.  Severe GI hemorrhages, including fa tal events, have been reported in pat ients with 
gastri c-GEJ cancer treated with ramucirumab in combinat ion with pacli taxel .
Serious hem orrhagic AEs have been reported from clinical studies invest igating ramucirumab.  
Hem orrhagic com plicat ions are associate d with some malignancies (that is, variceal bleeding 
I4T-MC-JVDL( c) Clinical Protocol Page 60
LY3009806 ; LY3012211from portal  hypertensio n in hepatocellular carcino ma, l ower GI hem orrhage from  bowel  
metastases in ovarian carcino ma), although the rate of these complicat ions varies considerably.  
As detailed in the ra mucirumab IB, the incidences of hemorrhagic events to date, significant 
background incidence of bleeding in so me malignancies, and use of conco mitant anti platel et 
therapy  in some of the reported cases preclude any definit ive associ ation between bleeding an d 
ramucirumab, al though ongoing surveillance and ident ificat ion (and exclusio n) of patients with 
high bleeding risk remain essent ial and are detailed in the inclusio n/exclusio n criteria.
[IP_ADDRESS].1.5. Gastrointestinal Perforation
An infrequent incidence of GI perforatio ns has been associated with so me ant iangiogenic 
therapeuti c agents, m ost specifically in the context of colorectal cancer (treated with combinat ion 
regimens, including ant i-VEGF ant ibodies and cyt otoxi c chem otherapy ) and in advanced ovari an 
cancer.  These events m ay be associated with extensive abdo minal/peritoneal disease burden.  
Gastrointestinal perforation has been reported from clinical studies invest igating ramucirumab.  
The incidences of these events to date and presence of significant comorbidit ies and ri sk factors 
precl ude any  defini tive association wit h ram ucirumab, al though ongoing surveillance remains 
essent ial.  More information about GI perforation may be found in the IB.
[IP_ADDRESS].1.6. Reversible Posterior Leukoencephalopathy Syndrome
Reversible posterior le ukoencephalopathy syndrome (RPLS) is a clinical and radio logic 
syndro me typi[INVESTIGATOR_702358] -imaging 
findings of subcortical edema invo lving the posterior circulat ion, parti cularly the occi pi[INVESTIGATOR_33934] 
(Hinchey et al. 1996).  The symptoms of RPLS mo st often include generalized seizures, 
headache, delirium, and cortical blindness, although these may vary significant ly and 
occasi onally  include focal  neurol ogical defici ts (Hinchey et al . 1996; Garg 2001; Lee et al. 
2008).  Magnet ic resonance imaging ( MRI )represents the most reliable method for diagnosis 
(Lee et al . 2008).  Clinical symptoms and MRI abnormalit ies usually  recover wi thin days to 
weeks with proper management, although permanent neurologic dy sfunct ion has been reported 
(Hinchey et al. 1996; Tajima et al. 1999; Garg 2001; Lee et al. 2008).
Across the clinical program to date, [ADDRESS_1179644] been reported:  One case occurred in 
each arm  of the recent ly completed double -blind, rando mized, p lacebo -controlled Phase 3 
Study RAISE evaluating ramucirumab in co mbinatio n with FOLFIRI versus FOLFIRI in 
combinat ion with placebo for pati ents wi th metastati c col orectal  cancer.
RPLS should be identified and treated prompt ly in order to minimize potentia l for perm anent 
neuro logical damage.  Treatment encompasses careful control of blood pressure, withdrawal of 
potenti ally causat ive medicat ion, and administration of ant iconvulsant agents to those 
experiencing seizures (Stott et al. 2005).
[IP_ADDRESS].1.7. Congestive Heart Failure
An increased risk of congest ive heart failure (CHF) has been associated with so me 
antiangiogenic therapeut ic agents, particularly in patients with metastatic breast cancer 
previously treated with anthracyclines.  A small number of CHF events (inclu ding fatal ) were 
I4T-MC-JVDL( c) Clinical Protocol Page 61
LY3009806 ; LY3012211also reported in patients who had received ramucirumab after prior treatment with anthracyclines 
in the Phase [ADDRESS_1179645] ing coronary artery disease or CHF.  Ramucirumab should be 
discontinued in the event of any Grade 3 or 4 events consistent with CHF.
[IP_ADDRESS].1.8. Fistula Formation
Becaus e fistul a formation has been associated with antiangiogenic agents, patients may be at 
increased risk for the development of fistula when treated with ramucirumab.  Some fistulas can 
be reso lved with surgical procedures; however, fistulas can be fatal.  Th e impact on the qualit y of 
life o f having a fistula varies according to the locatio n and extent of the fistula (Chen and Cleck 
2009).
[IP_ADDRESS].1.9. Surgery and Impaired Wound Healing
Because ramucirumab is an ant iangiogenic therapy, it may have the potential to adversel y affect 
wound healing.  Ramucirumab did not impair wound healing in a study  conducted in animals; 
however, the impact of ramucirumab on serious or nonhealing wounds has not been evaluated in 
humans.
[IP_ADDRESS].1.10. Liver Failure and Other Significant Liver Injury
Liver failure or other significant liver injury events, such as hepatic encephalopathy, have been 
observed in patients receiving ramucirumab.  Patients wi th 1) ci rrhosis at a l evel of Child -Pugh 
Class B (or worse) or 2) cirrhosis (any  degree) and a history of hepatic encephalopathy or 
clinically meaningful ascites result ing from cirrhosis shoul d not be enrolled in clinical trials with 
ramucirumab.  “Clinically meaningful ascites” is defined as ascites result ing from cirrhosis and 
requi ring ongo ing treatment with diuretics and/or paracentesis.
[IP_ADDRESS].2. Supporti ve Care Agents for Ramucirumab - Guidelines
Supportive care measures may include but are not limited to antiemet ic agents, opi[INVESTIGATOR_848401], appetite stimulants, and granulocy te and ery throid growth factors.  
Guidelines regarding the use of specific supportive care agents are presented below.
[IP_ADDRESS].2.1. Antiemetic A gents
Although emesis is not an expected side effect of ramucirumab, the use of ant iemetic agents is 
permitted at the discretion of the inve stigator.  Acceptable ant iemetic agents include 5 -HT 3
receptor antagonists (for example, ondansetron), dopamine receptor antagonists (for example, 
metocl opramide), corti costeroi ds (for exam ple, dexamethasone), and others.
[IP_ADDRESS].2.2. Analgesic A gents
The use of analge sic agents is permitted at the discretion of the invest igator.  Opi[INVESTIGATOR_848402] (including acetaminophen/paracetamo l); however, use 
of NSAIDs and/or aspi[INVESTIGATOR_702361] (Appendix 7 ).
I4T-MC-JVDL( c) Clinical Protocol Page 62
LY3009806 ; LY30122117.[IP_ADDRESS].3. Appetite Stimulants
The use of appet ite stimulants is permitted at the discretion of the invest igator.  Examples 
include megestrol acetate, dronabino l, and others.
[IP_ADDRESS].2.4. Granulocyte -Colony Stimulating Factors
The as -needed use of granul ocyte-colony st imulat ing factors is permitted at the discretion of the 
investigator based on American Societ y of Clinical Oncol ogy (ASCO) gui delines (Smi th et al . 
2006) ( Appendix 7 ).
[IP_ADDRESS].2.5. Erythroid Growth Factors
The as -needed use of eryt hroid-stimulat ing factors (for example, ery thropoi etin) is permitted at 
the discret ion of the invest igator based on ASCOguidelines (Rizzo et al. 2008) ( Appendix 7 ).
[IP_ADDRESS].2.6. Other Supportive Care A gents
The use of benzodiazepi[INVESTIGATOR_1651], ant idepressants, laxatives, and other agents that may be helpful in 
controlling disease -related symptom s are al so permi tted and enco uraged, except as prohibited in 
Appendix 7 .
[IP_ADDRESS]. Supportive Care for Necitumumab by [CONTACT_702368]
[IP_ADDRESS].1. Skin Reactions
React ive treatment r ecommendat ions for skin reactio n, based on the Canadian recommendations 
presented by [CONTACT_328480]. (2009), are summarized in Table JVDL. 12.
Skin rash (any  grade) shoul d be treated as per  Table JVDL. 12.  If a patient experiences a Grade [ADDRESS_1179646] ions, 
treatm ent wi th necitumumab shoul d be permanent ly discont inued .
I4T-MC-JVDL( c) Clinical Protocol Page 63
LY3009806 ; LY3012211Table JVDL. 12. Managing Skin Reactions
Grade of 
Reaction Recommendations for Management
1 Administer topi[INVESTIGATOR_47288] 2% and topi[INVESTIGATOR_8746] 1% in lotion base twice daily to 
affected areas until resolution of reaction.
Patients are advised to take appropriate protective measures prior to sun exposure to avoid 
exacerbation of rash severity.
2 Administer topi[INVESTIGATOR_47288] 2% and topi[INVESTIGATOR_8746] 1% in lotion base twice daily  to 
affected areas until resolution of reaction.
If clinically appropriate in the opi[INVESTIGATOR_871], administer oral minocycline or 
doxycycline 100 mg twice daily (or equivalent), for a minimum of 4 weeks and continuing for as 
long as rash is symptomatic.
Patients are advised to take appropriate protective measures prior to sun exposure to avoid 
exacerbation of rash severity.
3 Administer topi[INVESTIGATOR_47288] 2% and topi[INVESTIGATOR_8746] 1% in lotion base twice daily to 
affected areas unti l resolution of reaction.
Administer oral minocycline or doxycycline 100 mg twice daily (or equivalent), for a minimum of 
4 weeks and continuing for as long as rash is symptomatic.
Patients are advised to take appropriate protective measures prior to sun e xposure to avoid 
exacerbation of rash severity.
Necitumumab administration will be temporarily withheld until symptoms resolve to Grade ≤2, 
but not for longer than a maximum of [ADDRESS_1179647] recent treatment cycle.
Following improveme nt to Grade ≤2, necitumumab may be re -administered, with a dose reduction 
of 50% but not below 400 mg.  This dose may be increased to 75% of the original dose after a 
minimum of 1 treatment cycle (3 weeks), if symptoms do not recur.  If symptoms do not rec ur for 
another treatment cycle, the dose may be re -escalated to the initial dose.
If reactio ns do not resolve to Grade ≤2 after 6 weeks (that is, after withholding 2 consecutive 
doses of necitumumab), or if reactions recur or become intolerable at 50% of t he original dose, 
necitumumab treatment should be permanently discontinued.
Patients who experience Grade 3 skin induration / fibrosis will be immediately discontinued from 
necitumumab.
4 Administer topi[INVESTIGATOR_47288] 2% and topi[INVESTIGATOR_8746] 1% in lotion base twice daily to 
affected areas until resolution of reaction.
Administer oral minocycline or doxycycline 100 mg twice daily (or equivalent), for a minimum of 
4 weeks and continuing for as long as rash is symptomatic.
Patients are advised to take appropriate protective measures prior to sun exposure to avoid 
exacerbation of rash severity.
Necitumumab administration must be immediately and permanently discontinued.
A dermatology  referral may be indicated for skin reactions that do not improve following 
1-2weeks of treatment, reactions that are severely symptomat ic (for example, necrosis, 
blistering, or petechial or purp uric lesio ns), reacti ons o f NCI CTCAE Grade ≥3, or reactions with 
an uncharacterist ic appearance.
As wi th all conco mitant medicat ions/procedures, any act ions taken to ameliorate skin toxicit y 
will be documented in the concomitant medication module o f the electroni c CRF (eCRF).
I4T-MC-JVDL( c) Clinical Protocol Page 64
LY3009806 ; LY30122117.[IP_ADDRESS]. Conjunctivitis
For pati ents wi th treatm ent-related conjunct ivitis <Grade 3, the investigator is advi sed to init iate 
symptom atic treatment and fo llow up observati on of  the event.  If the severit y increases to 
Grade ≥3, or symptoms persists for >[ADDRESS_1179648] for further evaluat ion and treatment.
[IP_ADDRESS].3. Electrolyte Abnormalities
Consistent with observat ions wi th other EGFR mAbs, hypo magnesemia has been very 
commo nly reported in pat ients treated with necitumumab in co mbinat ion with cisplat in-based 
regimens.  Hy pomagnesemia is considered a class effect for EGFR mAbs.  Moni tor pati ents for 
hypo magnesemia, hypocalcemia, hypokalemia, and hy pophosphatemia pri or to each 
administration of necitumumab and after complet ion of necitumumab, unt il wit hin normal limits.  
Prom pt repleti on is recommended, as appropriate.
[IP_ADDRESS].4. Thromboembolic Events
In the Phase [ADDRESS_1179649] igational arm 
(necitumumab in co mbinat ion with gemci tabine and cisplat in) compared to the active control 
arm (gem citabine and cisplat in).  The relat ive risk of VTEs or ATEs was approximately 3 -fold 
higher in pat ients with a reported hi story  of VTEs or ATEs.
In Study  JFCB (INSPI[INVESTIGATOR_21392]), which invest igated necitumumab in co mbinat ion with pemetrexed 
and cisplat in (PC+N) in patients with nonsquamous NSCLC, patients experienced an increased 
rate of serious thromboembo lic events (including fatal events) in the PC+N Arm as co mpared to 
pemetrexed and cisplat in (PC) alone.  Further more, the addi tion of  necitumumab did not improve 
the efficacy  outcom e over PC al one in advanced nonsquamous NSCLC.  
Administrati on of  neci tumumab in combinat ion with pemetrexed and cisplat in is not 
recommended.
Discontinuati on of  necitumumab in pat ients who experience a VTE or ATE should be considered 
after a thorough benefit -risk assessment for the individual patient.
[IP_ADDRESS].5. Pneumonia and Sepsis
During the conduct of Study  JFCL (JFCL; Phase [ADDRESS_1179650] igate carboplat in and so luble 
paclitaxel wit h or without necitumumab in pat ients with squamous NSCLC), following the non -
blinded review o f SAE cases that included reports related to pneumonia and sepsis, an imbalance 
in the number of SAEs, including fatal cases, for the necitumumab group com pared wi th the 
paclitaxel -carbopl atin group was found.
The early occurrence of a number of these cases may  have indicated an issue regarding the 
enrollment of the appropriate patients.  The sponsor had therefore provided clarification and 
reinforc ement of  the inclusio n/exclusio n criteria, request ing the invest igator’s particular attention 
with regard to infect ions and condit ions predi sposing to infect ions ongoing at the time of 
enrollment in a protocol amendment.  During the further conduct of this trial, only  single 
I4T-MC-JVDL( c) Clinical Protocol Page 65
LY3009806 ; LY3012211additional reports were received, notably  of cases reporting pneumo nia and sept ic co mplications 
with concurrent neutropenia.
The review of the data from the Phase 3 study  of neci tumumab in co mbinat ion with gemci tabine 
and cisplat in (JFC C; SQUIRE) di d not show any  evidence of an increased risk of serious lung 
infect ions associated with necitumumab in this combinat ion.
Speci al attenti on shoul d be given to pati ents wi th clinical evidence of conco mitant infect ious 
condi tions including early signs of act ive infections.  Treatment of any infection should be 
initiated according to local standards.
[IP_ADDRESS].6. Cardiorespi[INVESTIGATOR_328436] o f cardi orespi [INVESTIGATOR_328437]. Cardi orespi [INVESTIGATOR_328438] 
(SQUIRE) in 2.8% (15/538) of patients treated with necitumumab plus gemcitabine and cisplat in 
compared to 0.6% (3/541) of patients treated with chemotherapy alo ne.  Twelve of the [ADDRESS_1179651] dose of necitumumab and had comorbid condit ions, 
including history  of chronic obstructive pulmo nary disease (n=7), hypertensio n (n=5), 
hypo magnesemia (n=4), and coronary  artery  disease (n=3).  El even of the 1 2 pati ents had an 
unwit nessed death.
[IP_ADDRESS]. Supportive Care for Osimertinib by [CONTACT_702368]
[IP_ADDRESS].1. Diarrhea
After 1month treatm ent wi th osimertinib ,there is an approximate 20% chance of an AE of 
diarrhea at any  point in time.  Where treatment was requi red,the most frequent ly used class of 
medicat ion administered were ant ipropulsives ( for example , loperamide).
Apply the fo llowing supportive care guidance for diarrhea:
Uncomplicated CTCAE v4.0 Grade ≤2 diarrhea:
Dietetic measures:
•Stop all lactose -containing products.
•Drink 8 to 10 large glasses of clear liquids per day .
•Eat frequent small meals.
•Reco mmend low- fat regimen enriched wit h rice, bananas, and apple sauce.
Pharmaco logical treatm ent:
•Administer loperamide:  init ial dose 4 mg, fo llowed by  2 mg every  4 hours of after 
every unformed stool.
• Grade 1 intermittent diarrhea may not require treatment.
•Consider continuat ion of loperamide unt il diarrhea -free for 12 hours.
•Consider electrolyte replacement, as appropriate.
I4T-MC-JVDL( c) Clinical Protocol Page 66
LY3009806 ; LY3012211CTCAE v4.0 Grade ≥3 or any grade with complications ( dehydration, fever ,and/or 
Grade ≥3 neutropenia):
Dietetic measures:
•As per Grade ≤2 diarrhea
Pharmaco logical treatm ent:
•As per Grade ≤2 diarrhea
•If dehydrat ion is severe, administer octreotide and use intravenous fluids as 
appropriate.
•Consider prophylact ic antibiot ics, especially  if diarrhea is persistent bey ond 24 hours 
or there is fever or Grade 3 -4 neutropenia.
• Consider electrolyte replacement, as appropriate, and consider more frequent 
measurement of electrolytes unt il AE resolves.
[IP_ADDRESS].2. Skin R eactions
Rash Treatment Guidance:
CTCAE v4.0 Grade 1:
•Emollient cream application ,and/or
•Topi [INVESTIGATOR_848403] ,and/or
•Topi [INVESTIGATOR_848404] v4.0 Grade 2:
• Treatment same as Grade 1
•Consider using oral ant ibiotic for 6 weeks .
CTCAE v4.0 Grade ≥3:
•Topi [INVESTIGATOR_53284] d moderate strength bid, and
•Oral antibiot ic for 6 weeks (switch to broad spectrum/gram negat ive cover if infect ion 
suspected [yello w crusts, purulent discharge, painful skin/nares])
• Consider skin swab for ba cterial culture.
Dry Skin / Xerosis Treatm ent Gui dance:
CTCAE v4.0 Grade 1:
•Face/Hands/Feet: over-the-counter moisturizing cream  or oi ntment bid
•Body :  amm onium  lactate 12% cream  bid or salicylic acid 6% cream bid
CTCAE v4.0 Grade 2:
• Treatment same as Gra de 1
I4T-MC-JVDL( c) Clinical Protocol Page 67
LY3009806 ; LY3012211CTCAE v4.0 Grade ≥3:
•Treatment same as Grade 1/2, plus
•Eczem atous areas of body : topi[INVESTIGATOR_53284] d moderate strength bid
Pruri tus Treatm ent Gui dance:
CTCAE v4.0 Grade 1:
•Topi [INVESTIGATOR_53284] d moderate strength bid or topi[INVESTIGATOR_848405] v4.0 Grade 2:
•Topi [INVESTIGATOR_53284] d moderate strength bid or topi[INVESTIGATOR_848406]
•Oral antihistamine
CTCAE v4.0 Grade ≥3:
•Oral antihistamine
•GABA agonist (gabapent in 300 mg or pregabalin 50- 75 m g every  8 hours)
Parony chia Treatm ent Gui dance:
CTCAE v4.0 Grade 1:
•Topi [INVESTIGATOR_848407]#
CTCAE v4.0 Grade 2:
•Topi [INVESTIGATOR_848407]#
•Topi [INVESTIGATOR_848408] v4.0 Grade ≥3:
•Topi [INVESTIGATOR_848407]#
•Topi [INVESTIGATOR_848409]
•Consider nail avulsio n / removal
#Soaking fingers or toes in a 1:1 solution o f white vinegar in water for 15 minutes every day
[IP_ADDRESS].3. QTc
Patients wi th QT interval corrected by [CONTACT_848440] (QTcF )prolongat ion to >[ADDRESS_1179652] study  treatm ent interrupted and regular ECGs performed u ntil reso lution to 
<481 msec or recovery to baseline if baseline QTcF is >481 msec and then restarted at a reduced 
dose of 40 mg. If the toxicit y does not resol ve to ≤Grade 1 within 21 days ,the pati ent will be 
perm anent ly wit hdrawn fro m osimertinib .
[IP_ADDRESS].4. Interstitial Lung Disease
If new or worsening pulmo nary symptom s (for example , dyspnea) or radi ological abnorm ality 
suggest ive of ILD is observed, an interruption in osimert inibdosing i s recommended, and the 
I4T-MC-JVDL( c) Clinical Protocol Page 68
LY3009806 ; LY3012211Lilly study  team shoul d be informed .  A questi onnaire regarding the results of the full diagnostic 
workup (including high -resolution computed tomography  [HRCT], bl ood and sputum culture, 
and hematol ogical param eters) will  be sent to investigators.  It is strongly  recommended to 
perform  a full diagnosti c workup to exclude alternative causes such as lymphangit ic 
carcino matosis, infect ion, allergy , cardi ogenic edema, or pulmo nary hemorrhage.  In the 
presence of confirmatory  HRCT scans where other causes of respi[INVESTIGATOR_29197] s have been 
excluded, a diagnos is of ILD shoul d be consi dered and osimertinib perm anent ly discont inued.
In the absence of a diagnosis of ILD, osimert inibmay be restarted following consultat ion with 
the Lilly CRP .
Patients with a diagnosis of ILD will not be permit ted to restart osimertinib .
7.8. Treatment after Study Completion
The s tudy com pletion will occur approximately [ADDRESS_1179653] ivities (Section  2) for all  patients until 
notified by [CONTACT_848441].
7.8.1. Continued Access Period
Patients who are still on study  treatm entat the time of study co mpletion may cont inue to receive 
study  treatm entif they are experiencing clinical benefit and no undue risks.  The continued 
access period begins after study  com pletion and ends at end of trial (Figure JVDL. 3).
Continued access period will apply  to this study  only  if at least [ADDRESS_1179654] igators when the continued 
access period begins.
The patient ’s cont inued access to study treatment will end when a criterion for discontinuation is 
met (Section 8).  Continued access fo llow-up will begin the day  after the pati ent and the 
investigator agree to discont inue study  treatm entand lasts appr oximately  30 (±7) day s.  
Follow-up procedures will be performed as shown in the Cont inued Access Schedule of 
Activities (Table JVDL .4).
I4T-MC-JVDL( c) Clinical Protocol Page 69
LY3009806 ; LY3012211aLilly  will notify  sites when the continued access period begins and ends.
bApproximately [ADDRESS_1179655] 
patient.
Figure JVDL. 3. Continued access diagram .
Patients who are in short -term follow-up when the continued access period begins will cont inue 
in short -term follow-up unt il the 30 -dayshort -term fo llow-up visit is completed.  Long -term 
follow-up does not apply.
Patients who are in long -term follow-up when the continued access period begins will be 
discontinued fro m long-term follow-up.   Study Treatment Period
Study CompletionbPatient and investigator 
agree to discontinue  
study treatmentStudy treatmentContinued access 
follow -up
(approximately 30 days)Continued Access Period a
End of Trialc
I4T-MC-JVDL( c) Clinical Protocol Page 70
LY3009806 ; LY30122118.Discontinuation Criteria
8.1. Discontinuation from Study Treatment
Patients will  be discont inued fro m study  treatm ent in the fo llowing circumstances:
The patient is enrolled in any other clinical trial invo lving an invest igational product or 
any other ty pe of medical research judged not to be scient ifically or medically co mpat ible 
with this study .
The patient, for any  reason, requi res treatm ent wi th another therapeuti c agent that has 
been demo nstrated to be effective for treatment of the study  indicati on, discont inuat ion 
from the study  treatm ent occurs pri or to introduction of the new agen t.
The invest igator decides that the patient should be discontinued fro m study  treatm ent.
The patient requests that the patient be withdrawn fro m study  treatm ent.
The patient is significant ly nonco mpliant with study procedures and/or treatment.
disease progressi on
Patients who are di scont inued fro m study  treatm entwill have fo llow-up procedures performed as 
shown in the Schedule of Act ivities (Secti on  2).
8.1.1. Discontinuation of Inadvertently Enrolled Patients
If Lilly or the invest igator ident ifies a patient who did not meet enrollment criteria and was 
inadvertent ly enro lled, a discussio n must occur between the Lilly  CRP and the invest igator to 
determi ne if the pat ient may  cont inue in the study .  If both agree i t is medically  appropriate to 
continue, the invest igator must obtain documented approval fro m the Lilly  CRP to all ow the 
inadvertent ly enro lled pat ient to conti nue in the study  with or wi thout st udy drug (s).
8.2. Discontinuation from the Study
Patients will  be discont inued fro m the study  in the fo llowing circumstances:
Participation in the study  needs to be stopped for medical, safet y, regul atory , or other 
reasons consistent with applicable laws, regul ations, and good clinical pract ice.
Thepatient becom es pregnant during the study .  See Secti on  9.2.[ADDRESS_1179656] -feeding.
The invest igator decides that the patient should be discontinued fro m the study .
The patient requests to be discontinued from the study .
The patient’s designee (for example, parents, legal guardian, or caregiver) req uests that 
the pati ent be di scont inued fro m the study .
Patients who discont inue from the study  early will  have end -of-study  procedures perform ed as 
shown in the Schedule of Act ivities(Secti on  2).
8.3. Lost to Follow -Up
A pat ient will be considered lost to fo llow-up if he or she repeatedly  fails to return for scheduled 
visits and is unable to be con tacted by  [CONTACT_4145].  Study  site personnel are expected to m ake 
I4T-MC-JVDL( c) Clinical Protocol Page 71
LY3009806 ; LY3012211diligent attempts to contact [CONTACT_57986] a scheduled visit or who the site is 
otherwi se unable to follow -up.
I4T-MC-JVDL( c) Clinical Protocol Page 72
LY3009806 ; LY30122119.Study  Assessments and Procedures
Secti on  2provides the Schedule o f Activities for this study .
Appendix [ADDRESS_1179657] results.  Certain 
samples may  be retained for a l onger peri od, if necessary , to com ply wi th applicable laws, 
regul ations, or laboratory  certificat ion standards.
9.1. Efficacy Assessments
Tumor assessments will be performed for each patient at the times shown in the Schedule of 
Activities (Section  2).
9.1.1. Efficacy Assessments at Baseline and during Study Treatment
RECIST 1.1 (Eisenhauer et al. 2009) will be applied as the primary  measure for assessment of 
tumor response and date of disease progression.   Local tumor imaging (invest igator assessment 
with site radi ological reading) will be used.
Tumor imaging shoul d be performed by [CONTACT_20420] (CT), whi ch is preferred for the 
majorit y of patients, as the m ore comm only used m odali ty.  Magnet ic resonance imaging (MRI) 
should only  be used when CT is contraindicated or for imaging in the brain.  The same imaging 
technique should be used for a patient throughout the trial.  CT scan or MRI of chest and upper 
abdo men including both adrenal glands are required, with pelvic imaging performed if clinically 
indicated.
The subsections below describe in detail the tumor imaging and assessment measures at baseline 
and during study  treatm ent.
[IP_ADDRESS]. Baseline Tumor Imaging
Initial tumor imaging at screening must be performed within 21 days prio r to the date of 
enrollment (assignment to treatment) or wi thin [ADDRESS_1179658] scan or MRI of the b rain will be performed at baseline prior to enrollment for all 
patients (per Excl usion Criterion[21]regarding brain metastases), and thereafter every 6 weeks 
(±7days)despi[INVESTIGATOR_848410], if a pat ient had brain metastases at study  entry  or if 
clinically indicated . Scans performed as part of routine clinical management are acceptable for 
use as init ial tumor imaging if they  are of diagnostic qualit y and perform ed wi thin the 
protocol -requi red time frame as described above.
I4T-MC-JVDL( c) Clinical Protocol Page 73
LY3009806 ; LY30122119.1.1.2. Tumor Imaging d uring Study Treatment
During study  treatm ent, tum or response will be assessed every  6 week s (± 7 days) by 
[CONTACT_1697], with confirmatory  assessment ob tained at the next routine scheduled imaging 
time point (that i s, after 6 weeks ± 7 day s), despi [INVESTIGATOR_848411] t delays.  After 24 weeks, tumor 
assessment will be conducted every  12 weeks (± 7 days). The start of treatment will be 
considered Cycle 1 Day  1 (C1D1) or the day  that the first dose of any study  treatm ent is 
administered.
Per RECIST 1.1, partial or complete response should be confirmed by  a repeat tum or-imaging 
assessment not less than [ADDRESS_1179659] 
indicat ionof response or at the next scheduled scan (that is, 6 weeks ±7 days later), whichever is 
clinically indicated.
Continue to perform imaging unt il whichever of the fo llowing occurs first:
disease progressi on confirmed by  [CONTACT_848442]
the start of new ant icancer treatment
withdrawal  of consent
death
end of trial
9.1.2. Efficacy Assessments during Postdiscontinuation Follow -Up
Postdiscontinuati on follow-up during the study  period will be conducted per the Schedule o f 
Activities(Secti on  2).
Tumor assessments m ay cont inue for pati ents who discontinue from the study  treatm ent for 
reasons other than disease progression every [ADDRESS_1179660] of care.
9.1.3. Efficacy Measures
The objective response rate (ORR) is the proportio n of enrolled pat ients who have received 
any amount of either study  drug, have at least [ADDRESS_1179661] 
overall response o f complete re sponse ( CR)or partial response (PR).
Duration of response (DO R)is defined only for responders (patients with a confirmed CR or 
PR).  It is measured from the date of first evidence of a confirmed CR or PR to the date of 
objective progression or the date o f death due to any cause, whichever is earlier.  If a responder 
is not known to have died or have object ive progressio n as of th e data inclusio n cutoff date, DO R 
will be censored at the date of the last complete object ive progression -free disease assessmen t.
Disease Control Rate (DCR) is defined as the proportion of enro lled patients who have a best 
overall response of CR, PR, or stable disease .
Progression -free survival (PFS) is defined as the time fro m the date of first study  treatm ent 
until the date of the first observed radiographically documented PD or death due to any cause, 
whichever i s earlier.  T he censoring is taken in the fo llowing order:
I4T-MC-JVDL( c) Clinical Protocol Page 74
LY3009806 ; LY3012211-if a pat ient does not have a complete baseline disease assessment, then the PFS time will 
be censored at the enro llment date, regardless of whether or not object ively determined 
disease progressi on or death has been observed for the patient; otherwise,
-if a pat ient is not known to ha ve died or have objective progression as of the data 
inclusio n cutoff date for the analysis, the PFS time will be censored at the last complete 
objective progression -free disease assessment date.
ORR, DOR, DCR, and PFS will be assessed based on RECIST 1.1 (Eisenhauer et al . 2009) .
Overall survival (OS), including [ADDRESS_1179662] study treatm ent until death due to any  cause.  If the patient was alive at the data inclusio n 
cutoff date for the analysis (or wa s lost to follow -up), OS will be censored on the last date the 
patient was known to be alive.
9.1.4. Appropriateness of Assessments
The m easures used in this study  are consistent wi th those used in m ost convent ional onco logy 
trials.
9.2. Adverse Events
The invest igator will use CTCAE Versi on 4.0 (NCI 2009) to assign AE terms and severit y 
grades.
Invest igators are responsible for:
monitoring the safet y of patients in this study  and for al erting Lilly or its designee to any  
event that seems unusual, even i f this event m ay be consi dered an unanticipated benefit 
to the patient
the appropriate medical care of patients during the study
docum enting their review of each laboratory  safet y report
following, through an appropriate health care option, AEs that are se rious or otherwi se 
medically important, considered related to study  treatm ent or the study , or that caused 
the pati ent to discont inue study  drug (s)before complet ing the study.  The patient should 
be followed unt il the event resolves, stabilizes wit h appro priate di agnosti c evaluat ion, or 
is reasonably explained.  Frequency  of follow-up evaluat ion is left to the discret ion of 
the invest igator.
Lack of drug effect is not an AE in clinical studies, because the purpose of the clinical study is to 
establish trea tment effect.
After the informed consent form ( ICF) is signed, study site personnel will record via CRF the 
occurrence and nature of each patient’s preexist ing conditions, including clinically significant 
signs and symptoms of the disease under treatment i n the study .  In addi tion, study  site personnel 
will record via CRF any change in the preexist ing condit ions and any  new condi tions as AEs.   
Invest igators should record their assessment of the potential relatedness of each AE to study 
procedure or study  treatment via CRF.
I4T-MC-JVDL( c) Clinical Protocol Page 75
LY3009806 ; LY3012211The invest igator will interpret and docum ent whether or not an AE hasa reasonable possibilit y 
of being related to study  treatm ent or a study  procedure, taking into account the disease, 
concomitant treatments ,or pathologies. A “reasonabl e possibilit y” means that there is a cause 
and effect relat ionship between the study  treatm ent and/or study  procedure and the AE.
Planned surgeries and nonsurgical intervent ions should not be reported as AEs unless the 
underlying medical condit ion has wors ened during the course of the study .
Study  site personnel  must report any  dose m odificati ons or treatm ent discont inuat ions that result 
from AEs to Lilly or its designee via CRF, clarifying, if possible, the circumstances leading to 
the dose m odificat ion ordiscont inuat ion of treatment.
9.2.1. Adverse Events of Special Interest
[IP_ADDRESS]. Infusion-Related Reactions -Ramucirumab and Necitumumab
Any treatment -related IRRs are defined according to the CTCAE Versio n4.0 definit ion (General 
Disorders and Administration Site Condi tions ).  Symptoms occurring during or following 
infusio n of invest igational therapy may also be defined according to AE categories such as 
allergic reaction, anaphylaxis, or cy tokine release syndrom e (Immune System Disorders ).  In the 
setting of symptoms o ccurring during or fo llowing infusio n of investigat ional therapy , 
investigators are encouraged to use the AE term “infusi on-related reaction” and any  addi tional 
terms (including those not listed here) that best describe the event.
[IP_ADDRESS]. Adverse Events of Special Interest -Ramucirumab
Secti on  [IP_ADDRESS].[ADDRESS_1179663] ions ari se concerning AESIs.
[IP_ADDRESS]. Adverse Events of Special Interest -Necitumumab
Secti on  [IP_ADDRESS] describes supportive care for necitumumab AESIs .  Table JVDL. 11provi des 
general trea tment recommendat ions for hypersensitivit y/IRRs to neci tumumab.  Contact [CONTACT_848443].
[IP_ADDRESS]. Adverse Events of Special Interest –Osimertinib
Secti on  [IP_ADDRESS] describes supportive care for osimertinib AESIs.  Contact [CONTACT_848444].
9.2.2. Serious Adverse Events
An SAE is any  AE from this study  that resul ts in one of the fo llowing outcom es:
death
initial or prolonged inpatient hospi[INVESTIGATOR_3094]
a life- threatening experience (that is, immediate risk of dying)
persistent or significant disabilit y/incapacit y
congenital ano maly/birth defect
I4T-MC-JVDL( c) Clinical Protocol Page 76
LY3009806 ; LY3012211considered significant by  [CONTACT_848445] r eason:  important medical events 
that may  not resul t in death, be life -threatening, or require hospi[INVESTIGATOR_848412], based upon appropriate medical judgment.
Although all AEs after signing the ICF are recorded in the CRF, SAE reporting begins after the 
patient has signed the ICF and has received study  treatm ent.  However, if an SAE occurs after 
signing the ICF, but prior to receiving study  treatment, i t needs to be reported ONLY if it is 
considered reasonably  possibly  related to study  procedure.
Study site personnel  must notify Lilly or its designee of any SAE within 24 hours of investigator 
aware ness of the event via a Lilly -approved m ethod.  If alerts are i ssued via telephone, they are 
to be immediately followed wit h official notificat ion on study -specific SAE forms.   This 24 -hour 
notification requirement refers to the init ial SAE informat ion and all fo llow-up SAE information.
Pregnancy (during maternal or paternal exposure to study  treatm ent) does not m eet the definit ion 
of an AE but s hould be reported.  However, to fulfill regulatory  requi rements any  pregnancy 
shoul d be reported following the SAE process to collect data on the outcome for both mother and 
fetus.
Invest igators are not obligated to actively seek AEs or SAEs in pat ients once they  have 
discontinued and/or completed the study  (the patientsummary CRF has been co mpleted).  
However, if the invest igator learns of any SAE, including a death, at any time after a patient has 
been discharged from the study , and he/she considers the event reasonably possibly related to the 
study  treatm ent or study  parti cipat ion, the invest igator m ust prom ptly notify Lilly .
Planned surgeries should not be reported as SAEs unless the underlying medical condit ion has 
worsened durin g the course of the stu dy.
Planned hospi [INVESTIGATOR_327765]’s medical history  at the time of enrollment should not be considered SAEs.  
Hospi[INVESTIGATOR_246638] a preci pi[INVESTIGATOR_2505] c linical AE (for 
example, for the administration of study  treatm ent or other protocol -requi red procedure) shoul d 
not be considered SAEs.
Serious adverse events, including death, caused by [CONTACT_848446].
9.2.3. Pregnancy
Cases of pregnancy that occur during maternal or paternal exposures to invest igational products 
(ramucirumab, neci tumumab, and osimert inib) shoul d be reported within [ADDRESS_1179664] feeding are collected for regulatory  reporting and drug safet y 
evaluat ion.  The following addit ional measures will be taken in the case of pregnancy:
A pat ient who becomes pregnant will be immediately removed from  the study .
I4T-MC-JVDL( c) Clinical Protocol Page 77
LY3009806 ; LY3012211It is the responsibilit y of invest igators or their designees to report any pregnancy or 
lactati on in a pat ient (spontaneously reported to them) that occurs during the trial or 
within 120 days of complet ing the trial or 30 day s following cessat ion of treatm ent if the 
patient init iates new ant icancer therapy , whichever is earlier.
All patients who become pregnant must be contact[CONTACT_702386]’s status documented to the complet ion/terminat ion of the pre gnancy; the 
investigator will make every  effort to obtain permissio n to follow the outcome o f the 
pregnancy and report the condit ion of the fetus or newborn to the Sponsor.
9.2.4. Suspected Unexpected Serious Adverse Reactions
Suspected unexpected serious adverse react ions (S[LOCATION_003]Rs) are serious events that are not listed 
in the IB and that the investigator ident ifies as related to study treatment or study procedure.  
[LOCATION_002] [ADDRESS_1179665] ive 2001/20/EC and the 
associ ated detailed guidances or nati onal regulatory  requirements in parti cipat ing countries 
requi re the reporting of S[LOCATION_003]Rs.  Lilly  has procedures that will be followed for the recording 
and expedited reporting of S[LOCATION_003]Rs that are consistent with glo bal regulat ions and associated 
detailed guidances.
9.2.5. Complaint Handling
Lilly co llects product complaints on invest igational products and drug delivery systems used in 
clinical studies in order to ensure the safet y of study  parti cipants, m onitor quali ty, and to 
facilitate process and product improvements.
Patients will  be instructed to contact [CONTACT_81129] a 
complaint or probl em wi th the invest igational product or drug delivery system so that the 
situation can be assessed.
9.3. Treatment of Overdose
Refer to the ramucirumab, necitumumab ,and osimertinib IBs.
9.4. Safety
9.4.1. Other Safety Measures
For each patient, ECGs, vital signs, laboratory  tests, or other tests should be collected as shown 
in the Schedule of Act ivities (Section  2).
[IP_ADDRESS]. Electrocardiograms
For each patient, 12 -lead digital ECGs will be co llected according to the Schedule of Activit ies
(Secti on  2) as triplicate ECGs at baseline and single ECGs in subsequent cycles .  Pati ents m ust 
be supi[INVESTIGATOR_17044] [ADDRESS_1179666] ion.
I4T-MC-JVDL( c) Clinical Protocol Page 78
LY3009806 ; LY3012211Electrocardiograms may be obtained at addit ional times , when deemed clinically necessary .  
Collect ion of more ECGs than expected at a particular time point is allowed when needed to 
ensure high -qualit y records.
Electrocardi ogram s will  be interpreted by  [CONTACT_848447] o f ECG collect ion as possible, and ideally while the patient is st ill present, to 
determine whether the patient meets entry  criteria and for immediate p atient management, should 
any clinically  relevant findings be ident ified.
After enro llment, if a clinically significant increase in the QT/ QTcFinterval fro m baseline, or 
other clinically significant quantitative or qualitat ive change fro m baseline, is pr esent, the 
investigator will assess the patient for symptoms (for example, palpi[INVESTIGATOR_814], near syncope, or 
syncope) and to determine if the patient can continue in the study .  The invest igator or qualified 
designee is responsible for determining if any  chan ge in patient management is needed and must 
docum ent his/her review of the ECG printed at the time of evaluat ion.
The invest igator (or qualified designee) must document his/her review of the ECG printed at the 
time of evaluat ion.  Local ECG findings at bas eline and end of treatment, and any  on study  
clinically significant abnormal findings, will be reported into the eCRF and any alert reports.
9.4.2. Safety Monitoring
The Lilly CRP will  monitor saf ety data throughout the course of the study .
Lilly will review SAEs wit hin time frames mandated by [CONTACT_17069].  The Lilly CRP 
will, as is appropriate, consult with the funct ionally  independent Gl obal Pat ient Safet y 
therapeuti c area physician or clinical scient ist, and review:
trends in safety  data
laboratory  analy tes (Appendix 3 )
adverse events, including ramucirumab and necitumumab AESI (Section 9.2.1 ).
If a patient experiences elevated ALT 5× ULN and el evated total bilirubin 2× ULN, 
clinical and laboratory  monitoring shoul d be ini tiated by  [CONTACT_3170].
Details for hepat ic monitoring depend upon the severit y and persistence of observed 
laboratory  test abnorm alities.To ensure patient safet y and co mply with regulatory  
guidance, the investigator is to consult with the Lilly  CRP regarding collect ion of spec ific 
recommended clinical information and fo llow-up laboratory  tests.  See  Appendix 5 .
Safety data will be reviewed during the study .A safet y review co mmittee (SRC) consisting o f 
the Lilly  CRP, Gl obal Patient Safet y physician, stati stician, the primary invest igator, and ad hoc 
SRC m embers as needed will be respons ible for review of safet y data.
9.5. Pharmacokinetics
Pharmacokinet icsamples will be co llected as shown in Appendix 4 .
Blood sam ples will be drawn for all pat ients for the assessment of ramucirumab and 
necitumumab concentrations in serum (also known as bioanalyt ical samples).  Sampling times 
I4T-MC-JVDL( c) Clinical Protocol Page 79
LY3009806 ; LY3012211were selected to coincide with expected C maxand C minand with considerat ion to draw minimum 
volume of blood from pat ients and ensuring that the patients do not to need to make an extra visit 
to provi de these samples.
Instructi ons for the collect ion and handling of bioana lytical bl ood sam ples will be provided by  
[CONTACT_1034].  The actual  start and end date and time of ramucirumab and necitumumab infusio n 
administration must be recorded on the eCRF.  The actual date and time that each bioanalyt ical 
blood sam ple was drawn m ust be recorded on the laboratory  accessi on page after the sample is 
drawn.
Ramucirumab and neci tumumab concentrati ons in bioanaly tical serum  samples will  be measured 
using a validated assay  methodol ogy in a laboratory  designated by [CONTACT_1034].
Bioanaly tical samples collected to measure ramucirum ab and necitumumab concentrati on will be 
retained for a maximum o f [ADDRESS_1179667] patient visit for the study , or f or a shorter period if local 
regul ations and/or ethical review boards ( ERBs )impose shorter time limit s, at a facilit y selected 
by [CONTACT_456] .  Thi s retenti on peri od enables use of new techno logies, response to questions 
from regulatory  agencies, and invest igation of variable response that may no t be observed unt il 
later in drug development or when the drugs become co mmercially available.
Molecular techno logies are expected to improve during the [ADDRESS_1179668] ion.
I4T-MC-JVDL( c) Clinical Protocol Page 80
LY3009806 ; LY30122119.8. Biomark ers
Biomarker research is performed to address questions of relevance to drug disposit ion, target 
engagement, pharmacodynamics, mechanism o f action, variabilit y of pat ient response (including 
safet y), and clinical outcome.  Sample collect ion is incorporate d into clinical studies to enable 
examinat ion of these questions through measurement of bio molecules including 
deoxy ribonucleic acid ( DNA ), ribonucleic acid ( RNA ), proteins, lipi[INVESTIGATOR_805] , and other cellular 
elements.
As part of Lilly’s ongoing efforts to underst and the relat ionship between cancer, genet ics, and 
response to therapy , this study  will analyze bio markers relevant to study treatment, angiogenesis, 
immune funct ioning, and/or NSCLC and/or for related research methods or validat ion of 
diagnosti c tool s or assays.
Samples for bi omarker research will be co llected as specified in  Appendix [ADDRESS_1179669] ion of ramucirumab (for Cohort A) , the EGFR pathway, immune 
funct ioning, and/or for research -related m ethods or validating diagnostic tools or assays.
All samples will be coded wi th the pati ent number.  These samples and any data generated can 
be linked back to the patient only by [CONTACT_327790].
Samples will  be retained for a m aximum  of [ADDRESS_1179670] patient visit for the study , or 
for a shorter peri od if local regulati ons and/or ERBs impose shorter time limits, at a facilit y 
selected by  [CONTACT_456] .  Thi s retent ion peri od enables use of new techno logies, response to 
questions fro m regul atory  agencies, and invest igation of variable response that may not be 
observed unt il later in drug development or when the drugs beco me commercially available.
9.8.2. Tumor Tissue Samples
Tumor tissue will  be examined for bio markers related to NSCLC, ramucirumab, necitumumab, 
the EGFR pathway, immune funct ioning, and/or research -related m ethods or validat ing 
diagnosti c tool s or assay .
Collect ion of the fo llowing tum or tissue sample(s) is required for all pat ients in order to 
participate in this study :
Formalin -fixed paraffin -embedded tum or tissue obtained fro m a biopsy taken afte r disease 
progression on the most recent EGFR TKI treatment fro m the primary  tumor or metastati c site 
I4T-MC-JVDL( c) Clinical Protocol Page 81
LY3009806 ; LY3012211shoul d be provi ded as a bl ock or unstained slides.  Due diligence should be used to make sure 
that tumor sample (not a normal adjacent or a tumor margin sample) is provided.  Pathology  
report accompanying archival t issue may  also be requested. The report must be coded with the 
patient number. Personal ident ifiers, including the patient’s name [CONTACT_133430], must be removed 
from the insti tutional pathol ogy report pri or to submissio n.  Archival blo cks will be sect ioned 
and returned to the study  site. Slides and t issue samples co llected on -study  will not be returned.
Samples will  be retained for a m aximum  of [ADDRESS_1179671] patient visit for the study , or 
for a shorter peri od if local regulations and/or ERBs impose shorter time limits, at a facilit y 
selected by  [CONTACT_1034] .  This retention period enables use of new techno logies, response to 
questions fro m regul atory  agencies, and invest igation of variable response that may not be 
observed unt il later in drug develop ment or when the drugs beco mecommercially available.
Techno logies are expected to improve during the [ADDRESS_1179672] ing techno logies, including mutation profiling, copy  number 
variabilit y,gene expressio n, and/or immunohistochemistry ,may be performed on these tissue 
samples to assess potential associat ions wi th these bi omarkers and clinical outcomes.
In addit ion to the required tumor tissue and bio marker sam ples discussed in Secti ons  9.8.[ADDRESS_1179673] ion of an addit ional biopsy  specimen and 
blood sam ple after treatment with study  drug(s) has been init iated, including potentially after 
disease progressi on.  Such addi tional bi opsies should be performed o nly if they do not create 
undue risk to the patient.  If these addit ional samples are requested, they  will be used to further 
investigate mo lecular features that may explain treatment response and resistance mechanisms.
9.8.3. Immunogenicity Assessments
Immunogen icity samples will be collected at baseline for all pat ients and when an IRR occurs.  
The immunogenicit y assessments will be performed only for those patients who experienced an 
IRR.
Blood sam ples f or immunogenicit y testing will  be collected as shown in  Appendix [ADDRESS_1179674] ram ucirumab (for Arm A and Cohor t A) or necitumumab 
(for Arm B).  Imm unogenici ty will be assessed by [CONTACT_848448] y assay sdesigned to 
detect anti -ramucirumab and ant i-necitumumab antibodi es in the presence of ramucirumab (for 
Arm A and Cohort A) and necitumumab (for Arm B), respecti vely.  Ant ibodies may be further 
characterized and/or evalua ted for thei r abili ty to neutralize the activit y of ramucirumab (for Arm 
A and Cohort A) or necitumumab (for Arm B).
Samples will  be retained for a m aximum  of [ADDRESS_1179675] the pati ent visi t for the study , or 
for a shorter peri od if regulat ions and ERBs impose shorter time limits, at a facilit y selected by  
[CONTACT_456].  The duration allows the sponsor to respond to future regulatory  requests related to 
ramucirumab or neci tumumab.
9.9. Health Economics
Not applicable.
I4T-MC-JVDL( c) Clinical Protocol Page 82
LY3009806 ; LY301221110.Statistical Considerations
10.1. Sample Size Determination
The primary  object ive for the Dose -Finding Portion and the Dose -Expansio n Portion is to 
evaluate safety  and tolerabilit y. The sample size of the Dose -Expansio n Portion is selected to 
allow adequate assessment of safet y at the recommended do ses for ramucirumab in co mbinat ion 
with osimertinib.
The fo llowing sample sizes apply  to each porti on of the study :
Dose- Finding P ortion :up to 12 DLT- evaluable patients each for Arms A and B
Dose- Expansion Portion:22patients for Cohort A 
During the Dose -Expansio n Portion, 22patients in Cohort A will be treated, to provide a 
preliminary assessment of tumor response and an assessment of safet y. All patients enro lled in 
the Dose -Finding Portion (Arm A) will also be included for all planned analyses. The null 
hypothesis is based on the assumption that the ORR is no greater than 60% and the target 
treatm ent effect (alternat ive response rate) of the combinat ion treatment on ORR is greater than 
70% and 75%, respectively . Based on these assumptions, a sample size of n=[ADDRESS_1179676] ical power of approximately  58% and 78%, respect ively, with a 1-sided 0.20 si gnificance 
level .
10.2. General Statistical Considerations
Statistical analysis o f this study  will be the responsibilit y of Lilly.
For the Dose -Finding P ortion, a 3+3 dose de-escalation design will be used to assess the safet y 
of ramucirumab or necitumumab in co mbinat ion with osimertinib. Addit ional pat ients will be 
enrolled in a dosing schedule to achieve the minimum of 3 evaluable pat ientsfor each arm , if 
dropouts or dose interruptions or reductions occur that result in a patient being nonevaluable for 
DLTs. Data will be reviewed by [CONTACT_702369] (3 patients) for each arm .
For the Dose -Expansio n Porti on, final analysis will occur upon the com pletion of the study .  
Primary analysis will be conducted approximately [ADDRESS_1179677] pati ent receive sinitial 
dose.   All patients enrolled in the D ose-Finding Porti on (Arm A)and the Dose -Expansio n 
Porti on (Co hort A) will be included for all planned analyses. Patients enro lled in Arm B of the
Dose -Findi ng Portion will be analyzed separately .
Descript ive statistics will be derived where appropriate. The rate of DLTs will be summarized
by [INVESTIGATOR_216]; dose exposure for each study  drug will be calculated.
Pharmacodynamics/ Biomarkers
Pharmacodynamic and tailoring bio marker analyses will be based on the subset of patients from 
the above cohorts from who m a valid assay  resul t (according to l aboratory  guideline) has been 
obtained.
General
I4T-MC-JVDL( c) Clinical Protocol Page 83
LY3009806 ; LY3012211Addit ional details may be provided in a separate statist ical analysis plan (SAP) for the study .  
Any change to the data analysis methods described in the protocol will require an amendment
ONLY if it changes a principal feature of the protocol .  Addit ional expl oratory  analyses of the 
data will be conducted as deemed appropriate.
10.3. Statistical Analyses
10.3.1. Efficacy Analyses
ORR and DCR (according to RECIST 1.1) , and the corresponding confidence intervals, will be 
provi ded for Arm A and Cohort A . Patient s enro lled in Arm B of the Dose -Finding Portion will 
be analyzed separately.  Time-to-event variables, such as time to response, DOR, PFS, and OS ,
will be estimated by [CONTACT_5263]- Meier (1958) methodology . Presentations of efficacy may include 
patients enrolled in the Dose -Finding Portion with the sam e treatm ent schedule.
10.3.2. Safety Analyses
All patients who receive at least [ADDRESS_1179678] igator using CTCAE Versio n 4.0.
Safety analyses will include summaries of the fo llowing:
DLTs:  the number of patients who experienced any DLTs during DLT observat ion 
periodwill besummarized by  [CONTACT_848449] -Finding Portion for each arm.
AEs, including severit y and possible rel ationship to study  drug
AEs by  [CONTACT_4131]®System  Organ Class (SOC) by 
[CONTACT_328462]
Laboratory  and nonlaboratory  AEs by [CONTACT_848450] 
(regardless of causalit y and at l east possibly related to study  treatm ent)
10.3.3. Other Analyses
[IP_ADDRESS]. Patient Disposition
A detailed description o f patient di sposi tion will be provi ded, including a summary  of the 
number and percenta ge of pati ents entered into the study , enrolled in the study , and treated as 
well as number and percentage of patients completing the study , as defined in the SAP, or 
discontinuing (overall and by [CONTACT_702391]).  A summary o f all important pr otocol  
deviat ions will be provided.
[IP_ADDRESS]. Patient Characteristics
Patient characterist ics which will be summarized by:
Patient dem ographics will be reported using descriptive statist ics. Demographic data are 
collected and reported to demonstrate that the study populati on represents the target 
patient popul ation consi dered f or regulatory  approval.
I4T-MC-JVDL( c) Clinical Protocol Page 84
LY3009806 ; LY3012211Baseline disease characterist ics will be summarized by [CONTACT_848451] (for example, for pathological diagnosis [histo logical or cy tological] and 
disease stage).
Disease -related therapi[INVESTIGATOR_848413] 
(such as t ype of therapy, regimen, and prior surgery) .
Other patient characterist ics will be summarized as deemed appropriate.
[IP_ADDRESS]. Concomitant Therapy
A summary  of prior and concomitant medications by [CONTACT_848452].
[IP_ADDRESS]. Postdiscontinuation Therapy
The numbers and percentages of patients reporting postdiscont inuat ion ant icancer therapi[INVESTIGATOR_246640], by  [CONTACT_67887]  (surgery , radi otherapy , or systemic therapy ), and by  [CONTACT_848453]/or nam e.
[IP_ADDRESS]. Treatment Compliance
The number of cycles received, dose omissio ns, dose reductions, dose delays, and dose intensit y 
will be summarized for all treated patients by  [CONTACT_2939] .
[IP_ADDRESS]. Pharmacokinetic Analyses
Serum  Cminand concentrati ons at [ADDRESS_1179679] end of infusio n (approximately  Cmax) for 
ramucirumab and neci tumumab will be summari zed by  [CONTACT_732673].
[IP_ADDRESS]. Immunogenicity Analyses
Immunogenicit y samples will be collected at basel ine for all pat ients and when an IRR occurs.  
The immunogenicit y analyses will be performed only  for those pati ents who experienced an IRR .
Immunogenicit y (anti-ramucirumab and ant i-necitumumab antibody ) incidence will be tabulated
for those individuals who experience an IRR , and correl ation to ramucirumab and necitumumab 
drug l evel, activit y, and safet y will be assessed, as appropriate, respectively.  The measures that 
will be analyzed include the presence of baseline antidrug ant ibodies (ADA ), treatm ent-emergent 
ADA, neutralizing ADA, and incidence of ADA related to IRRs.
[IP_ADDRESS]. Biomarker Analysis
Biomarkers may be summarized and assessed for corre lations with clinical outcomes.
10.3.4. Interim Analys is
For the Dose -Finding Portion , safet y and PK data will be reviewed on an arm-by-armbasis 
during the study .The purpose of these data reviews is to evaluate the safet y and tol erabili ty for 
each dose schedule and determine if a DLT has been observed. The invest igators and the Lilly 
study  team  will evaluate the totalit y of data to determine whether or not to move into the 
Dose -Expansion Porti on.
I4T-MC-JVDL( c) Clinical Protocol Page 85
LY3009806 ; LY301221111.References
Bell DW, Lynch TJ, Haserlat SM, Harris PL, Okimoto RA, Brannigan BW, Sgroi DC, Muir B, 
Riemenschneider MJ, Iacona RB, Krebs AD, Johnson DH, Giacc one G, Herbst RS, 
Manego ldC, Fukuoka M, Kris MG, Baselga J, Ochs JS, Haber DA. Epi[INVESTIGATOR_848414]-small -cell lung cancer: m olecular analysis o f 
the IDEAL/INTACT gefit inib trials. J Clin Oncol. 2005;23( 31):8081 -8092.
Bray  F, Jemal A, Grey  N, Ferl ay J, Form an D. Gl obal cancer transit ions according to the Human 
Development Index (2008- 2030): a populat ion-based study . Lancet Oncol . 
2012;13(8):790 -801.
Bunn PA. Worldwide overview of the current status of lun g cancer di agnosis and treatm ent. 
Arch Pathol Lab Med . 2012;136(12):[ADDRESS_1179680]. NatRev 
Clin Oncol . 2009;6(8):465 -477.
Cockcroft DW, Gault MD. Prediction of creat inine clearance fro m serum  creat inine. Nephron . 
1976;16:[ADDRESS_1179681] P, Al -Kadhimi K, Rowlinson R, Klinowska T, Richmo nd GH, Cantarini M, Kim DW, 
Ranson MR, Pao W. AZD9291, an irreversible EGFR TKI, overcomes T790M -mediated 
resistance to EGFR inhibitors in lung cancer. Cancer Discov. 2014;4(9):1046-1061.
Eisenhauer EA, Therasse P, Bogaert J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, 
Gwy ther S, Mooney  M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Laco mbe D, Verweij J. 
New response evaluat ion criteria in so lid tumours: revised REC IST gui deline (versi on 1.1). 
Eur J Cancer . 2009;45(2): 228-247.
Garg RK. Posterior leukoencephalopathy  syndrome. Postgrad Med J . 2001;77(903):[ADDRESS_1179682].
2013;18 (11):1214 -1220.
Hanna N, Lilenbaum R, Ansari R, Lynch T, Govindan R, Jänne PA, Bonomi P. Phase II trial of 
cetuximab in pat ients with previ ously  treated n on-small -cell l ung cancer. J Clin Oncol.
2006;24(33):[ADDRESS_1179683] in F, Flynn P , Hart L, Otterson GA, Vlahovic G, Soh CH, O'Connor P, 
Hainsworth J. Efficacy  of bevacizumab plus erlotinib versus erlotinib alo ne in advanced non -
small -cell l ung cancer after failure of standard first -line chemotherapy (BeTa): a double -blind, 
placebo -controlled, phase 3 trial. Lancet. 2011;377(9780):1846- 1854.
Hinchey J, Chaves C, Appi[INVESTIGATOR_179901] B, Breen J, Pao L, Wang A, Pessin MS, Lamy C, Mas JL, 
Caplan LR. A reversible posterior leukoencephalo pathy  syndrom e. N Engl J Med . 
1996;334(8):494 -500.
I4T-MC-JVDL( c) Clinical Protocol Page 86
LY3009806 ; LY3012211Janjigian YY, A zzoli  CG, Krug LM, Pereira LK, Rizvi NA, Pi[INVESTIGATOR_33006], Kris MG, 
Ginsberg MS, Pao W, Miller VA, Riely GJ. Phase I/II trial o f cetuximab and erlotinib in 
patients wi th lung adenocarcinom a and acqui red resistance to erl otinib. Clin Cancer Res.
2011;17(8):[ADDRESS_1179684], Riely GJ, Wang B, Fu Y, 
Chand VK, Miller VA, Pao W. Dual inhibit ion of EGFR with afatinib and cetuximab in kinase 
inhibitor -resistant EGFR -mutant lung cancer wi th and wi thout T790M mut ations. Cancer 
Discov. 2014;4(9):[ADDRESS_1179685] D, Ohe Y, Ramalingam SS, Ahn MJ, Kim SW, Su WC, 
Horn L, Haggstrom D, Felip E, Kim JH, Frewer P, Cantarini M, Brown KH, Dickinso n PA, 
Ghiorghiu S, Ranson M. AZD9291 in EGFR inh ibitor -resistant non -small-cell lung cancer. 
N Engl J Med. 2015;372(18):1689 -1699.
Johnson BE, Kabbinavar F, Fehrenbacher L, Hainsworth J, Kasubhai S, Kressel B, Lin CY, 
Marsland T, Patel T, Poliko ff J, Rubin M, White L, Yang JC, Bowden C, Miller V. ATLAS:
rando mized, double -blind, placebo -controlled, phase IIIB trial co mpar ing bevacizumab 
therapy  with or wi thout erl otinib, after com pletion of chemotherapy , with bevacizumab for 
first-line treatment of advanced non -small -cell l ung cancer. J Clin Oncol.
2013; 31(31):3926 -3934.
Kaplan EL, Meier P. Nonparametric estimat ion of inco mplete observat ions. J Amer Stat Assoc . 
1958;53:457 -481.
Lee VH, Wijdicks EF, Manno EM, Rabinstein AA. Clinical spectrum of reversible posterior 
leukoencephalopathy  syndrom e. Arch Neurol . 2008;65(2):205 -210.
Meador CB, Jin H, de Stanchina E, Nebhan CA, Pi[INVESTIGATOR_657864] V, Wang L, Lu P, Vuong H, 
Hutchinson KE, Jia P, Chen X, Eisenberg R, Ladanyi M, Po liti K, Zhao Z, Lovly CM, 
Cross DA, Pao W. Optimizing the sequence of ant i-EGFR -targeted therapy  in EGFR -mutant 
lung cancer. Mol Cancer Ther. 2015;14(2):[ADDRESS_1179686] inal malignancies: 
Canadian recommendat ions. Curr Oncol .2009;16(1):16 -26.
Mok T, Wu YL, Zhang L. A small step towards personalized medicine for non -small cell lung 
cancer. Discov Med. 2009;8(43):227 -231.
Mok TS, Lee K, Leung L. Targeting epi[INVESTIGATOR_848415]. Semin Oncol. 2014;41(1):101 -109.
[NCCN] National Co mprehensive Cancer Network. NCCN Guidelines for Treatment of 
Non-small cell  lung cancer. Version 4. 201 6.
[NCI] National Canc er Insti tute. Cancer Therapy Evaluat ion Program , Comm on Termino logy 
Criteria for Adverse Events, Version 4.0, DCTD, NCI, NIH, DHHS. 2009. Publish date: 
29May 2009.
I4T-MC-JVDL( c) Clinical Protocol Page 87
LY3009806 ; LY3012211Neal JW, Heist RS, Fi dias P, Tem el JS, Huberman M, Marcoux JP, Muzikansky A, Lynch TJ, 
Sequi st LV. Cetuximab monotherapy  in pat ients wit h advanced non -small cell lung cancer 
after pri or epi [INVESTIGATOR_848416] . J Thorac Oncol.
2010;5(11):1855 -1858.
Oken MM, Creech RH , Torm ey DC, Horton J , Davis TE, McFadden ET, Carbone PP. Toxi city 
and response criteria of the eastern cooperative oncology  group .Am J Clin Oncol . 
1982;5:649 -655.
Patel  D, Saxena B, Zhou Q, Walton W, Srikakulum  R, Mantei ga R, Haurum  J, Tonr a JR, 
Kang X. Different ial induction o f antibody -dependent cellular cy totoxi city (ADCC) against 
human EGFR -expressing NSCLC cell lines by  [CONTACT_328477], cetuximab, and panitumumab. 
JClin Oncol 2011;29 (suppl; abstr e21075).
Paz-Ares L, Mezger J, Ciuleanu TE, Fischer JR, von Pawel J, Provencio M, Kazarnowicz A, 
Losonczy  G, de Castro G Jr, Szczesna A, Crino L, Reck M, Ramlau R, Ulsperger E, 
Schumann C, Miziara JE, Lessa ÁE, Dediu M, Bálint B, Dep enbrock H, Soldatenkova V, 
Kurek R, Hirsch FR, Thatcher N, Socinski MA; INSPI[INVESTIGATOR_848417]. Necitumumab plus 
pemetrexed and cisplat in as first -line therapy in patients wi th stage IV non -squamous non -
small cell lung cancer (INSPI[INVESTIGATOR_21392]): an open -label, rando mized, controlled phase -3 study . 
Lancet Oncol .2015 ;16(3): 328-337 .
Peters S, Zimmermann S, Adjei AA. Oral epi[INVESTIGATOR_848418]- small  cell lung cancer: comparat ive pharmacokinetics and 
drug-drug interactions. Cancer Treat Rev. 2014;40(8):917 -926.
Portrazza (necitumumab) [package insert]. Indianapolis, IN: Eli Lilly and Co mpany; 2015.
Ramalingam S, Forster J, Naret C, Evans T, Sulecki M, Lu H , Teegarden P, Weber MR, 
Belani CP. Dual  inhibit ion of the epi[INVESTIGATOR_848419], an IgG1 
monoclonal antibody , and gefi tinib, a ty rosine kinase inhibitor, in pat ients with refractory  non-
small cell lung cancer (NSCLC): a phase I study . J Thorac Oncol. 2008;3(3):258 -264.
Riemenschneide r MJ, Bell  DW, Haber DA, Loui s DN. Pulm onary adenocarcinomas with mutant 
epi[INVESTIGATOR_848420]. N Engl J Med. 2005;352(16):1724 -1725.
Rizzo JD, Somerfield MR, Hagerty  KL, Sei denfeld J, Bohlius J, Bennett CL, Cella DF, 
Djulbegovic B, Goode MJ, J akubowski AA, Rarick MU, Regan DH, Licht in AE ; American 
Society of Clinical  Oncol ogy; American Society  of Hematol ogy. Use of epoetin and 
darbepoetin in pat ients with cancer: 2007 American Society  of Clinical Onco logy/American 
Society of Hematol ogy clinical pract ice guideline update. J Clin Oncol . 2008;26(1):132 -149. 
Erratum  in: J Clin Onco l. 2008;26(7):1192.
I4T-MC-JVDL( c) Clinical Protocol Page 88
LY3009806 ; LY3012211Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massut i B, Felip E, Palmero R, Garcia -
Gom ez R, Pallares C, Sanchez JM, Porta R, Cobo M, Garrido P, Lon go F, Moran T, Insa A, 
De Marinis F, Corre R, Bover I, Illiano A, Dansin E, de Castro J, Milella M, Reguart N, 
Altavilla G, Jimenez U, Provencio M, Moreno MA, Terrasa J, Muñoz -Langa J, Valdivia J, 
IslaD, Domine M, Molinier O, Mazieres J, Baize N, Garcia -Campel o R, Robinet G, 
Rodri guez -Abreu D, Lopez -Vivanco G, Gebbia V, Ferrera -Delgado L, Bombaron P, 
Bernabe R, Bearz A, Artal A, Cortesi E, Rolfo C, Sanchez -Ronco M, Drozdowskyj A, 
Queral tC, de Aguirre I, Ramirez JL, Sanchez JJ, Molina MA, Taron M, Paz -Ares L; Spanish 
Lung Cancer Group in co llaboration with Groupe Français de Pneumo -Cancérologie and 
Associ azione Italiana Oncol ogia Toraci ca. Erl otinib versus standard chemotherapy  as first -line 
treatm ent for European patients with advanced EGFR mutation- positive non-small -cell lung 
cancer (EURTAC): a mult icentre, open -label, randomised phase 3 trial. Lancet Oncol.
2012;13(3):[ADDRESS_1179687] LV, Yang JC, Yamamoto N, O'By [CONTACT_7943] K, Hirsh V, Mok T, Geater SL, Orlov S, Tsai CM, 
Boyer M, Su WC, Bennouna J, Kato T, Gorbunova V, Lee KH, Shah R, Massey D, 
Zazulina V, Shahidi M, Schuler M. Phase III study of afatinib or cisplat in plus pemetrexed in 
patients wi th metastati c lung adenocarcinom a with EGFR m utations. J Clin Oncol.
2013;31(27):[ADDRESS_1179688]-line therapy in pat ients with 
advanced non -squam ous non -small -cell l ung cancer harbouring EGFR mutations (JO25567): 
an open -label, rando mised, mult icentre, phase 2 study . Lancet Oncol . 2014;15(11):[ADDRESS_1179689] FA, Rodrigues Pereira J, Ciulean u T, Tan EH, Hi rsh V, Thongprasert S, Campos D, 
Maoleekoonpi[INVESTIGATOR_810539] S, Smylie M, Martins R, van Kooten M, Dediu M, Findlay B, Tu D, 
Johnston D, Bezjak A, Clark G, Santabárbara P, Seymour L; National Cancer Inst itute of 
Canada Clinical Trials Group. Erlotinib i n previously treated non -small-cell l ung cancer. N 
Engl J Med. 2005;353(2):[ADDRESS_1179690]. 2005;97(5):[ADDRESS_1179691] J, Cross SJ, Demetri G, Desch CE, Pi[INVESTIGATOR_4607], Schiffer CA, 
Schwartzberg L, Som erfield MR, Somlo G, Wade JC, Wade JL, Winn RJ, Wozniak AJ, 
WolffAC. Update of recommendat ions for the use of white blood cell growth factors: an 
evidence -based clinical pract ice guideline . J Clin Oncol . 2006;24(19):3187- 3205.
I4T-MC-JVDL( c) Clinical Protocol Page 89
LY3009806 ; LY3012211Stahel  RA, Dafni  U, Gautschi O, Felip E, Curioni -Fontecedro A , Peters S, Massutí B, 
Cardenal F, Aix SP, Früh M, Pless M, Popat S, Kotsakis A, Cuffe S, Bido li P, Favaretto A, 
Carcereny E, Sanchez Ronco M, Molina MA, Ro sell R. A phase II trial of erlotinib (E) and 
bevacizumab (B) in pat ients with advanced non -small -cell lung cancer (NSCLC) with 
activat ing epi[INVESTIGATOR_3506] (EGFR) mutations with and without T790M 
mutati on.The Spanish Lung Cancer Group (SLC G) and the European Thoracic Onco logy 
Platform (ETOP) BELIEF tri al. European Cancer Congress [ADDRESS_1179692] number: 3BA .
Stott VL, Hurrell MA, Anderson TJ. Reversible posterior leukoencephalopathy syndrome: a 
misno mer reviewed. Intern Med J . 2005;35(2):83 -90.
Tagrisso (osimertinib) [package insert]. Wilmington, DE: [COMPANY_008] Pharmaceut icals LP; 
2015.
Tajima Y, Isonishi K, Kashiwaba T, Tashiro K. Two similar cases o f encephalopathy , possibly a 
reversible posterior leukoencephalopathy  syndrome: serial findings of magnet ic resonance 
imaging, SPECT and angiography. Intern Med . 1999;38(1):54 -58.
Thatcher N, Hirsch FR, Luft AV, Szczesna A, Ciuleanu TE, Dediu M, Ramlau R, Galiulin RK, 
Bálint B, Losonczy  G, Kazarnowi cz A, Park K, Schumann C, Reck M, Depenbrock H, 
Nanda S, Kruljac -Letunic A, Kurek R, Paz -Ares L, Socinski MA; SQUIRE Invest igators.
Necitumumab plu s gemci tabine and cisplatin versus gemcitabine and cisplat in alone as first -
line therapy  in pat ients with stage IV squam ous non -small -cell lung cancer (SQUIRE): an 
open -label, rando mised, controlled phase 3 trial. Lancet Oncol. 2015;16(7):[ADDRESS_1179693] ivity in 
patients wi th non-small cell lung cancer (including squamous cell carcino mas) and wild -type 
EGFR or resistant mutations. Mol Cancer Ther. 2013;12(10):2167 -2175.
Yoshimura N, Okishio K, Mitsuoka S, Kimura T, Kawaguchi T, Kobayashi M, Hirashima T, 
Daga H, [COMPANY_005] K, Hirata K, Kudoh S. Prospective assessment of continuation o f erlotinib or 
gefitinib in pat ients with acquired resistance to erlotinib or gefit inib fo llowed by [CONTACT_848454]. J Thorac Oncol. 2013;8(1):[ADDRESS_1179694] -line treatment for patients with 
advanced EGFR mutation -positive non-small -cell lung cancer (OPTIMAL, CTONG -0802): a 
multicentre, open -label, rando mised, phase 3 study. Lancet Oncol. 2011;12(8):735 -742.
I4T-MC-JVDL( c) Clinical Protocol Page 90
LY3009806 ; LY3012211Appendix 1. Abbreviations and Definitions
Term Definition
ADA antidrug antibody
AE Adverse event:  any untoward medical occurrence in a patient or clinical investigation 
patient administered a pharmaceutical product and that does not necessarily have a 
causal relationship with this treatment.  An adverse event can therefore be any 
unfavorable and unintended sign (including an abnormal laboratory finding), symptom, 
or disease temporally associated with the use of a med icinal (investigational) product, 
whether o r not related to the medicinal (investigational) product.
AESI adverse event of special interest 
ALT alanine aminotransferase 
ANC absolute neutrophil count 
aPTT activated partial thromboplastin time 
ASCO American Society of Clinical Oncology 
AST aspartate aminotra nsferase
ATE arterial thromboembolic event
AUC ss area under the plasma concentration -time curve at steady state
BCRP breast cancer resistance protein
β-hCG beta human chorionic gonadotropin 
BICR blinded independent central review 
C1D1 Cycle 1 Day  1
CHF congestive heart failure
CI confidence interval
Cmax maximum concentration
Cmin minimum concentration
Cmin,ss minimum concentration at steady state
CR complete response
CRF case report form 
I4T-MC-JVDL( c) Clinical Protocol Page 91
LY3009806 ; LY3012211CRP Clinical research physician:  Individual responsible for the medical conduct of the 
study.  Responsibilities of the CRP may be performed by a physician, clinical research 
scientist, global safety physician, or other medical officer.
CRS clinical research scientist
CSR clinical study report 
CT computed tomography 
CTCAE Common Terminology Criteria for Adverse Events
ctDNA circulating tumor deoxyribonucleic acid
CYP cytochrome P450
DCR disease control rate
DLT dose-limiting toxicity
DNA deoxyribonucleic acid
DOR duration of response
ECG Electrocardiogram
ECHO Echocardiogram
ECOG Eastern Cooperative Oncology Group
eCRFelectronic case report form 
effective method of 
contraceptionmale condom with spermicide, female condom with spermicide, diaphragm with 
spermicide, cervical sponge, or cervical cap with spermicide.
Also see the definition of highly effective method of contraception.
EGFR epi[INVESTIGATOR_848421] a patient to a treatment.  Patients who are enrolled in the trial are 
those who have been assigned to a treatment.
enter Patients entered into a trial are those who sign the informed consent form directly or 
through their legally acceptable representatives.
ERB ethical review board
EU European Union
FOLFIRI irinotecan, 5-fluorouracil, and folic acid
FSH follicle -stimulating hormone
GCP good clinical practice
I4T-MC-JVDL( c) Clinical Protocol Page 92
LY3009806 ; LY3012211GEJ gastroesophageal junction 
GI gastrointestinal 
highly effective 
method of 
contraceptioncombined o ralcontraceptive pi[INVESTIGATOR_81061] -pi[INVESTIGATOR_4382], NuvaRing ®, implantable contraceptives, 
injectable contraceptives (such as Depo -Provera ®), intrauterine device (such as 
Mirena ®and ParaGard ®), contraceptive patch for women <90 Kg (<198 pounds), total 
abstinence, or vasec tomy .
Also see the definition of effective method of contraception.
HIV human immunodeficiency virus
HR hazard ratio
HRCT high-resolution computed tomography
IB investigator’s brochure
ICF informed consent form
ICH International Conference on Harmonisation
IDMC independent data monitoring committee
IgG immunoglobulin G
ILD interstitial lung disease
INR International Normalized Ratio
interim analysis An interim analysis is an analysis of clinical trial data conducted before the final 
reporting database is created/locked.
investigational 
productA pharmaceutical form of an active ingredient or placebo being tested or used as a 
reference in a clinical trial, including products already on the market when used or 
assembled (formulated or packaged) in a way different from the authorized form, or 
marketed products used for an unauthorized indication, or marketed products used to 
gain further information about the authorized form.
IRR infusion -related reaction
I.V. intravenous 
IWRS intera ctive web -response sy stem
mAb monoclonal antibody
mCRC metastatic colorectal cancer
mPFS median progression -free survival
MRI magnetic resonance imaging
I4T-MC-JVDL( c) Clinical Protocol Page 93
LY3009806 ; LY3012211MTD maximal tolerated dose
MUGA Multiple-gated acquisition
NC not calcula ble
NCCN Natio nal Comprehensive Cancer Network
NCI Natio nal Cancer Institute 
NSAIDs nonsteroidal anti -inflammatory agents
NSCLC non-small cell lung cancer
OR objective response
ORR objective response rate
OS overall survival
PD progressive disease 
PFS progression -free survival
PI [INVESTIGATOR_848422] n pharmacokinetics
PR partial response
PRO patient -reported outcome
PT prothrombin time
PTT partial thromboplastin time
Q2W every [ADDRESS_1179695] Response Evaluation Criteria in Solid Tumors
reporting database A point -in-time copy of the collection database.  The final reporting database is used to 
produce the analyses and output reports for interim or final analyses of data.
I4T-MC-JVDL( c) Clinical Protocol Page 94
LY3009806 ; LY3012211re-screen to screen a patient who was previously declared a screen failure for the same study
RNA ribonucleic acid
RPLS reversible posterior leukoencephalopathy syndrome
SAE serious adverse event
SAP Statistical Analysis Plan
screen The act of determining if an individual meets minimum requirements to become part of 
a pool of potential candidates for participation in a clinical study.
screen failure patient who does not meet one or more criteria required for participation in a trial
SmPC Summary of Product Characteristics
SOC System Organ Class
SRC safety review committee
S[LOCATION_003]Rs suspected unexpected serious adverse reactions
T3 triiodothyronine
T4 thyroxine
TEAE Treatment -emergent adverse event:   a n untoward medical occurrence that emerges 
during a defined treatment period, having been absent pretreatment, or worsens relative 
to the pretreatment state, and does not necessarily have to have a causal relationship 
with this treatment .
TKI tyrosine kinase inhibitor
TSH thyroid-stimulating hormone
ULN upper limit of normal
US [LOCATION_002]
VEGF vascular endothelial growth factor
VEGFR2 vascular endothelial growth factor receptor 2
VTE venous thromboembolic event
I4T-MC-JVDL( c) Clinical Protocol Page 95
LY3009806 ; LY3012211Appendix 2. Study  Governance, Regulatory , and 
Ethical Considerations
Informed Consent
The invest igator is responsible for:
ensuring that the patient understands the potential risks and benefits of participat ing in 
the study
ensuring that informed consent is given by [CONTACT_57996].  This 
includes obtaining the appropriate signatures and dates on the ICF prior to the 
perform ance of any study procedures and prior to the administration of study  treatm ent.
answering any quest ions the pati ent m ay have throughout the study  and sharing in a 
timely  manner any  new inform ation that m ay be relevant to the patient’s willingness to 
continue his or her participat ion in the trial.
Ethical Review
Docum entati on of  ERB approval  of the protocol and the ICF must be provided to Lilly before the 
study  may begin at the investi gative si te(s).  Lilly or its representatives must approve the ICF, 
including any  changes made by [CONTACT_522120] s, before it is used at the invest igative site(s).  All ICFs 
must be compliant with the ICH guideline on GCP.
The invest igator must give assurance that the ERB was properly const ituted and convened as 
requi red by [CONTACT_848455] d regulati ons.  
The study  site’s ERBs shoul d be provi ded wi th the fo llowing:
the current IB and updates during the course of the study
the ICF
relevant curri cula vi tae
Regulatory Considerations
This study  will be conducted in accordance wit h:
consensus et hics principles derived fro m internat ional ethics guidelines, including the 
Declaration of Helsinki and Council for International Organizat ions of Medical Sciences 
(CIOMS) International Ethical Guidelines 
applicable ICH GCP Guidelines
applicable laws and regulati ons.
Some obligat ions of Lilly may  be assigned to a thi rd-party  organizat ion.  
An identificat ion code assigned to each patient will be used in lieu of the patient’s name [CONTACT_92396]’s identit y when reporting AEs and/or other trial -related data.
I4T-MC-JVDL( c) Clinical Protocol Page 96
LY3009806 ; LY3012211Investigator Information
Physicians with a specialt y inonco logy will participate as invest igators in this clinical trial.
Protocol Signatures
Lilly ’sresponsible medical officer will approve the protocol, confirming that, to the best of his 
or he r knowledge, the protocol accurately  describes the planned design and conduct of the study .
After reading the protocol, each principal invest igator will sign the protocol signature [CONTACT_25327] a copy  of the signed page to a Lilly representative.
Final Re port Signature
[CONTACT_314867] (CSR) coordinating investigator [INVESTIGATOR_848423] , indicat ing agreement that, to the best of his or her knowledge, the report 
accurately describes the conduct and results of the study . 
The invest igator with the most enroll ed pat ientswill serve as the CSR coordinat ing investigator.  
If this invest igator is unable to fulfill this funct ion, another invest igator will be chosen by [CONTACT_221078].
The Lilly responsible medical officer and sta tistician will approve the final CSR for this study , 
confirming that, to the best of his or her knowledge, the report accurately describes the conduct 
and results of the study .
Data Quality Assurance
To ensure accurate, complete, and reliable data, Lilly o r its representatives will do the fo llowing:
provi de instructi onal materi al to the study  sites, as appropriate
sponsor start -up training to instruct the invest igators and study  coordinators.  This sessio n 
will give instruction on the protocol, the completi on of  the CRFs, and study  procedures.
make periodic visit s to the study  site
be available for consultation and stay  in contact [CONTACT_47556], 
telephone, and/or fax
review and evaluate CRF data and use standard computer edits to dete ct errors in data 
collect ion
conduct a qualit y review of the database
In addit ion, Lilly or its representatives will periodically check a sample of the patient data 
recorded against source documents at the study  site.  The study  may be audi ted by  [CONTACT_81144], and/or regulatory  agencies at any  time.  Invest igators will be given notice before 
an audit occurs.
To ensure the safet y of parti cipants in the study , and to ensure accurate, complete, and reliable 
data, t he invest igator will keep reco rds of all original source data.  This might include laboratory  
tests, m edical records, and clinical notes.  If requested, the invest igator will provide Lilly, 
I4T-MC-JVDL( c) Clinical Protocol Page 97
LY3009806 ; LY3012211applicable regulatory  agencies, and applicable ERBs with direct access to original source 
docum ents.
Data Capture System
An electronic data capture sy stem  will be used in this study .  The si te maintains a separate source 
for the data entered by  [CONTACT_848456] -provi ded el ectroni c data capture system.
Case report form data will be encoded and stor ed in a clinical trial database.
Data m anaged by  a central  vendor, such as laboratory  test data, will be stored electronically  in 
the central  vendor’s database system.  Data will subsequent ly be transferred fro m the central  
vendor to the Lilly data warehouse .
Data from co mplaint forms submitted to Lilly will be encoded and stored in the global product 
complaint m anagement sy stem .
Study and Site Closure
Discontinuation of Study Sites
Study  site parti cipat ion may be discont inued if Lilly, the invest igator, or the ERB of the study  
site judges i t necessary  for m edical, safety , regul atory , or other reasons consistent with 
applicable laws, regulat ions, and GCP.
Discontinuation of the Study
The study  will be di scontinued if Lilly judges it necessary for medical, safet y, regul atory , or 
other reasons consistent with applicable laws, regulat ions, and GCP.
I4T-MC-JVDL( c) Clinical Protocol Page 98
LY3009806 ; LY3012211Appendix 3. Clinical Laboratory  Tests
Clinical Laboratory Tests
Hematology –Local lab Clinical Chemistry –Local lab and Central laba
Erythrocy te (RBC) 
Hemoglobin (HGB)Serum Concentrations of:
Hematocrit (HCT) Alkaline phosphatase
Platelet (PLT) Alanine aminotransferase (ALT)
Leukocytes (WBC) Aspartate aminotransferase (AST)
Absolute Neutrophil Count Lactate dehydrogenase (LDH)
Lymphocy tes Creatine kinase (CK)
Monocytes
Eosinophils
BasophilsCreatinine 
Uric acid 
Calcium
Glucose 
Thyroid Function Tests –Central lab Albumin
Thyroid stimulating ho rmone (TSH) Phospho rus
Total triiodothyronine (T3) Potassium
Free thy roxine (T4) Sodium
Magnesium
Total bilirubin
Urinalysis –Local lab
Routine dipstick measurements, and if clinically 
indicated, microscopic analysis.
Proteinb
Blood
GlucoseDirect bilirubin (if total bilirubin is elevated above 
the upper limit of normal)
Total protein
Blood urea nitrogen (BUN)
Chloride
Specific gravity
Coagulation Test –Local lab
Prothrombin time (PT) or International normalized 
ratio (INR) 
Partial thromboplastin time (PTT) or activated PTT 
(aPTT)Pregnancy Testc–Local lab
Urine or Serum
β-human chorionic gonadotropin (β -hCG)
Abbreviations:  RBC = red blood cell; WBC = white blood cell.
aCentral chemistry laboratories will be required to determine patient eligibility at baseline; local chemistry 
laborato ry testing will not be permitted for a determination of patient eligibility. Local chemistry laboratory 
results may be used for on -study dosing decisions; if so, chemistry testing must also still be performed by [CONTACT_19979]. These central chemistry laboratory results will be used for subsequent safety analyses.
bIf urine dipstick or routine analysis indicates proteinuria ≥2+, a 24 hour urine collection (to assess protein) must 
be obtained.
cMinimum sensitivity 25 IU/L or equivalent units of β -human chorionic gonado tropin (β -hCG), for women of 
childbearing potential (WOCBP).  If urine pregnancy results cannot be confirmed as negative, a serum pregnancy 
test will be required.
I4T-MC-JVDL( c) Clinical Protocol Page 99
LY3009806 ; LY3012211Appendix 4. Sampling Schedule for Phar macokinetic s, 
Immunogenicity , Biomarkers , and Pharmacogenetics
It is essent ial that the exact infusio n start and stop times (actual clock readings), as well as 
infusio n parameters (such as, ty pe of  infusio n pump, flow rate settings) are recorded.  The exact 
time of co llection of each venous blood sample will be based on the clock used to record 
infusio n times.  It is essent ial that the pharmacokinetic blood samples not be withdrawn fro m the 
same site as the drug infusio n.
I4T-MC-JVDL( c) Clinical Protocol Page 100
LY3009806 ; LY3012211Sampling Schedule for Pharma cokinetic s, Immunogenicity, Biomarker s, and 
Pharmacogenetics –Ramucirumab A rm and Cohort
Visit/Cycle Day Sample TimePKa
(Serum)IGa
(Serum)Biomarker
(Plasma)PGf
(Whole Blood)
Day -[ADDRESS_1179696] end of ramucirumab 
infusionc X
Day 1 of Cy cle 2 PredosedX
Day 1 of Cy cle 4 PredosedX
Day 1 of Cy cle 5 PredosedX
Day 1 of Cy cle 7 PredosedX X
Day 1 of Cy cle 13 PredosedX
Short -term 30 -day 
Safety Follow -Up 
PeriodAnytimeeX
Note: It is essential that the dosing days, dosing times, draw dates and draw times are accurately recorded.
Abbreviations:  IG = immunogenicity; PG = pharmacogenetic(s); PK=pharmacokinetic(s).
aIn the event of an infusion -related reaction, a blood sample will be collected for both PK and immunogenicity 
analy sis as close to the onset of the reaction as possible, at the resolution of the event, and [ADDRESS_1179697] infusion (baseline; may be obtained within 14 days prior to the initial infusion of 
ramucirumab/placebo on Day 1 Cycle 1).
cCollection window: within 1 to 1.5 hours after the end of ramucirumab infusion .
dCollection window: w ithin [ADDRESS_1179698] dose.  However, it can be collected later during the study if necessary.
I4T-MC-JVDL( c) Clinical Protocol Page 101
LY3009806 ; LY3012211Sampling Schedule for Pharm acokinetics, Immunogenicity, Biomarker s, and 
Pharmacogenetics –Necitumumab A rm
Visit/Cycle Day Sample TimePKa
(Serum)IGa
(Serum)Biomarker
(Plasma)PGf
(Whole Blood)
Day -[ADDRESS_1179699] end of necitumumab 
infusiond X
Day 1 of Cycle 5 PredosecX X
Day 1 of Cy cle 7 PredosecX
Day 1 of Cy cle 9 PredosecX
Short -term 30 -day 
Safety Follow -Up 
PeriodAnytimeeX
Note:  It is essential that the dosing days, dosing times, draw dates and draw times are accurately recorded.
Abbreviations:  IG = immunogenicity; PG = pharmacogenetic(s); PK=pharmacokinetic(s).
aIn the event of an infusion -related reaction, a blood sample will be collected for both PK analysis and 
immunogenicity as close to the onset of the reaction as possible, at the resolution of the event, and [ADDRESS_1179700] infusion (baseline; may be obtained within 14 days prior to the initial infusion of necitumumab 
on Day  1 Cy cle 1).
cPrior to necitumumab infusion.
d1 hour ±[ADDRESS_1179701] dose.  However, it can be collected later during the study if necessary.
I4T-MC-JVDL( c) Clinical Protocol Page 102
LY3009806 ; LY3012211Appendix 5. Hepatic Monitoring Tests for 
Treatment -Emergent A bnormality
Selected tests m ay be obtained in the event of a t reatment -emergent hepatic abnormalit y and may  
be required in fo llow-up wi th patients in consultat ion with the Lilly clinical research physician.
Hepatic Monitoring Tests
Hepatic HematologyaHaptoglobina
Hemoglobin
Hematocrit Hepatic Coagulationa
RBC Prothrombin time
WBC Prothrombin time, INR
Neutrophils
Lymphocy tes Hepatic Serologiesa, b
Monocytes Hepatitis A antibody, total
Eosinophils Hepatitis A antibody, IgM
Basophils Hepatitis B surface antigen
Platelets Hepatitis B surface antibody
Hepatitis B Core antibody
Hepatic ChemistryaHepatitis C antibody
Total bilirubin Hepatitis E antibody, IgG
Direct bilirubin Hepatitis E antibody, IgM
Alkaline phosphatase
ALT Anti -nuclear Antibodya
AST
GGT
CPKAnti -Smooth Muscle Antibodya
Abbreviations:  ALT = alanine aminotransferase; AST = aspartate aminotransferase; CPK = creatine phosphokinase; 
GGT = Gamma -glutamyl transferase; IgG = immunoglobulin G; IgM = immunoglobulin M; INR = international 
normalized ratio; RBC = red blood cell; WBC = white blood cell.
aAssay ed by [CONTACT_11007] -designated laboratory .
bReflex/confirmation dependent on regulatory requirements and/or testing availability.
I4T-MC-JVDL( c) Clinical Protocol Page 103
LY3009806 ; LY3012211Appendix 6. Creatinine Clearance Formula
Note:   This formula is to be used for calculat ing creatinine clearance ( CrCl ) from local 
laboratory results only.
For serum creatinine concentration in 
mg/dL:
CrCl =
(mL/min) (140 – agea) (wt)    0.85 (if female) , or1.0 (if male)
72serum creatinine (mg/dL )
For serum creatinine concentration in mol/L:
CrCl   =
(mL/min)(140 – age a) (wt)  0.85 (if female) , or1.0 (if male)
0.81serum creatinine (mol/L )
aAge in y ears, weight (wt) in kilograms.
Source:  Cockcroft and Gault 1976.
I4T-MC-JVDL( c) Clinical Protocol Page 104
LY3009806 ; LY3012211Appendix 7. Protocol JVDL Restricted and Prohibited 
Concomitant Therapy
The table below describes medicat ions, treatments, and drug classes restricted or prohibited, with 
exceptions and condit ions for use during the study  treatm ent peri od (there ar e no prohibited 
therapi [INVESTIGATOR_848424]-up period).  Patients who, in the assessment by  [CONTACT_3170], 
requi re the use of any of the prohibited treatments for clinical management should be remo ved 
from the trial.  Pati ents m ay receive other support ive therapy or vaccinat ions that the invest igator 
deems to be medically necessary .
In addit ion, there are potential interact ions between osimertinib and either CYP3A4 inducers or 
CYP3A4 inhibitors .  Drugs that induce CYP3A4, such as carbamazepi[INVESTIGATOR_050], fospheny toin, 
oxcarbazepi[INVESTIGATOR_050], pentobarbital, phenobarbital, phenyto in, rifabut in, rifamp in, rifapentine, orSt. 
John’s wort , may reduce the effects of osimertinib through increased osimertinib metabolism and 
decreased plasma concentrations.  Therefore, avoid strong CYP3A4 inducers if possible.  For 
strong CYP3A4 inhibitors, avoid concur rent administrati on if possible; however, if no alternat ive 
exists, the patient should be closely mo nitored for si gns of  toxicity.
I4T-MC-JVDL( c) Clinical Protocol Page 105
LY3009806 ; LY3012211TherapyAs 
NeededChronic 
Use Exceptions or Conditions for Use
Anti-platelet therapy yes no Chro nic use of aspi[INVESTIGATOR_155752] 325 mg/day is permitted.
Anticoagulation therapy no Yes, with 
restrictionsAt enrollment, patients on full -dose anticoagulation must be on 
a stable dose (minimum duration 14 days) of oral anticoagulant 
or low molecular weight heparin or similar agent.  If on 
warfarin, the patient must have an INR ≤3 and no active 
bleeding or pathological condition present that carries a high 
risk of bleeding (e.g., tumor i nvolving major vessels or known 
varices).
Anti-cancer biological 
therapyno no
Chemotherapy no no
Colon y-stimulating 
factorsyes no Follow local guidelines.
Erythroid growth factors yes no Follow local guidelines.
Experimental medicines 
or investigational 
agentsno no Other than ramucirumab, necitumumab, or osimertinib
Glucocorticoids no no Systemic glucocorticoids are permitted to modulate symptoms 
from an event of clinical interest of suspected immunologic 
etiology.  The use of physiologic doses of corticosteroids may 
be approved after consultation with the Sponsor.
Note:  Inhaled steroids are allowed for management of asthma.
Immunotherapy no no Other than inhaled steroids and vaccinations 
NSAIDs yes no Chro nic use of aspi[INVESTIGATOR_155752] 325 mg/day is permitted.
In addition, in certain medical situations, NSAIDs may be the 
best treatment option (for example, for pain management). 
Increased risk of bleeding should be considered by [CONTACT_702402]. 
Radi ation therapy no no Localized radiation therapy to a symptomatic, solitary lesion or 
to the brain may be allowed after consultation with the Sponsor.
BCRP Yes Yes Monitor for AEs (including CK) of the BCRP substrate (e.g., 
rosuvastatin, sulfasalazine) and signs of changed tolerability of 
osimertinib , unless otherwise instructed in its approved labeling, 
when coadministered with osimertinib.
If the patient experiences any potentially relevant AEs 
suggestive of muscle toxicity including unexplained muscl e 
pain, tenderness, or weakness, particularly if accompanied by 
[CONTACT_205288] o r fever, rosuvastatin must be stopped and any 
appropriate further management should be taken.
Abbreviations:  BCRP = breast cancer resistance protein; INR = international normalized ratio; NSAIDs = 
nonsteroidal anti -inflammatory drugs.
I4T-MC-JVDL( c) Clinical Protocol Page 106
LY3009806 ; LY3012211Appendix 8. Protocol A mendment I4T -MC-JVDL c 
Summary  An Open- Label, Multicenter, Phase [ADDRESS_1179702]-Line 
EGFR TKI Therapy , has been amended.  The new protocol is indicated by  [CONTACT_61504] ( c) and 
will be used to conduct the study  in place o f any preceding versio n of the protocol.
The overall changes and rationale for the changes made to this protocol are as fo llows:
Study  com pletion was redefined as occurring approximately  [ADDRESS_1179703].  
I4T-MC-JVDL( c) Clinical Protocol Page 107
LY3009806 ; LY3012211Revised Protocol Sections
Note: Deletions have been ident ified by [CONTACT_58001] .
Addit ions have been identified by  [CONTACT_58002] .
Section 1. Synopsis
Length of Study Portion
The duration of the Dose -Expansio n Portio n (excluding the Continued Access Period) from first 
patient enrolled to the completion of the study is approximately 2.52years .  The completion of the 
study is defined as [ADDRESS_1179704] patient enrolled, or when 18 of the 22 (80%) patients in Cohort A in 
the Dose -Expansion Portion have confirmed progressive disease, unacceptable toxicity, or 
discontinuation for any other reason, adequate number of events are observed for survival outcome 
estimation, whichever comes first.
Section 5.3. Study Completion and End of Trial Definition
There will be a database lock to report the primary data analyses approximately [ADDRESS_1179705] pati ent receives init ial dose in the Dose -Expansion Portion of the study .
The complet ionof the stu dy (Study  Com pletion) is defined as [ADDRESS_1179706] pati ent enrolled, or when 18 of  the 22 (80%) patients in Cohort A in the Dose- Expansio n 
Porti on have confirmed PD, unacceptable toxicit y, or di scont inuat ion for any  other reason 
adequate number of events are observed for survival outcome est imation , whichever com es first.  
Section 7.8. Treatment after Study Completion
Thestudy com pletion will occur [ADDRESS_1179707] pati ent enrolled, or when 
18 of the 22 (80%) patients in Cohort A in the Dose -Expansio n Porti on have confirmed PD, 
unacceptable toxicit y,or discont inuat ion for any  other reason adequate number of events are 
observed for survival outcome estimat ion, whichever comes first. Invest igators will con tinue to
follow Schedule of Act ivities (Section 2) for all patients unt il notified by [CONTACT_848457].
7.8.1. Continued A ccess Period
Figure JVDL. [ADDRESS_1179708] patient enrolled, or when 18 of the 22 
(80%) patients in Cohort A in the Dose -Expansio n Portion have confirmed progressive 
disease, unacceptable toxicity, or discontinuation for any other reason adequate number 
of events are observed for surviv al outcome estimation, whichever comes first .
Leo Document ID = 62c44003-1388-46b3-9002-fc9b01d4f568
Approver: 
Approval Date & Time: 28-Mar-2018 14:05:35 GMT
Signature [CONTACT_32869]: Approved
[COMPANY_003]